1
Status: Approved, Date: 31 October 2017 Janssen Research & Development*
Clinical Protocol
A Randomized Phase 2/3Study of DACOGEN®(Decitabine) Plus Talacotuzumab 
(JNJ-56022473 ; Anti -CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML 
who are not Candidates for Intensive Chemotherapy
Protocol 56022473AML2002 ; Phase 2/3
Amendment 7
Talacotuzumab ( JNJ-56022473 )
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag Intern ational NV; Janssen, Inc ; Janssen Sciences Ireland UC ,or Janssen 
Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these 
various legal entities; the sponsor is identified on the Contact [CONTACT_170117].
This study  will be conducted under US Food & Drug Administration IND regulations (21 CFR 
Part 312).
EudraCT NUMBER: 2015-001611-12
Status: Approved
Date: 31October 2017
Prepared by: [CONTACT_12945] & Development, a division of Janssen Pharmaceutica NV
EDMS number :EDMS- ERI-91414970, 10.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements . 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or 
confidential and may not be disclosed unless such disclosure is required by [CONTACT_170118]. In any 
event, persons to whom the information is disclosed must be informed that the information is privileged or 
confidential and may not be further disclosed by [CONTACT_476]. These restrictions on disclosure will apply equally to all 
future information supplied to you that is indicated as privileged or confidential.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
2
Status: Approved, Date: [ADDRESS_199020] OF IN -TEXT T ABLES.......................................................................................................................... 6
PROTOCOL A MENDMENTS ....................................................................................................................... 7
SYNOPSIS .................................................................................................................................................. 20
OBJECTIVES, ENDPOINT S, AND HYPOTHESIS .................................................................................... 20
OBJECTIVES ............................................................................................................................................. 20
TIME AND EVENTS SCHE DULE –TABLE 1A  [PART A]........................................................................ 27
TIME AND EVENTS SCHE DULE –TABLE 1B [PA RT B] UP TO A ND INCLUDING 
AMENDMENT 5 ................................................................................................................................ .32
TIME AND EVENTS S CHEDULE –TABLE 1C [PA RT B] DURING A MENDMENT 6 ............................. 37
TIME AND EVENTS SCHE DULE –TABLE 1D [PA RT B] FO LLOWING A MENDMENT 7 ..................... 37
TIME AND EVENTS SCHE DULE (PK A ND BIOM ARKERS) –TABLE 2A  [PART A ]............................. 38
TIME AND EVENTS SCHE DULE (PK A ND BIOM ARKERS) –TABLE 2B [PA RT B] UP TO A ND 
INCLUDING A MENDMENT 5............................................................................................................ 39
ABBREVIA TIONS ...................................................................................................................................... 41
1. INTRODUCTION ................................................................................................................................ 43
1.1. Talacotuzumab (JNJ -56022473; CSL362): Second Generation Anti -CD123 Antibod y................ 44
1.2. CSL362 Phase 1 Experience ......................................................................................................... 44
1.2.1. Recommended Phase 2 Dose (RP2D): ...................................................................................... 47
1.3. DACOGEN (decitabine) ................................................................................................................. [ADDRESS_199021] POPUL ATION.................................................................................................................. 59
4.1. Inclusion Criteria ............................................................................................................................ 60
4.2. Exclusion Criteria ........................................................................................................................... 61
4.3. Prohibitions and Restrictions ......................................................................................................... 63
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 63
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 63
6.1. Dosing Schedule ............................................................................................................................ 63
6.1.1. Part A .......................................................................................................................................... 63
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
3
Status: Approved, Date: 31 October 2017   6.1.2. Part B .......................................................................................................................................... 64
6.2. Decitabine ...................................................................................................................................... 65
6.2.1. Preparation and Administration of Decitabine ............................................................................ 65
6.2.2. Decitabine: Premedication .......................................................................................................... 65
6.2.3. Decitabine Dose Modifications ................................................................................................... 65
6.3. Talacotuzumab ............................................................................................................................... 66
6.3.1. Preparation and Administration of Talacotuzumab .................................................................... 66
6.3.2. Talacotuzumab: Premedication .................................................................................................. 66
6.3.3. Talacotuzumab Dosing Modifications ......................................................................................... 67
6.3.4. Management of Potential Hypersensitivity/ Infusion -related Reactions ..................................... 68
[IP_ADDRESS]. Guidelines for the Interruption of Talacotuzumab Infusion due to Infusion -related 
Reaction ................................................................................................................................... 69
7. TREA TMENT COMPLIA NCE ............................................................................................................ 69
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 69
8.1. Permitted Medications and Supportive Therapi[INVESTIGATOR_014] ......................................................................... 70
8.2. Prohibited Therapi[INVESTIGATOR_014] ...................................................................................................................... 70
8.3. Subsequent Antineoplastic Therapi[INVESTIGATOR_014] ........................................................................................... 70
9. STUDY EVA LUATIONS .................................................................................................................... 71
9.1. Study Procedures ........................................................................................................................... 71
9.1.1. Overview ..................................................................................................................................... 71
9.1.2. Screening Phase ........................................................................................................................ 72
9.1.3. Open -Label Treatment Phase .................................................................................................... 72
9.1.4. Follow -up Phase ......................................................................................................................... 72
9.1.5. Disease Evaluation and Clinical Cutoff ....................................................................................... 73
9.2. Efficacy ........................................................................................................................................... 73
9.2.1. Evaluations ................................................................................................................................ .73
[IP_ADDRESS]. Disease Status ........................................................................................................................ 73
9.3. Pharmacokinetics and Immunogenicity ......................................................................................... 75
9.3.1. Evaluations ................................................................................................................................ .75
9.3.2. Analytical Procedures ................................................................................................................. 75
9.3.3. Pharmacokinetic Parameters ..................................................................................................... 76
9.3.4. Immunogenicity Assessments .................................................................................................... 76
9.4. Pharmacokinetic/Pharmacodynamic Evaluations .......................................................................... 77
9.5. Biom arkers ..................................................................................................................................... 77
9.5.1. Assessment of Pharmacodynamic Markers (Part A and Part B) ................................................ 77
9.5.2. Assessment of CD123 Expression (Part B) ................................................................................ 77
9.5.3. Minimal Residual Disease Assessment (Part B) ........................................................................ 78
9.5.4. Immunophenotypi[INVESTIGATOR_007] (Part B) ...................................................................................................... 78
9.5.5. Cytokine Analysis ....................................................................................................................... 78
9.6. Pharmacogenomic (DNA and RNA) Evaluations (Part B) ............................................................. [ADDRESS_199022]- Leu................................................................................................................................... 79
9.7.2. EQ-5D-5L.................................................................................................................................... 79
9.8. Medical Resource Utilization .......................................................................................................... 79
9.9. Safety Evaluations ......................................................................................................................... 80
9.10. Sample Collection and Handling .................................................................................................... 82
10. DISCONTINUA TION OF S TUDY TREA TMENT/ WITH DRA WAL FROM STUDY ........................... [ADDRESS_199023] Information ........................................................................................................................ 84
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
4
Status: Approved, Date: 31 October 2017   11.2. Interim and Final Analyses ............................................................................................................. 84
11.3. Sample Size Determination ........................................................................................................... 86
11.4. Efficacy  Analyses ........................................................................................................................... 87
11.5. Pharmacokinetic Analy ses............................................................................................................. 87
11.6. Immunogenicity Analyses .............................................................................................................. 88
11.7. Pharmacokinetic/Pharmacodynamic Analy ses.............................................................................. [ADDRESS_199024] Quality ............................................................................ 97
14. STUDY DRUG INFORM ATION......................................................................................................... 97
14.1. Physical Description of Study Drug(s) ........................................................................................... [ADDRESS_199025] ................................................. 100
16.2.3. Informed Consent ..................................................................................................................... 102
16.2.4. Privacy of Personal Data .......................................................................................................... 103
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 103
16.2.6. Countr y Selection ..................................................................................................................... 104
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 104
17.1. Protocol Amendments .................................................................................................................. 104
17.2. Regulatory Documentation .......................................................................................................... 104
17.2.1. Regulatory Approval/Notification .............................................................................................. [ADDRESS_199026] Identification, Enrollment, and Screening Logs .............................................................. 106
17.4. Source Documentation ................................................................................................................. 106
17.5. Case Report F orm Completion .................................................................................................... 107
17.6. Data Quality Assurance/Quality Control ...................................................................................... [ADDRESS_199027] Retention ......................................................................................................................... 108
17.8. Monitoring .................................................................................................................................... 109
17.9. Study Com pletion/Termination ..................................................................................................... 109
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
5
Status: Approved, Date: 31 October 2017   17.9.1. Study Com pletion/ End of Study ............................................................................................... 109
17.9.2. Study Termination ..................................................................................................................... 109
17.10. On-Site Audits .............................................................................................................................. 110
17.11. Use of Information and Publication .............................................................................................. 110
REFERENCES .......................................................................................................................................... 112
INVESTIGA TOR A GREEME NT............................................................................................................... 122
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
6
Status: Approved, Date: [ADDRESS_199028] OF A TTACHMENTS
Attachment 1: Sample FACT- Leu (Version 4) ................................................................................. 114
Attachment 2: Sample EQ -5D-5L.................................................................................................... 117
Attachmen t 3: ECOG Performance Status Score ............................................................................ 120
Attachment 4: Anticipated Events .................................................................................................... [ADDRESS_199029] OF IN -TEXT TA BLES
TABLES
Table 1: Treatment -Emergent Adverse Events Occurring in [ADDRESS_199030] -AML-11-73................................................................................................................... 46
Table 2: Dosing Schedule for Part A ...................................................................................................... 64
Table 3: Dosing Schedule for Part B - Arm 1 .......................................................................................... 64
Table 4: Dosing Schedule for Part B - Arm 2 .......................................................................................... 64
Table 5: Premedication for Subjects Receiving Talacotuzumab ............................................................ 67
Table 6: Response Assessments ........................................................................................................... 74
Table 7: Overall Statistical Inference ...................................................................................................... 85
Table 8: Study Continuation Decision Rule, Operating Characteristics ................................................. 86
Table 9: Sample S ize Determination ...................................................................................................... 87
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
7
Status: Approved, Date: [ADDRESS_199031] recent amendment.
Amendment 7 (31October 2017 )
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union, in that it does not significantly 
impact the safety or physical/mental i ntegrity of subjects, nor the scientific value of the study.
The overall reason for the amendment: To further clarify the end of the study ,as the end of study data collection
to permit subjects who are deriving benefit from decitabine treatment to contin ue to receive decitabine after the end 
of study data collection . 
Applicable Section(s) Description of Change(s)
Rationale: To further clarify the end of the study ,as the end of study data collection and tolimit themonitoring of 
subjects who continue to receive decitabine to serious adverse events only. 
Synopsis :Overvie w of 
Study Design; Section 3.1 
Overvie w of Study Design; 
Section 9.1.4 Follow -up 
Phase; Section 10.1
Com pletion; Section 14.5 
Drug Accountability;
Section 17.9.1 Study 
Com pletion/ End of StudyChanged “end of study” to “end of study data collection”. Clarified that for subjects 
who are continuing to derive benefit from decitabine treatment and are continuing to 
receive decitabine, only serious adver se events will be monitored and entered into the 
Com pany safety repository.   
Rationale: To limit monitoring of subjects who continue to receive decitabine to serious adverse events only.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
8
Status: Approved, Date: 31 October 2017   Applicable Section(s) Description of Change(s)
Synopsis : Efficacy 
Evaluations, Safety 
Evaluations; Time and 
Events Schedules 1C and 
1D; Section 6.1 Dosing 
Schedule; Section 8 
Prestudy and Concomitant 
Therapy; Section 9 Study 
Evaluations; Section 9.9 
Safety Evaluations; Section 
12.3 Procedures; Section 
16.1 Study -Specific Design 
Considerations
Sectio n 6.2.3 Decitabine 
Dose Modifications
Section 7 Treatment 
Com plianceModified Time and Events Schedules; Clarified that for subjects who are continuing 
to derive benefit from decitabine treatment and are continuing to receive decitabine, 
only serious ad verse events will be monitored and entered into the Company safety 
repository
Deleted sentence requiring consultation with Sponsor to resume decitabine treatment 
following a 28 -day dose delay
Added statement that eCRFs will be closed
Amendment 6 ([ADDRESS_199032] 2017 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and th e Council of the European Union.
The overall reason for the amendment: This am endm ent is based on Independent Data Monitoring Committee 
(IDMC )recommendation after results from the second interim analysis (final analysis for respons e endpoints and 
first ana lysis for overall survival [ OS]) were reviewed. T he IDMC recommended to close study enrollment and 
stop talacotuzumab treatm ent due to lack of efficacy in the talacotuzumab arm. Subjects i n the combination arm 
should stop treatment of with talacotuzumab andcan continue to receive D ACO GEN only, in accordance with 
Principal I nvestigator decision and subject agreement.
Applicable Section(s) Description of Change(s)
Rationale: Study conduct was changed due to IDMC recommendation after review of results from the second 
interim analysis .
Synopsis: Overvie w of 
Study Design Part B; 
Section 3.1: Overvie w of 
Study Design; Section 3.2: 
Study Design Rationale; 
Section 5: Treatment 
Allocation and Blinding; 
Section 6.1.2 Part B; 
Section 16.1: Study -
Specific Design 
ConsiderationsEnrollment in the study was closed; Subjects receiving talacotuzumab should 
discontinue talacotuzumab treatment and may continue decitabine treatment 
according to Principal Investigator [INVESTIGATOR_170076].
Rationale: Data collection for ongoing subjects w as changed due to changes in study conduct . 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
9
Status: Approved, Date: 31 October 2017   Applicable Section(s) Description of Change(s)
Synopsis: Overvie w of 
Study Design Part B , 
Efficacy Evaluations, Safety 
Evaluations ; Time and 
Events Schedule s 1B, 1C, 
and 2B ; Section 3.1: 
Overvie w of Study Design; 
Section 3.2: Study Design 
Rationale; Section 9. 1.1 
Overvie w; Section 9.1.3 
Open -label Treatment 
Phase; Section 9.1.4:
Follow -up Phase; Section 
9.2.1 Evaluations; Section 
9.5.2 Assessment of CD123 
Expression; Section 9.9 
Safety Evaluations; Se ction 
12.3: Procedures ; Section 
16.1: Study -Specific Design 
Considerations; Added Time and Events Schedule 1C: a ll subjects w ill continue to be followed for 
survival and subsequent anti -cancer therapy. Subjects during the treatment phase 
with decitabine will be monitored for serious adverse events .
Rationale: End of study definition and time of final OS analysis was changed due to changes in study conduct.
Synopsis: Overvie w of 
Study Design, Statistical 
Methods; Section 3.1: 
Overvie w of Study Design; 
Section 9.1.4: Follow -up 
Phase; Section 9.1.5:
Disease Evaluation and 
Clinical Cut -off;Section 
10.1: Completion; Section 
17.9.1 Study Completion/ 
End of StudyChanged definition of end of study to [ADDRESS_199033]; Changed time of final OS anal ysis to [ADDRESS_199034] . 
Amendment 5 (26April 2017)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union. 
The overall reason for the amendment: This amendment specifies enhan cedprecautionary measures to 
mitigate infusion -related reactions for subjects receiving talacotuzumab infusion.
Applicable Section(s) Description of Change(s)
Rationale: To clarify procedures during talacotuzumab infusion to reduce the incidence of infusion -related react ions
Section 6.3.1 Preparation 
and Administration of 
TalacotuzumabChanged infusion -rate guidance to slow  initial infusion rate to 10 mL/hr with a 
maximum rate of 60 mL/hr for the first 4 cycles
Rationale: To add premedications for talacotuzumab infusion to reduce the incidence of infusion -related reaction s
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
10
Status: Approved, Date: 31 October 2017   Applicable Section(s) Description of Change(s)
Synopsis: Dosage and 
Administration; Section 
6.3.2 Talacotuzumab: 
Prem edicationsAmended dexamethasone 8 mg from 12 hours prior to infusion to BID approximately 
2 days prior to infusion and approximately 3 hours prior to infusion. Added 
cimetidine
Rationale: To change maximum infusion rates after occurrence of an infusion -related reaction 
Section [IP_ADDRESS] Guidelines 
for the Interruption of 
Talacotuzumab Infusion 
due to Infusion -Related 
ReactionChanged the maximum infusion rates following infusion -related reaction to 60 mL/hr 
for Cycles 1 to 4 and 150 ml/hr for subsequent cycles 
Rationale: To increase the maximum volume of blood collected for subjects in the Talacotuzumab + DACOGEN 
arm to account for cytokine sampling
Section 9.1.1 Overview Increased maximum blood volumes for samples from subjects in the DACOGEN 
plus Talacotuzumab arm
Rationale: To add samples for cytokine analysis to investigate the mechanism of IRRs
Time and Events Schedul e 
2B; Section 9.5.5 Cytokine 
Analysis (new section)Added blood sampling for cytokine analysis
Amendment 4 (29March 2017)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union. 
The overall reason for the amendment: This amendment specifies new g uidance for patient monitoring and 
availability of resuscitation equipment during talacotuzumab infusion.
Applicable Section(s) Description of Change(s)
Rationale: To clarify procedures during talacotuzum ab infusion 
Section 6.3.1 Preparation 
and Administration of 
TalacotuzumabAdded clarification for patient monitoring during talacotuzumab infusion and 
availability of resuscitation equipment due to the occurrence of a fatal event of 
infusion -related reaction during talacotuzumab infusion; changed infusion -rate 
guidance and increased monitoring from 30 minutes to 1 hour after completion of 
infusion
Rationale: To continue ECG m onitoring though no safety signal is seen
Time and Events Schedule 
1B; Section 9.9 Safety 
EvaluationsRemoved language to stop ECG monitoring if no safety signal is seen
Rationale: To clarify biom arker and cytogenetic testing of bone m arrow sam ples
Time and Events Schedule 
1BAdded language to clarify biomarker and cytogenetic testing to be performed per 
local standard of care at screening, suspected CR/CRi, and every disease assessment 
until, relapse or EOT 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
11
Status: Approved, Date: 31 October 2017   Amendment 3(14October 2016)
This amendment is considered to be nonsubstantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union , in that it does not significantly 
impact the safety or physical/mental integrity of subjects, nor the scientific value of the study.
The overall reason for the amendment: This amendment specifies additional required premedication prior 
totalacotuzumab infusion in order to reduce th e risk and severity of infusion -related reactions.
Applicable Section(s) Description of Change(s)
Rationale: To reduce th e risk and severity of infusion -related reactions.
Synopsis; Section 6.3.2 
Talacotuzumab: 
Prem edication ; Section 
16.[ADDRESS_199035] ,and specified diphenhydramine as 
premedications prior to infusion of talacotuzumab ; clarified premedication procedures
Rationale: To change the name [CONTACT_170199] -56022473 to talacotuzum ab
Throughout the protocol Changed name [CONTACT_170199] -56022473 to talacotuzumab
Rationale: To clarify when disease evaluations are performed
Time and Events Schedule 
1BChanged disease evaluation from “at the end of each cycle ”to every 2 cycles between 
Day 14 and D ay 28and at time of suspected CR /CRi and at time of suspected
treatment failure or relapse from CR/CRi .
Rationale: To provide clarity for biom arker sampling 
Time and Events 
Schedule s1B and 2BClarified table for biomarker sampling 
Rationale: To correct reasoning for leukopheresis and hydroxyurea treatm ent
Section 4.1 Inclusion 
Criteria #3Changed w ording from “ leukopheresis or hydroxyurea is permitted to decrease blast 
count” to “permitted to decrease WBC count”
Rationale: To clarify that prior systemic therapi[INVESTIGATOR_170077] 8: Prestudy and 
Concomitant Therapi[INVESTIGATOR_170078]: To align with previous am endment changing inclusion criterion 1
Section 4.2: Exclusion 
Criteria ; AttachmentsDeleted “[LOCATION_001] Heart Association class 3 or 4 congestive heart failure scale ” 
from exclusion criteria to align with inclusion criterion 1 ;Deleted Attachment 3
Rationale: To correct definition of end of study
Section 10.1 Completion; 
Section 17.9.1 Study 
Com pletion/ End of StudyCorrected definition of end of study to when [ADDRESS_199036] is ran domized, w hichever occurs later.
Rationale: Minor errors were noted and corrected
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
12
Status: Approved, Date: 31 October 2017   Amendment 2 (28June 2016)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: This amendment was prepared in response to health authority review 
and clarif ies inclusion criteria and the recommended dose of preinfusion medications prior to JNJ -56022473 
administration.
Applicable Section(s) Description of Change(s)
Rationale: To allow flexibility in scheduling due to patient / provider availabilities
Time and Events Schedule 
1B; Section 6.1.2 Part BAdded a ± 48 hour window (unless otherwise indicated) for Day 1 procedures
For JNJ -56022473 administration window is ± 24 hours
Rationale: To provide clarity regarding sponsor oversight of subjects prior to inc lusion
Time and Events Schedule 
1BAdded sponsor review of key eligibility data required prior to randomization
Rationale: To align with m odifications that will be m ade to eligibility
Time and Events Schedule 
1BLaboratory assessments for HBV surface antigen and hepatitis C antibodies removed 
and replaced by [CONTACT_170119]: Bone m arrow block no longer required at screening
Time and Events Schedule 
1B; Section 9.5.2 
Assessment of CD123 
Expression (part B)Removed requirement for a bone marrow block at screening, and bone marrow  
aspi[INVESTIGATOR_337]/biopsy to be collected w ithin 6 w eeks of randomization; however, bone 
marrow  samples are collected as indicated in the Time and Events schedule for central 
analysis
Rationale: To c larify the role of the IDMC and Sponsor in overall study decisions
Synopsis Overview of 
Study Design Part B; 
Section 3.[ADDRESS_199037]; deleted repeated sentence in third paragraph
Rationale: To add objective per health authority feedback
Synopsis, Secondary 
Objectives; Section 2.1.[ADDRESS_199038] negative CRi as an objective
Rationale: To add endpoint per health authority feedback
Synopsis, Secondary 
Endpoints; Section 2.1.2 
Endpoints; Section 11.[ADDRESS_199039] negative CRi as an endpoint
Rationale: Added inclusion criteria to define subjects ineligible for intensive chemotherapy 
Synopsis Subject 
Population Part B; Section 
4.1 Inclusion Criteria , 
Criterion 3.1Added inclusion criteria to define subjects ineligible for intensive chemotherapy ; 
aligned other criteria to agree with additions
Rationale: Aligned criteria to agree with added inclusion criteria
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
13
Status: Approved, Date: 31 October 2017   Applicable Section(s) Description of Change(s)
Section 4.2 Exclusion 
CriteriaClarified criteria regarding other malignancies, removed chronic respi[INVESTIGATOR_170079] <45% to align with modifications to inclusion criteria
Rationale: To define exclusion of subjects who have an active infection requiring treatm ent
Section 4.2 Exclusion 
CriteriaClarified criteria regarding infection 
Rationale: There is no known hepatotoxicity or hepatitis reactivation with JNJ -56022473 , so medical history 
of these conditions is acceptable for study entry
Section 4.2 Exclusion 
CriteriaExclusion criteria changed to active liver disease or hepatitis infection
Rationale: To agree with language and form at of protocol template
Section 4.3 Prohibitions 
and RestrictionsAdded this section
Rationale: To increase m onitoring and m inimize the severity of infusion reactions
Synopsis, Dosage and 
Administration; Section 
6.3.1 Preparation and 
Administration of JNJ -
56022473; Section 6.3.2 
JNJ-56022473: 
Prem edication
Section [IP_ADDRESS] Gu idelines 
for the Interruption of JNJ -
56022473 Infusion due to 
Infusion -related ReactionsClarified maximum rate of infusion and monitoring of subjects; Increased mandatory 
premedication to 100 mg methylprednisolone and clarified number of cycles for 
premedication; 
Rationale: To clarify JNJ -56022473 dosing m odifications
Section 6.3.3 JNJ -
56022473 Dosing 
ModificationsClarified text regarding JNJ -56022473 dose delays
Rationale: To provide clarity for recommended supportive therapi[INVESTIGATOR_170080] 8.1 Permitted 
Medications and 
Supportive Therapi[INVESTIGATOR_170081] w ording regarding grow th factor and anti-infective use
Rationale: To clarify that plasm apheresis must be discontinued prior to start of study therapy
Section 8.[ADDRESS_199040] be discontinued prior to start of study therapy
Rationale: Corrected blood volum es collected during the study
Section 9.1.1. Overview Changed blood volumes to agree w ith section 16.1
Rationale: To provide the definition of end of study
Section 9.1.[ADDRESS_199041] israndomized
Rationale: To ensure discontinuation criteria defined in the protocol are m et
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
14
Status: Approved, Date: 31 October 2017   Applicable Section(s) Description of Change(s)
Section [IP_ADDRESS] Disease 
Status; Section 10.2 
Discontinuation of the
Treatment PhaseAdded te xt to ensure that criteria for discontinuation of subjects is revie wed by [CONTACT_170120]: Proteom ics evaluations s will not be perform ed
Section 9.5.5 Proteomics 
Evaluation (Part B)Deleted this s ection
Rationale: To align with m odified eligibility criteria
Section 9.9 Safety 
EvaluationsRemoved HBsAg and hepatitis C virus antibody testing at screening
Rationale: To provide clarity and to docum ent the level of sponsor oversight
Section 10.2 
Discontinuation of the 
Treatment PhaseAdded text that all treatment discontinuations will be reviewed and approved by [CONTACT_170121]: To conform  to health authority feedback
Synopsis, Statistical 
Methods, Section 11.2 
Interim and Final 
AnalysesClarified role of the IDMC. Modified text and statistical parameters for efficacy 
analyses 
Rationale: To clarify the composition and role of the IDMC
Section 11.12 Independent 
Data Monitoring 
CommitteeAdded text defining the IDM C and function of the IDMC
Rationale: To provide anticipated events
Section 12.3.1 All 
Adverse Events; 
Attachment 4Added language regarding anticipated adverse events
Rationale: To provide reference for suitable bloods volumes withdrawn during the study
Section 16.1 Study -
specific Design 
ConsiderationsRemoved blood volumes withdraw n for the study; added reference for suitability of 
blood volume withdrawn
Rationale: Minor errors were noted and corrected
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
Amendment 1 (14 January 2016 )
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
15
Status: Approved, Date: 31 October 2017   This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union .
The overall reason for the amendment: The study was originally designed as a Phase 2 study with a total
of 120 subjects and aprimary endpoint ofevent -free survival (EFS) . An interim analysis with [ADDRESS_199042] the end with 120 subjects. This 
amendment changes the primary endpoint of the study to 2prim ary endpoints of complete response (CR) rate and 
overall survival (OS) and up to [ADDRESS_199043] been randomized ( approximately 40 subjects per arm) and followed for 4 months .The 
results of this interim analysis will provide guidance fora decision to continue enrollment to 400 subjects or stop 
enrollment .
Applicable Section(s) Description of Change(s)
Rationale: To em phasize study endpoints
Synopsis Objectives, 
Endpoints and 
Hypothesis; Section 2.1 
Objectives and EndpointsMoved subsection that defined study endpoints
Rationale: To advance development of JNJ -56022473 
Synopsis Objectives and 
Endpoints ; Section 2.1 
Objectives and 
Endpoints ; Section 9.5.3 
Minimal; Residual 
Disease Assessment (Part 
B)Changed primary and secondary objectives and endpoints for Part B of the study ; 
Added minimal residual disease evaluation as a secondary endpoint
Rationale: To change the hypothesis based on changes in primary objectives
Synopsis Hypothesis; 
Section 2.[ADDRESS_199044] complete response rate and overall survival as 
primary objectives
Rationale: To change the timing of and agent used for premedication for subjects who receive JNJ -56022473
Synopsis Dosageand 
Administration ;Section 
6.3.2 JNJ -56022473 
Prem edication; Section 
16.[ADDRESS_199045] 2 cycles of JNJ -56022473 treatment
Rationale: To change the study design to perm it accelerated development of JNJ -56022473 if predefined
statistical criteria are met
Synopsis Overview of 
Study Design; Section 3.1 
Overvie w of Study 
Design ; Section 11.2 
Interim and Final 
AnalysesAdded details of a revised design to continue Part B; limited Study Evaluation Team 
evaluations to Part A; Added Independent Data Monitoring Committee participation 
in Part B; Added independent central review of efficacy
Rationale: It can take 2 to4 weeks for cytogenetic results. Newly diagnosed patients cannot wait this l ong to 
begin treatment for acute myeloid leukemia ( AML).The remaining stratification factors ( Eastern Cooperative 
Oncology group [ ECOG] performance status score and primary vs secondary AML) adequately account f or 
factors that influence outcomes in patients with AML .
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
16
Status: Approved, Date: 31 October 2017   Applicable Section(s) Description of Change(s)
Synopsis Overview of 
Study Design; Section 3.1 
Overvie w of Study 
Design; Section 3.2 Study 
Design Rationale; Section 
5 Treatment Allocation 
and Blinding; Section 
11.4 Efficacy AnalysesRemoved cytog enetic (adverse vs other) as a stratification factor
Rationale: To describe interim and final analyses forPart B of the study 
Synopsis Statistical 
Methods; Section 11.2 
Interim and Final 
AnalysesDescribed statistical decision making rules for Part B of the study
Rationale: To update Time and Events Schedule 1B based on investigator feedback and consistency with rest of 
protocol
Time and Events 
Schedule 1B ; Section 9.9 
Safety Evaluations Expanded the window  for pre -dosing assessments for each cycle from 48 hours to 3 
days; added Medical Resource Utilization determination as a procedure under Safety 
Assessments; added peripheral blast counts to Hema tology Laboratory Assessments; 
clarified t hat the diagnostic bone marrow block required at screening may be from a 
historic sample; added a procedure that defines disease evaluation under Disease 
Evaluations ; changed frequency of Day 1 bone marrow assessments from Cycle 4 to 
every second cycle sta rting at Cycle 2.
Rationale: To expand cardiac testing of subjects
Time and Events
Schedule 1B; Section
9.9 Safety EvaluationsAdded LVEF determination at end -of-treatment; Added ECG monitoring during the 
study for both treatment arms and at end-of-treatment.
Rationale: To clarify criteria and measurement of LVEF
Time and Events
Schedule 1A and 1B; 
Section 4.2 Ex clusion 
CriteriaAdded LVEF determination as clinically indicated during the study to the Time and 
Events Schedule for consistency with Section 9.9; revised exclusion criterion #12 so 
that only LVEF<45% is excluded 
Rationale: To clarify Adverse event information collected during the follow -up phase
Time and Events 
Schedule 1A and 1B, 
Section 9.9 Safety 
Evaluations, Section 
12.3.1 All Adverse 
EventsDrug -related ≥Grade 3 adverse events and drug -related serious adverse events will 
be follow ed until resolution during the follow -up phase
Rationale: To clarify source documentation for eligibility criteria
Time and Events 
Schedules 1A and 1B Added note regarding source documentation and to assess the clinical status of the 
subject again prior to the first dose of study drug
Rationale: ToClarif y Disease Evaluations to include clinical presentation
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
17
Status: Approved, Date: 31 October 2017   Applicable Section(s) Description of Change(s)
Synopsis Efficacy 
Evaluations; Time and 
Events Schedule 1B;
Section 3.1 Overview of 
Study Design; Section 
9.2.1 Efficacy 
EvaluationsAdded clinical presentation to disease assessments evaluated for efficacy ; clarified 
details for bone marrow  biopsy/aspi[INVESTIGATOR_170082]: To update Time and Events Schedule 2B to remove unneeded pharmacokinetic ( PK)andbiomarker
samples
Timeand Events 
Schedule 2B ; Section 
9.5.4 
Immunophenotypi[INVESTIGATOR_007] 
(Part B)Removed the JNJ -56022473 PK sample on Day 1 Cycle 4 ; limited PK sampling 
after [ADDRESS_199046] enrolled ; removed samples for testing NK cell directed 
ADCC and T -cell mediated cytotoxicity assay
Rationale: To update safety information for CSL362
Section 1.2 CSL362 
Phase 1 Experien ceUpdated safety information with a clinical cut -off date of 28 January 2015
Rationale: To change therationale to accommodate the change in primary objectives and endpoints
Section 3.2 Study Design 
RationaleChanged rationale for primary endpoints
Rationale: ToProvide a statement that w aivers to eligibility criteria are not allow ed
Section [ADDRESS_199047] 
PopulationAdded statement: Waivers are not allow ed.
Rationale: To clarifyinclusion criteria for blood cell counts
Section 4.1 Inclusion 
CriteriaClarified that the platelet count of ≥ 1 0 X 109/L was with or without transfusion; 
defined the white blood cell count criteria as ≤ 40 x 109/L
Rationale: To Expand the exception to exclusion criterion to include patients with myelofibrosis 
Section 4.2 Exclusion 
CriteriaDeleted repetitive criterion of Hepatitis B or C virus positivity 
Rationale: To clarify treatment discontinuation for Part B
Section 6.12 Part B ; 
Section 6.23 Decitabine 
Dose Modifications; 
Section 6.33 JNJ -
56022473 Dose 
Modifications; Section 
9.1.3 Open -Label 
Treatment Phase; Section 
10.2 Discontinuation of 
the Treatment PhaseClarified that subjects in Arm 1 (Part B) could discontinue 1 drug treatment and 
continue treatment with the other agent 
Rationale: To Extend themaximum delay of decitabine dosing to 28 days
Section 6.2.3 Decitabine 
Dose ModificationsChanged the maximum delay for decitabine treatment to 28 days from 14 days 
Rationale: Tofurther define the administration of JNJ -56022473 to minimize infusion -related reactions
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
18
Status: Approved, Date: 31 October 2017   Applicable Section(s) Description of Change(s)
Section 6.3.[ADDRESS_199048] at the Day 
1 Assessment of each cycle; Clarified that the volume of infusion is 2 50 m L; 
Defined the infusion rates for JNJ -56022473 
Rationale: To Chang e requirements for dose modifications due to Grade 4 hematological toxicity based upon 
investigator feedback
Section 6.3.3 JNJ -
56022473 Dosing 
ModificationsChanged the requirement for dose delays of JNJ -56022473 due to hematological 
toxicity from not responsive to supportive care to per investigator judgment 
Rationale: To Clarif y the clinical management of infusion -related reactions and JNJ -56022473 dose 
modifications due to infusion -related reactions
Section 6.3.4 
Management of Potential 
Hypersensitivity/ 
Infusion -related 
ReactionsDefined the recommended management of infusion -related reactions and 
modifications for JNJ -56022473 treatment
Rationale: To expand permitted medications for febrile neutropenia
Section 8.1 Permitted 
Medications and 
Supportive Therapi[INVESTIGATOR_170083]: Toallow  vaccination with killed virus vaccines 
Section 8.2 Prohibited 
Therapi[INVESTIGATOR_170084]: Todescribe clinical cutoffs in Part B of the study
Section 9.1.5 Disease 
Evaluation and Clinical 
CutoffAdded clinical cutoff inPart B of t he study
Rationale: To define an Independent Data Monitoring Committee
Section 11.12 
Independent Data 
Monitoring Committee; 
Section 16.1 Study -
Specific Design 
ConsiderationsAdded details for a Data Monitoring Committee
Rationale: To m odify sample size for revised study design
Section 11.3 Sample Size 
DeterminationDescribed operational characteristics forPart B of the study
Rationale: To describe statistical analyses for CR, OS primary endpoints
Section 11.4 Efficacy 
AnalysesDescribed analyses for primary endpoints for Part B of the study
Rationale: To define immunogenicity results formats
Section 11.5 
Immunogenicity AnalysesAdded description of immunogenicity analysis result formats
Rationale: Provide description of methods for adverse event detection
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
19
Status: Approved, Date: 31 October 2017   Applicable Section(s) Description of Change(s)
Section 12 Adverse Event 
ReportingAdded subsection of methods of detecting adverse events and serious adverse events
Rationale: ToProvide an eSource system as an alternate data source for clinical data
Section 17.4 Source 
DocumentationDefined the eSource system
Rationale: To clarify language regarding Case Report Form completion
Section 17.5 Case Report 
Form  Com pletionClarified language regarding Case Report Form completion 
Rationale: Minor errors w ere noted and corrected
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
20
Status: Approved, Date: 31 October 2017   SYNOPSIS
ARandomized Phase 2/3Study of DACOGEN®(Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti-
CD123) Versus DACOGEN (Decitabine) Alone in Patients with Acute Myeloid Leukemia (AML )who 
are not Candidates for Intensive Chemotherapy
EudraCT NUMBER: 2015-011611-12
DACOGEN (decitabine) is a hypomethylating agent approved in the European Union and 21 other
countries for the treatment of patients with AML who areover the age of 65andwho are not candidates 
for intensive chemotherapy. DACOGEN (decitabine) is also recommended in the National 
Comprehensive Cancer Network (NCCN) Guidelines in the [LOCATION_003] for the treatment of patients with AML .
For the purposes of this protocol the generic name [CONTACT_170200] .
Talacotuzumab , previously known as JNJ-[ADDRESS_199049] the α-subunit of the interleukin -3 (IL-3) receptor also known as the CD123 
antigen. 
OBJECTIVES , ENDPOINTS ,AND HYPOTHESIS
OBJECTIVES
Primary Objective s
Part A
The primary objective s of Part A of the study are toassess safety and to confirm therecomme nded 
Phase 2 dose (RP2D) of talacotuzumab monotherapy .
Part B
The primary objectives of Part B of the study are to assess complete response (CR) rate and overall 
survival (OS) inpatients with previously untreated AML who are not eligible for intense induction 
chemotherapy and who are randomly assigned to receive decitabine plus talacotuzumab at the RP2D or 
decitabine alone . 
Secondary Objectives
Part B
The secondary objectives are to assess the event -free survival (EFS), the overall response rate (ORR, 
defined as the rate of CR+ complete response with incomplete blood count recovery [CRi]),the rate of 
CR plus MRD negative CRi, relapse -free survival (RFS), time to and duration of response, and the safety  
profile of study treatments ; to assess the pharmacokinetics (PK) of decita bine and talacotuzumab when 
used alone or in combination; to assess the immunogenicity of talacotuzumab in combination with 
decitabine, to evaluate minimal residual disease (MRD) and to evaluate patient -reported outcomes 
measures (PRO) using the FACT LEU a nd EQ -5D-5L instruments.
ENDPOINTS
Part A
To assess safety and determine dose -limiting toxicities (DL Ts)
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
21
Status: Approved, Date: 31 October 2017   Part B
2Primary Endpoint s(Part B)
 CR rate
 Overall survival ( OS)
Secondary Endpoints (Part B)
 EFS, defined as the time from randomization to treatment failure, relapse from CR/CRi, or death 
from any cause, whichever occurs first. Treatment failure is defined as >25% absolute increase in the 
bone marrow blast count from baseline to the present assessment.
 ORR (CR + CRi) ;
 Rate of CR plus MRD negative CRi ;
 Time to response , defined for subjects who achieved best response of CR or CRi as time from  
randomization to achieving the best response;
 Duration of response, defined for subjects who achieved best response of CR or CRi as time from 
achieving CR or CRi to relapse;
 Relapse -free survival (RFS) defined for subjects who achieved CR or CRi as the time from achieving 
CR or CRi to disease relapse or death from any cause;
 Safety profile;
 Pharmacokinetics; 
 Immunogenicity;
 MRD ;
 Patient- reported outcomes (PROs) u sing the FACT -Leu and EQ 5D 5L. 
Exploratory Endpoints (Part B)
 Pharmacokinetic/pharmacodynamic relationships associated with biomarkers, pharmacodynamic 
(PD)markers and clinical end points;
 To explore biomarkers associated with clinical response ;
 Medical resource utilization .
Hypothesis
In patients with untreated AML who are not eligible for intense induction chemotherapy it is 
hypothesized that treatment with a combination regimen of decitabine and talacotuzumab as compared 
with decitabine alon e wil l improve the CRrateor extend survival or both .
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
22
Status: Approved, Date: 31 October 2017   OVERVIEW OF STUDY DESIGN
Part A
This is an open label, multicenter study; in Part A, the RP2D of talacotuzumab monotherapy will be 
confirmed in subjects with AML for whom experimental therapy is appropriate (as assessed by [CONTACT_170122]). Part A will include approximately 6 subjects toassess the clinical safety and 
pharmacokinetics/pharmacodynamics (PK/PD) of talacotuzumab as part of the comparability testing 
package for talacotuzumab , a monoclonal antibody with the same amino acid sequence as CSL362, but 
produced in a different cell linewith a different process . A prior Phase 1 study of CSL362 assesse d the 
safety and PK profile and established the RP2D as 9 mg/kg. Comparability testing of talacotuzumab and 
CSL362 has shown the antibodies to behave similarly in biophysical, biochemical, and preclinical 
assessments. Pharmacodynamic studies in cynomolgus monkeys showed similar levels of biological 
activity between CSL362 and talacotuzumab (ie, basophil and plasmacytoid dendritic cell [pDC]
depletion; natural killer [NK]cell number and activity). Addit ionally, the PK profiles of talacotuzumab
following 30 and 100 mg/kg IV dosing of cynomolgus monkeys are highly similar to those of CSL362. 
Following the first weekly IV dose, mean C maxand AUC 0-167hof talacotuzumab are 91% and 94% of those 
observed for CSL362, respectively. Further detail regarding preclinic al studies of CSL362 and 
talacotuzumab is provided in the JNJ -56022473 Investigator’s Brochure.   
Subject participation will include a Screening Phase, a Treatment Phase, and a Follow -up Phase. During 
Part A,the safety, PK, and PD of talacotuzumab will beassessed . After [ADDRESS_199050]-dose assessment period , subjects will be assessed for safety to confirm
the RP2D andwill then start subsequent cycles ofcombination therapy of decitabine + talacotuzumab
using the same dosing schedule described for Part B . 
Part B
In PartB, subjects with AML who are not candidates for intensive chemotherapy will be assigned 
randomly in a 1:1 ratio to receive decitabine + talacotuzumab (Arm 1)or decitabine alone (Arm 2). 
Approximat ely400subjects will be enrolled in Part B.
Part B of the study will begin after theRP2D of talacotuzumab is confirmed in Part A. Randomization 
will be stratified by [CONTACT_170123] (ECOG) performance status (0 -1 versus 2)and
type of AML (de novo versus secondary) . Subjects in both treatment arms will receive decitabine
(20mg/m2per day) on Days 1 to 5 of each 28-day cycle. For subjects randomized to the decitabine + 
talacotuzumab arm, talacotuzumab will be administered intravenously (IV) at the RP2D determined in 
Part A on Day 8 and Day 22 every 28 days. Treatment is continued until treatment failure ,relapse from 
CR or CRi, unacceptable toxicity, or death.
Part B is designed to be a seamless Phase 2/[ADDRESS_199051] interim analysis will occur after approximately 80 subjects 
(40subjects per arm) have been randomized and followed for at least 4 months. Guided by [CONTACT_170124]+CRi the study willcontinue enrollment to the prespecified Phase 
[ADDRESS_199052] been randomized by [CONTACT_170125]; this is the estimated 
Phase 2 sample size. No changes in design elements are planned based on this interim analysis.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
23
Status: Approved, Date: 31 October 2017   If the enrollment continues to 400 subjects (approximately 200 subjects per arm), the pre- specified design 
elements are:
 A second interim analysis occurs after approximately 160 subjects (approximately 80 subjects per 
arm) have been randomized and followed for at least 4 months; this is the final analysis for CR and 
the first interim analysis for OS. The study will not be stopped on the basis of the CR results;
 A third interim analysis (ie, the second interim analysis of OS) will be conducted when [ADDRESS_199053] occurred;
 The final analysis of OS will take place when [ADDRESS_199054] occurred.
Safety reviews willbe performed in Part A and Part B. The safety assessment sin Part A will occur prior 
to the initiation of Part B. This will include safety and available PK and PD data from single -agent 
talacotuzumab and thepreliminary safety of thecombination of decitabine + talacotuzumab. A Study 
Evaluation Team (SET) will monitor safety and study conduct on an ongoing basis during Part A ofthe 
study.
An Independent Data Monitoring Committee (IDMC) will be established toevaluate safety and efficacy 
data collected during Part B of the study as described in Section 3.1.
In addition to evaluations by [CONTACT_431], disease status will be reviewed and determined by [CONTACT_170126] a blinded fashion .Disease status based on independent central review will be the 
primary source for efficacy analyses.
After review of the data from Interim Analysis #2, the IDMC informed the Sponsor that the futility  
criteri on for OS was met and that the CR rate did not meet per-protocol defined statistical significance. 
Given the lack of efficacy advantage of talacotuzumab + decitabine versus decitabine alone, the incidence 
of infusion- related reactions, and the complexities with premedications for drug administration, the 
benefit/ risk ratio is not favorable to continue treatment with talacotuzumab. The IDMC recommended 
closure of enrollment to the study and that subjects receiving talacotuzumab + decitabine should 
discontinue talacotuzumab treatment and may continue decitabine alone, according to Principal 
Investigator [INVESTIGATOR_170076]. All subjects will continue to be followed for survival and 
subsequent anti-cancer therapy. During the treatment phase with decitabine , subjects will be monitored 
for serious adverse event s.
The end of study data collection is defined as when [ADDRESS_199055]. At that time, follow up of subjects will end. Subjects who are 
continuing to derive benefit from decitabine treatmen t as assessed by [CONTACT_170127]; during this period, only serious adverse events will be monitored and entered into the 
Company safety repository as described under Amendment 7.
SUBJECT POPULATION
Part A
Key eligibili ty criteria include the following: subjects diagnosed with AML according to the World 
Health Organization ( WHO )2008 classification system fulfilling all of the following criteria:
 Patients with AML (treatment naive or relapsed) for whom experimental therapy is appropriate as 
assessed by [CONTACT_24018] ;subjects should not have had prior treatment with a 
hypomethylating agent ;
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
24
Status: Approved, Date: 31 October 2017    White blood cell (WBC) count ≤ 40 X 109/L.
Part B
Key eligibility criteria include the following: subjects who are:
Age ≥75 years old
Age ≥[ADDRESS_199056] 1 of the following :
1.Congestive heart failure or ejection fraction ≤50%
2.Creatinine >2 mg/dL, dialysis or prior renal transplant
3.Documented pulmonary disease with lung diffusing capacity for carbon monoxide (DLCO) 
≤65% of expected, or forced expi[INVESTIGATOR_3741] 1 second (FEV1) ≤65% of expected or 
dyspnea at rest requiring oxygen
4.ECOG performance status of 2
5.Prior or current malignancy that does not require concurrent treatment
6.Unresolved infection
7. C omorbidity that, in the Investigator’s opi[INVESTIGATOR_1649], makes the patient unsuitable for intensive 
chemotherapy which must be documented and approved by [CONTACT_170128]
 De novo or secondary AML according to the World Health Organization ( WHO ) 2008 classification ;
(post myelodysplastic syndrome [MDS] or myeloproliferative neoplasm [MPN] or after 
leukemogenic chemotherapy),
 Previously untreated AML (except emergency leukopheresis and/or hydroxyurea during the 
screening phase to control hyperleukoc ytosis but must bediscontinued at least one day prior to start 
of study therapy ;
 Not eligible for an allogeneic hematopoietic stem cell transplantation,
 Eastern Cooperative Oncology Group (ECOG) Performance Status score of ≤ 2
DOSAGE AND ADMINISTRATION
Part A
InPart A, 6 subjects will receive 1 dose of talacotuzumab at 9mg/kg on Day 1as a 180-minute IV 
infusion. Dose -limiting toxicities (DLTs) will be assessed during the DLT evaluation period which is 
Cycle 1 (14 days).If no DLTs are observed or are observed in 1 of the 6 subjects, the dose of 9mg/kg 
talacotuzumab may be established as the RP 2D by [CONTACT_66859].If DLTs are observed in ≥2 of the 6 subjects, 
Part A may continue with additional enrollment of 3 to 6 subjects at a lower dose level of talac otuzumab
to be determined by [CONTACT_66859]. All subjects will receive premedication with hydrocortisone or equivalent 
IV steroid to prevent infusion reactions. After completion of Cycle 1, all subjects in Part A will then start 
subsequent cycles ofcombination t herapy of decitabine + talacotuzumab .
Part B
In Part B of the study , subjects in the decitabine plus talacotuzumab arm will receive talacotuzumab IV at 
the RP2D over approximately 180minutes. Talacotuzumab will be administered on Days 8 and 22. 
Decitabine will be administered at 20mg/m2as a 1 -hour IV infusion for 5 consecutive days (Days 1 to 5)
every 28 days (1 treatment cycle)to subjects in both treatment arms .During the first 4 treatment cycles, 
all subjects in the decitabine + talacotuzumab arm must receive premedication with dexamethasone, 
methylprednisolone , acetaminophen (paracetomol), cimetidine, diphenhydramine, and montelukast prior 
to talacotuzumab dosing to prevent infusion -related reactions. If no infusion -related reactions are seen for 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
25
Status: Approved, Date: [ADDRESS_199057] 4 cycles, then premedication may be modified by [CONTACT_170129] 5 and subsequent talacotuzumab treatments. In the event an 
infusion- related reaction (independent of severity ) occurs in Cycle 5 and subsequent talacotuzumab
treatments, premedication sneed to be reintroduced.
Subjects in the decitabine only arm will receive the 5-Day decitabine dosing regimen (20mg/m2as a 
1-hour IV infusion for 5 consecutive days every 28 days) alone .
EFFICACY EVALUATIONS
Disease evaluations will include peripheral blood assessments ,bone marrow assessments , and clinical 
presentation . Disease status will be evaluated according to Response Criteria in AML with modifications 
for treatment failure. Survival status andsubsequent anticancer therapy will also be collected. Blood 
samples will also be collected to assess pharmacokinetics, immunogenicity, pharmacodynamics, MRD, 
and biomarkers.
Following Amendment 6, which incorporated the IDMC’s recommendations toclose enrollment to the 
study and discontinue talacotuzumab treatment for subjects receiving talacotuzumab + decitabine and 
offer tocontinue decitabine alone , all subjects will continue to be followed for survival and subsequent 
anti-cancer therapy. During the treatment phase with decitabine, subjects will be monitored for serious 
adverse events.
Following Amendment [ADDRESS_199058] is enrolled
(whichever occurs first) ,follow up ofsubjects and data collection will end. Subjects who are continuing 
to derive benefit from decitabine treatment as assessed by [CONTACT_170130]; during this period, only serious adverse events will be monitored and entered into the 
Company safety repository .
SAFETY EVALUATIONS
Safety evaluations will include adverse event monitoring, vital signs measurements , physical 
examinations, electrocardiograms ,clinical laboratory parameters (hematology and chemistry), and ECOG 
performance s tatus. Other malignancies will also be recorded. 
In addition, a safety review by [CONTACT_170131] n approximately 
20 subjects (10 subjects from each arm) have been enrolled in Part B and followed for at l east 1 month to 
assess the safety and tolerability of the combination treatment. This review will also include all safety, 
PK, and PD data available from Part A.
Following Amendment 6, which incorporated the IDMC’s recommendations toclose enrollment to the 
study and discontinue talacotuzumab treatment for subjects receiving talacotuzumab + decitabine and 
offer tocontinue decitabine alone , all subjects will continue to be followed for survival and subsequent 
anti-cancer therapy. During the treatment phase with decitabine, subjects will be monitored for serious 
adverse events.
Following Amendment [ADDRESS_199059] is enrolled
(whichever occurs first) ,follow up of subjects and data collection will end. Subjects who are continuing 
to derive benefit from decitabine treatment as assessed by [CONTACT_170130]; during this period, only serious adverse events will be monitored and entered into the 
Company safety repository .
STA TISTICAL METHODS
Approximately 6subjects will be enrolled in Part A of the study in order to confirm the recommended 
dose of talacotuzumab for Part B.The SET consisting of selected investigators, sponsor medical 
monitors, the sponsor’s statistician, and the sponsor’s clinical pharmacologist, will review all available 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
26
Status: Approved, Date: 31 October 2017   data upon completion of the 14-day period followin g 9 mg/kgtalacotuzumab treatment (Cycle 1) to 
determine DLTs, if the dose is acceptable, and subsequently, will confirm the RP2D. If no DLTs are 
observed or are observed for 1 of the 6 subjects, the dose of 9 mg/kg talacotuzumab may be established as 
the RP2D by [CONTACT_66859]. If DLTs are observed in ≥2 of the 6 subjects, Part A may continue with additional 
enrollment of 3 to 6 subjects at a lower dose level of talacotuzumab to be determined by [CONTACT_66859].
Additionally, the SET will review accumulated safety data from Part A prior to the initiation of Part B .
Part B of the study includes an interim analysis based on response rates of CR and CR+CRi that will 
occur after approximately 80 subjects (40 subjects per arm) have been randomized and followed for at 
least 4 m onths. The results of this interim analysis will be used to guide if the study contin ues enrollment 
to the prespecified 400 subjects or stops enrollment .Enrollment will continue during the interim analysis; 
it is estimated that approximately [ADDRESS_199060] interim analysis are available. 
The statistical criteria to guide the decision making will be based on the difference (Δ)in response rate 
between the 2 treatment arms (decitabine + talacotuz umab minus decitabine alone) as the following:
 If ΔCR ≥15% or Δ(CR+CRi) ≥25 %, then the study may continue enrollment to 400 subjects
 If ΔCR <15% and Δ(CR+CRi) <25%, then the study maystop enrollment at approximately 
120subjects
Event -free survival and all available safety, PK, PD,MRD, and biomarker data will also be reviewed at 
the time of this interim analysis. The final decision to continue enrollment will be based on the totality of 
the data and other development considerations.
If the study continu es enrollment to 400 subjects, then the overall Type 1 error of 0.05 (2-sided) will be 
allocated between the primary endpoints of CR rate and OS using a gate-keepi[INVESTIGATOR_170085]:
 There will be a formal statistical testing for superiority for CR at the interim analysis of 80 subjects 
with 2 -sided α=0.001. T he final analysis of CR (in terms of form al statistical hypothesis testing ) will 
take place [ADDRESS_199061] been randomized (to occur at the same time as the first 
interim analysis of OS) with 2-sided α=0.009. The study and collection of response data continue 
after the final CR analysis regardless of the outcome of the analysis.
 Overall 2-sided α=0.04 for OS; and if the final analysis of CR achieves statistical significance, then 
α=0.009 allocated to CR can be reclaimed by [CONTACT_170132], ie, OS can be tested at the overall 
level of 0.049.
 The 2 interim analyses and final analysis for OS will utilize the O’Brien -Flem ing α-spending  
procedure.
If the study continues enroll ment to [ADDRESS_199062] occurred . Enrollment was terminated after Interim Analysis #[ADDRESS_199063] are provided in 
Section 11.2.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
27
Status: Approved, Date: 31 October 2017   TIME A NDEVENTS SCHEDULE –TABLE 1A [PART A]
Procedure (Part A) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before Day 1Cycle 1
(14 days)Day 1 of each 
subsequent cycle
(28 days) unless 
otherwise notedEOT Every 3 months ( 7days)
NOTE :The EOT Visit should occur w ithin 30 days ( 7days) of last dose for subjects. The Follow -up Phase will continue until death, loss to follow -up, consent 
withdrawal for study participation, or study end, whichever occurs first.
Screening/Administrative
Informed consent ICF must be signed before any 
study -related proceduresX
Dem ography/medical history X
Eligibility criteria Minimum criteria for the 
availability of documentation 
supporting the eligibility criteria are 
described in Section 17.4, Source 
Documentation. Check clinical 
status again before first dose of 
study medication.X
Study Drug Administration (for details see also Section 6)
Decitabine Days 1, 2, 3, [ADDRESS_199064] be assessed within 48 hrs of 
Day 1 of each specified cycleX X X X
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
28
Status: Approved, Date: 31 October 2017   Procedure (Part A) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before Day 1Cycle 1
(14 days)Day 1 of each 
subsequent cycle
(28 days) unless 
otherwise notedEOT Every 3 months ( 7days)
Vital signs Temperature, blood pressure (BP) 
and heart rate (HR) will be assessed 
prior to each study treatment dosing;
On talacotuzumab dosing days 
BP/HR are measured pre-dose and 
every [ADDRESS_199065]-infusion up to 1.5 hr 
after the infusion; as clinically 
indicated .X X X X
Weight Must be assessed prior to dosing on 
Day 1 of each specified cycle, in 
case of weight loss of >10% within 
a cycle, the dose of study drug must 
be recalculatedX X X X
Height X
LVEF MUGA scan is preferred. 
Echocardiogram can be used if MUGA 
is not available.X as clinically indicated
ECG QTcF will be assessed at the time of 
screening. If QTcF is >470 msec, 
repeat ECG 2 additional times 
approximately 3 –[ADDRESS_199066] ion8for detailed 
instructions; includ estransfusion 
requirements Continuous from the time of signing of ICF until [ADDRESS_199067] 
study drug doseConcomitant medications 
for related AEs of Grade ≥3 
and SAEs regardless of 
relationship only;
subsequent anticancer
therapy
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
29
Status: Approved, Date: 31 October 2017   Procedure (Part A) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before Day 1Cycle 1
(14 days)Day 1 of each 
subsequent cycle
(28 days) unless 
otherwise notedEOT Every 3 months ( 7days)
Adverse events See Section 12for detailed 
instructions.Continuous from the time of signing of ICF until [ADDRESS_199068] study drugRelated AEs of Grade 3 
and related SAEs; follow 
until resolution
Patient -reported outcom es
FACT -Leu PROs should be performed on Day 
[ADDRESS_199069] the following parameters 
(hem oglobin, platelet count, WBC,
monocytes, basophils, eosinophils,
absolute neutrophil count, absolute 
lymphocyte count , and peripheral 
blasts ) must be assessed within 48 
hrs of the indicated days of each 
cycle and results reviewed prior to 
dosing .X Day 1 Days 1, 8 and 22 X
Coagulation panel aPTT, INR or prothrombin time 
(PT) must be assessed at screening 
and as clinically indicatedX
Clinical chemistry At least the following parameters 
(AST, ALT, sodium, potassium, 
magnesium, BUN, phosphate, uric 
acid, calcium, alkaline phosphatase, 
creatinine, LDH, total bilirubin) 
must be assessed within 48 hrs of 
Day 1 of each cycle and results 
reviewed prior to starting the cycle.X X X X
HBV surface antigen and 
hepatitis C (antibodies)X
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
30
Status: Approved, Date: 31 October 2017   Procedure (Part A) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before Day 1Cycle 1
(14 days)Day 1 of each 
subsequent cycle
(28 days) unless 
otherwise notedEOT Every 3 months ( 7days)
Serum β -hCG or urine 
pregnancy testFor w omen of childbearing potential 
onlyX Only if clinically indicated
Disease Evaluations : Every effort should be made to conduct disease evaluations as per schedule (window  ±7days). Refer to Section 9.2for details on efficacy 
evaluations
Bone marrow  aspi[INVESTIGATOR_337]/biopsyBone marrow  diagnostic block 
required at screening from historic 
sampleX
Disease status evaluation XAt time of 
suspected 
treatment 
failureAt Cycle 5
(betw een Day 14 
to 28)
At time of 
suspected 
CR /CRi
At time of
suspected
treatment failure
orrelapse from 
CR/CRiX (unless 
done w ithin 
2 weeks)
ImagingPer local standard of care and as 
clinically indicated. Report the 
disease assessment for AML related 
abnormalities including all sites of 
extramedullary diseaseXRepeat as clinically indicated per local standards. If 
extramedullary disease at baseline, repeat imaging (using the 
same modality) at time of best response 
Survival, subsequent 
therapy, other malignanciesX
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
31
Status: Approved, Date: 31 October 2017   Procedure (Part A) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before Day 1Cycle 1
(14 days)Day 1 of each 
subsequent cycle
(28 days) unless 
otherwise notedEOT Every 3 months ( 7days)
Pharm acokinetic, Pharm acodynamic, and Biom arker Assessments see TIME AND EVENTS SCHEDULE (PK A ND BIOMARKERS) –TABLE 2A
Abbreviations: AE=adverse event; ALT= alanine aminotransferase; AML=acute myeloid leukemia; AST= aspartate aminotransferase; β-hCG=beta human chorionic 
gonadotropin; BP=blood pressure; BUN= blood urea nitrogen; CR= complete response; CRi= complete response with incomplete blood cell count recovery;
ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; EOT=end of treatment; EQ=EuroQol; F/U= follo w-up; HBV: hepatitis B virus; HR=heart rate; 
ICF=informed consent form; INR= international normalized ratio; LDH= lactate dehydrogenase; LVEF= left ventricular ejection fraction; MUGA= Multi Gated 
Acquisition Scan ;NK= natural killer (cells); PD=pharmacodynamics(s); PK=pharmacokinetic(s); PRO= patient -reported outcomes; PT= prothrombin time; aPTT= 
partial thromboplastin time; SAE=serious adverse event; T&E=Time & Events; WBC= white blood cell.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
32
Status: Approved, Date: 31 October 2017   TIME A NDEVENTS SCHEDULE –TABLE 1B [PA RT B] UP TO AND INCLUDING AME NDMENT 5
Procedure (Part B) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before 
randomization Day 1 of each cycle (± 48 hours) 
unless otherwise indicated
(each cycle = 28 days)EOTEvery 3 months 
(7days)
NOTE :The EOT Visit should occur w ithin 30 days ( 7days) of last dose for subjects. The Follow -up Phase will continue until death, loss to follow -up, consent 
withdrawal for study participation, or study end, whichever occurs first.
Screening/Administrative
Informed consent ICF must be signed before any study -related procedures X
Dem ography/
medical historyX
Eligibility criteria Minimum criteria for the availability of documentation 
supporting the eligibility criteria are described in 
Section 17.4, Source Documentation. Sponsor review 
of key eligibility and approval is required prior to 
randomization. Check clinical status again before first 
dose of study medication.X
Study Drug Administration (for details see also S ection 6)
Randomization Within [ADDRESS_199070] dose X
Decitabine Days 1, 2, 3, 4 ,and 5
Talacotuzumab Subjects randomized to Arm 1 Days 8 and 22 (± 24 hours)
Safety Assessments
Physical examination Must be assessed within [ADDRESS_199071] be assessed within 3 days of Day 1 of each 
specified cycleX X X
Vital signs Temperature, blood pressure (BP) and heart rate (HR) 
will be assessed prior to each study treatment dosing 
On talacotuzumab dosing days BP/HR are 
measured pre-dose and every [ADDRESS_199072]-infusion up to 1.5 hr 
after the infusion X X X
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
33
Status: Approved, Date: 31 October 2017   Procedure (Part B) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before 
randomization Day 1 of each cycle (± 48 hours) 
unless otherwise indicated
(each cycle = 28 days)EOTEvery 3 months 
(7days)
Weight Must be assessed within 3 days prior to dosing on Day 
1 of each specified cycle, in case of weight loss of 
>10% w ithin a cycle, the dose of study drug must be 
recalculatedX X X
Height X
LVEF MUGA scan is preferred. Echocardiogram can be used 
if MUGA is not available.X as clinically indicated X
ECG QTcF will be asse ssed at the time of screening. If 
QTcF is >470 msec, repeat ECG 2 additional times 
approximately 3 –[ADDRESS_199073] ion 8for detailed instructions; Includes
transfusion requirements
Continuous from the time of signing of ICF until [ADDRESS_199074] study drug doseConcomitant 
medications for 
related AEs of 
Grade 3 and 
SAEs regardless 
of relationship ;
subsequent 
anticancer therapy
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
34
Status: Approved, Date: 31 October 2017   Procedure (Part B) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before 
randomization Day 1 of each cycle (± 48 hours) 
unless otherwise indicated
(each cycle = 28 days)EOTEvery 3 months 
(7days)
Adverse events See Section 12for detailed instructions.
Continuous from the time of signing of ICF until [ADDRESS_199075] study drugRelated AEs of 
Grade  3 and
related SAEs; 
follow  until 
resolution
Medical resource 
utilizationInformation on all health care needs during treatment 
(eg, physiotherapi[INVESTIGATOR_541]) to be collectedContinuous from the time of signing of the ICF until [ADDRESS_199076] the following parameters ( hemoglobin, platelet 
count, absolute WBC count, absolute monocyte count, 
absolute basophil count ,absolute eosinophil count
absolute neutrophil count, absolute lymphocyte count , 
and peripheral blast count) must be assessed within 
3days of the indicated days of each cycle and results 
reviewed prior to starting dosing if applicable.X Days 1, 8, and 22 X
Coagulation panel aPTT, INR or prothrombin time (PT) must be assessed 
at screening and as clinically indicated afterwardX
Clinical chemistry At least the following param eters (AST, ALT, sodium, 
potassium, magnesium, BUN, phosphate, uric acid, 
calcium, alkaline phosphatase, creatinine, total 
bilirubin ) must be assessed within 3 days of Day 1 of 
each cycle and results reviewed prior to starting the 
cycle.X X X
Assessment for active 
hepatitis or history of 
HIVX
Serum β -hCG or urine 
pregnancy testFor w omen of childbearing potential onlyX Only if clinically indicated
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
35
Status: Approved, Date: 31 October 2017   Procedure (Part B) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before 
randomization Day 1 of each cycle (± 48 hours) 
unless otherwise indicated
(each cycle = 28 days)EOTEvery 3 months 
(7days)
Disease Evaluations : A +/- 7-day window exists for completion of disease evaluation visits. Refer to Section 9.2for details on efficacy evaluations
Bone marrow  
aspi[INVESTIGATOR_337]/biopsy A portion of each sample should be sent to the central 
lab for confirmation of disease status. A portion of the 
aspi[INVESTIGATOR_170086], at suspected CR/CRi, 
then every diseas e assessment until relapse or EOT.
Blood samples at matching time points will be taken 
for biomarker evaluations (CD123 expression, 
genomic characterization, and immunophenotypi[INVESTIGATOR_007]).
Molecular genetics and cytogenetics samples analyzed 
per the local stand ard of care at screening, at suspected 
CR/CRi and  then every disease assessment until 
relapse or EOTX (A biopsy 
can be used for 
confirmation of 
disease if taken 
within [ADDRESS_199077] and 
biomarker 
analysis .)Every 2 Cycles starting at 
Cycle 2 (betw een Day 14
and28)until treatment 
failure or relapse from 
CR/CRi or CCO
At time of suspected CR 
/CRi
At time of suspected 
treatment failure or 
relapse from CR/ CRiX 
(unless done 
within 2 
weeks)
ImagingPer local standard of care and as clinically indicated.
Report the disease assessment for AML related 
abnormalities including all sites of extramedullary 
diseaseXTo repeat as clinically indicated per local standards. If 
extramedullary di sease at baseline, repeat imaging (using the same 
modality) at time of best response 
Disease evaluation Disease evaluation should be done based on 
information available; hematology, clinical 
presentation and bone marrow assessments.  Every 2 Cycles starting 
at Cycle 2 (betw een Day 
14 and 28)until treatment 
failure or relapse from 
CR/CRi or CCO
At time of suspected CR 
/CRi
At time of suspected 
treatment failure or 
relapse from CR/ CRiX
Survival, subsequent 
therapy, other 
malignanciesX
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
36
Status: Approved, Date: 31 October 2017   Procedure (Part B) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before 
randomization Day 1 of each cycle (± 48 hours) 
unless otherwise indicated
(each cycle = 28 days)EOTEvery 3 months 
(7days)
Pharm acokinetic, Pharm acodynamic, and Biom arker Assessments see TIME AND EVENTS SCHEDULE (PK AND BIOMARKERS) –TABLE 2B
Abbreviations: AE=adverse event; ALT= alanine aminotransferase; AML=acute myeloid leukemia; ANC= absolute neutrophil count; AST= aspartate aminotransferase; 
β-hCG=beta human chorionic gonadotropin; CCO=clinical cut -off; CR= complete response; CRi= complete response with incomplete blood count recovery; BP=blood 
pressure; BUN= blood urea nitrogen ;ECG=electrocardiogram; ECOG=Eastern Cooperative Oncology Group; EOT=end of treatment; EQ=EuroQol; HBV: hepatitis B 
virus; HR=heart rate; ICF=informed consent form; INR= international normalized ratio ; LDH= lactate dehydrogenase; LVEF= left ventricular ej ection fraction; MRD= 
minimal residual disease; MUGA= multi gated acquisition scan; NK= natural killer (cells); PD=pharmacodynamics(s); PK=pharmacokinetic(s); PT= prothrombin time; 
aPTT= p artial thromboplastin time ;SAE=serious adverse event; T&E=Time & Ev ents; WBC= white blood cell .
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
37
Status: Approved, Date: 31 October 2017   TIME A NDEVENTS SCHEDULE –TABLE 1C[PART B] DURING AMENDMENT 6
Procedure (Part B) NotesScreening 
PhaseOpen -Label Treatment Phase Follow -up Phase
Within 28 days 
before 
randomization Day 1 ofeach cycle (± 48 hours) 
unless otherwise indicated
(each cycle = 28 days)EOTEvery 2 months 
(7days)
NOTE Following Amendment 6, which incorporated the IDMC ’s recommendations toclose enrollment to the study and discontinue talacotuzumab 
treatment for subjects receiving talacotuzumab + decitabine and offer tocontinue decitabine alone , all subjects will continue to be followed for survival 
and subsequent anti -cancer therapy. During the treatment phase with decitabine, subjects will be monitored for serious adverse events.
Serious adverse events Follow  until resolution X
Survival, subsequent 
therapyX X X
EOT= end -of-Treatm ent; IDMC= Independent Data Monitoring Committee
TIME A NDEVENTS SCHEDULE –TABLE 1D [PA RT B] FOLLOWIN G AMENDMENT 7
Procedure (Part B)
NOTE Following Amendment [ADDRESS_199078] is enrolled (whichever occurs first) , follow up of 
subjects and data collection will end. Subjects who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170133]; during this period, only serious adverse events will be monito red and entered into the Company safety repository .
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
38
Status: Approved, Date: 31 October 2017   TIME A NDEVENTS SCHEDULE (PK A ND BIOMA RKERS) –TABLE 2A [PART A]
PART ACycle 1 Cycle 2 Cycles 3 and 5 EOT1
Talacotuzumab alone Decitabine + Talacotuzumab
Day 1 Day 2 Day 3 Day 4 Day 8 Day 1 Day 8
predose 30 min 
after end 
of infusion24 hour
postdose 48 hour
postdose 72 hour
postdose 168 hours 
postdosepredoseTalacotuzumab
predose
Talacotuzumab PK sample2X X3X X X X X X X
Immunogenicity Evaluation2, 4X X X
PD/RO/biomarker sample (blood)5X X X X X X X
Notes: EOT= End -of-Treatm ent (up to 30 days (+/-7 days) after last dose of any study drug) Visit ;PD= pharmacodynamics; 
PK= pharmacokinetics; RO= receptor (CD123) occupancy
1The End -of-Treatment visit is after combination treatment. 
2For subjects who experience a talacotuzumab infusion reaction, if possible, an unscheduled PK/immunogenicity sample should be drawn as soon as possible after the reaction.
3In the case that the talacotuzumab infusion is terminated before all the drug is administered, an additional PK sample will be taken immediately after the infusion is stopped.
4An aliquot from the talacotuzumab PK sample will be used to assess immunogenicity . 
5 Including assessment of NK cell activity by [CONTACT_4133]
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
39
Status: Approved, Date: 31 October 2017   TIME AND EVENTS SCHE DULE (PK AND BIOMA RKERS) –TABLE 2 B[PART B]UP TO A ND INCLUDING AMENDMENT [ADDRESS_199079] 
Follow 
Up
Day 1 Day 5 Day 8 Day 9 Day 22 Day 23 Day 1 Day 8 Day 9
decitabine talacotuzumab
Predose Predose5 minutes 
prior to
end of 
infusion1 hour after 
end of 
infusionPredose 30 min 
after end 
of 
infusion24 hour 
postdose Predose 
(14d post 1st 
dose)24hr post 
2nd dose Predose 
decitabinePredose 
talacotuzuma
b
Decitabine PK X1X1X1
Talacotuzumab PK 
sample,2,3 X4X X5X1X X1X1X X X
Immunogenicity 
Evaluation2,3,6 X X X X
PD/RO sample 
(blood)X X X1,2X2X1,2X1,2X2X
Biomarker sample 
for Methylation/ 
GEP (blood)X X X X X
Cytokine sample 
(blood): Cycles 1 
and 2 only7XCycle 1 
only: at 
end of 
infusion 
and 2 hrs 
after (30 
min 
collection 
is not 
taken)X
Cycle 1 
only (if 
feasible)Xandat end 
of infusion 
and 2hrs 
afterX (if 
feasible)
Notes: EOT= End of Treatment; GEP= gene expression profiling; PD= pharmacodynamics; PK= pharmacokinetics; RO= receptor occupancy
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
40
Status: Approved, Date: [ADDRESS_199080] 120 subjects only
2 Decitabine + talacotuzumab arm only.
3For subjects who experience a talacotuzumab infusion -related reaction, if possible, an unscheduled PK/immunogenicity sampleshould be drawn as soon as po ssible after the reaction.
4Cycle [ADDRESS_199081] ion and another approximately 
1day later, if feasible.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
41
Status: Approved, Date: [ADDRESS_199082] aspartate transaminase
AUC area under the concentration -time curve 
β-HCG beta human chorionic gonadotropin
BP blood pressure
BUN blood urea nitrogen
CI confidence intervals
CL total systemic clearance of drug after IV administration
Cmax maximum observed concentration
Cmin minimum observed concentration
CR complete response/remission
CRi complete response with incomplete recovery
CRp Com plete response with incomplete platelet recovery
CTCAE Common Terminology Criteria for Adverse Events
DLT dose- limiting toxicity
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
eDC electronic data capture
EFS event -free survival
EOT end-of-treatment
EQ EuroQol
EU European Union
FFPE formalin -fixed paraffin -embedded
FLT3 -ITD FLT3 -Internal Tandem Duplication
F/U follow -up
GCP Good Clinical Practice
HBsAg hepatitis B surface antigen
HIV human immunodeficiency virus
HBV hepatitis B virus
HR heart rate
HSC hematopoietic stem cells
HSCT hematopoietic stem cell transplantation
ICF informed consent form
ICH International Conference on Harm onization
IEC Independent Ethics Committee
IHC Immunohistochemistry
IL-[ADDRESS_199083] minimal residual disease 
MRU medical resource utilization
MUGA multi -gated acquisition scan
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
42
Status: Approved, Date: 31 October 2017   NCCN National Comprehensive Cancer Netw ork
NCI National Cancer Institute
NK natural killer (cells)
NPM Nucleophosmin
ORR overall response rate
OS overall survival
PD Pharmacodynamics
pDC plasmacytoid dendritic cell
PK Pharmacokinetics
PQC Product Quality Complaint
PRO patient -reported outcomes
PT prothrombin time
Q2W every 2 weeks
RFS relapse- free survival
RO receptor occupancy
RP2D recommended Phase2 dose
RT-PCR reverse transcriptase –polymerase chain reaction
SAE serious adverse event
SET Study Evaluation T eam
SNP single nucleotide polymorphism
T&E Time and Events (Tables)
WBC white blood cells
WHO World Health Organization
βc beta common
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
43
Status: Approved, Date: 31 October 2017   1. INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by [CONTACT_170134].26As the second most common form of leukemi a, 
AML  accounts for the largest number of annual deaths from leukemia. This poor prognosis is in 
part due to the fact that AML  affects patients at a more advanced median age of 67years with a 
third of patients diagnosed at an age of over 75 years.26,28Advanced age associated with 
comorbidities, concomitant end-organ dysfunction, and poor performance status severel y limits 
tolerance to cytotoxic chemotherap y. In addition, the biology  of AML in the elderly  also 
contributes to the poor therapeutic outcome. In older patients, AML  arises more frequentl y from 
an overt or unrecognized myelodysplastic syndrome (MDS), and appears to be associated with 
complex , monosomal , or combination karyotypes, adverse cytogenetics, as well as a multidrug 
resistant phenoty pe.25Although these patients may respond to chemotherap y,increased 
drug-related deaths offset clinical benefit.20As a consequence, major therapeutic advances 
associated with intensification of chemotherapi[INVESTIGATOR_170087]. In contrast, the choice of more effective treatment options for the 
majority  of elderl y patients has remained very limited. In recent years, the hypomethy lating 
agent decitabine (formulated product, DACOGEN®) has emerged as one of the preferred 
therapi[INVESTIGATOR_170088] y.5,25Decitabine promotes cellular differentiation by [CONTACT_170135][INVESTIGATOR_170089], thus inducing durable response s in a subset of patients with 
AML . In a Phase 3study ,DACOGEN demonstrated a higher rate of complete responses (CRs) 
compared to the standard of care therapy  of low-dose cytarabine ( 17.8% versus 7.8% ).21Given 
thewell described and predictable safety  profile, multiple clinical studies are currentl yunderway  
to improve the efficacy  of decitabine in AML patients in novel combination regimens. 
In this Phase 2/3study ,the safet y and clinical efficacy  of a combination of decitabine with the 
novel, therapeutic antibody  talacotuzumab, directed against the α-subunit of the interleukine -3 
receptor (CD123) overexpressed on leukemic blast sand leukemic stem cells (LSCs) ,will be 
explored in patients with previously untreated AML  who are not eligible for intense induction 
chemotherap y.
For the most comprehensive nonclinical and clinical information regarding talacotuzumab and 
decitabine, refer to the latest version of the Inves tigator's Brochure and Addenda.15,16The term 
"sponsor" used throughout this document refers to the entities listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
44
Status: Approved, Date: 31 October 2017   1.1. Talacotuzumab (JNJ-56022473; CSL362 ): Second Generation A nti-CD123 
Antibody
Acute myeloid leukemia is a disorder of early  hematopoietic progenitor cells, characterized by 
[CONTACT_170136], clonal, myeloid cells. Constitutive 
overexpression of theα-subunit of the interleukin -3 receptor ie,IL-3Risa hallmark of the 
early AML progenitor cell population (ie,leukemic stem cells) as well as leukemic blasts. 
CD123 is unique to the IL-3 receptor and is responsible for the high specificity  and low affinity 
binding of IL-3. Upon ligand binding, the α-subu nit CD123 associates with the βc-subunit 
(CD131) to form a high-affinit y receptor complex initiating an intracellular signaling cascade 
through phosphory lation and activation of at least [ADDRESS_199084] s:the 
JAK/STAT -kinase, MAP -kinase-, and PI3-kinase -pathway s. Under physiological conditions, 
activation of the IL- 3 receptor induces proliferative, anti -apoptotic, and differentiat ingsignals.12
Talacotuzumab (JNJ-56022473; CSL362)is a second generation antibody  developed from the 
murine 7G3 anti-CD123 monoclonal antibody  (mAb) in a stepwise process of humanization, 
affinity  maturation ,and Fc engineering. To enhance the cytotoxi city of the first-generation 
antibody  CSL360,the proprietary  Xencor (Xmab®) technology  was applied and two amino acid 
mutations (S239D and I332E) were introduced into the Fc region.16These amino acid 
substitutions led to improved binding to CD16 (FcγRIIIa) on natural killer (NK) cells and 
significantl y enhanced the ability  to induce antibody -dependent cell-mediated cytotoxicity  
(ADCC).[ADDRESS_199085] similarly  in biophy sical, biochemical, and preclinical 
assessments. The primar y structure, charge heterogeneity , size heterogeneity , purity , higher order 
structure, and process impurities were found to be highly  similar between CSL-362 and 
talacotuzumab. Pharmacody namic (PD) studies in cynomolgus monkey s showed similar levels 
of biological activity  between CSL362 and talacotuzumab (ie, basophil and pDC depletion; NK 
cell number and activity ). Additionall y, the PK profiles of talacotuzumab following 30 and 
100mg/kg IV dosing of cynomolgus monkey s are highl y similar to those of CSL362. Following 
the first weekl y IV dose, mean Cmaxand AUC 0-167hof talacotuzumab are 91% and 94% of those 
observed for CSL 362, respectively . 
1.2. CSL362 Phase 1 Experience
CSL362 entered clinical development in 2012 in the ongoing study (CSL CT-AML -11-73 ;
[STUDY_ID_REMOVED]) entitled “A Phase 1 Study  of CSL362 (Anti -IL3Rα/Anti -CD123 Monoclonal 
Antibody ) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or 
Complete Remission with I ncomplete Platelet Recovery  at High Risk for Earl y Relapse.” 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
45
Status: Approved, Date: 31 October 2017   Desig n, Objectives: The study  follows a 3+3 dose escalation design. The primary  and secondary  
objectives are to evaluate the safety , pharmacokinetics, and immunogenicity  of repeat eddoses of 
CSL362 inAML  patients in CR. Exploratory endpoints include CSL362 effects on 1) 
CD123- expressing normal blood cells (basophils and plasmacy toid dendritic cells [pDCs ], NK 
cells), 2)levels of serum cytokines, 3) binding to CD123 on monocy tes, as well as 4) changes in 
the status of minimal residual disease ( MRD )measured by  [CONTACT_170137] -PCR.
Study Therapy: The study  therap y consists of IV CSL362 a ntibody infusion given every 
14days for 6 doses over a total treatment period of 12 weeks. The final evaluation for safety  is 
conducted at Study  Week16.As of a data cutof f of 28 January  2015, 27subjects had been 
enrolled and dosed.
Safety: The most frequent adverse event was severe infusion- related reaction characterized by
[CONTACT_134974], nausea, vomiting, pain, headache, dizziness, breathlessness, chest pain, low or 
high blood pressure, rash, itchiness or weakness. The majorit y of these infusion -related reactions 
were observed in the first 2 dose cohorts (0.3 mg/kg and 1mg/kg) in which premedication with 
hydrocortisone was not used. After mandatory  pre-medication (including corticosteroids, see
Section 6.3.2 ) was instituted and the infusion time was extended , no additional adverse events of 
severe infusion-related reaction were observed from the third cohort (0.75 mg/kg) onward up to 
the highest dose (9 mg/kg) given to date. A cohort exploring the safet y of 12 mg/kg of CSL362
is underway . 
For the 27subjects treated with CSL362 as of the data cutoff of [ADDRESS_199086] 
frequentl y reported ( ≥2subjects) adverse events are summarized in Table 1 .
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
46
Status: Approved, Date: 31 October 2017   Table 1: Treatment -Emergent Adverse Events Occurring in [ADDRESS_199087] -AML -11-73
Number of Subjects (%)
CSL-362
0.3 mg/kg
(N=6)
n (%)CSL-362
0.75 mg/kg
(N=3)
n (%)CSL-362
1.0 mg/kg
(N=6)
n (%)CSL-362
3.0 mg/kg
(N=3)
n (%)CSL-362
9.0 mg/kg
(N=9)
n (%)CSL-362
Overall
(N=27)
n (%)
Infusion -related 
reaction6 (100) 2 (66.7) 3 (50.0) 0 5 (55.6) 16 (59.3)
Headache 4 (66.7) 1 (33.3) 3 (50.0) 1 (33.3) 2 (22.2) 11 (40.7)
AML Recurrent 1 (16.7) 2 (66.7) 1 (16.7) 0 4 (44.4) 8 (29.6)
Fatigue 1 (16.7) 2 (66.7) 2 (33.3) 0 2 (22.2) 7 (25.9)
Nausea 2 (33.3) 1 (33.3) 3 (50.0) 0 0 6 (22.2)
Chills 0 0 2 (33.3) 1 (33.3) 2 (22.2) 5 (18.5)
Dizziness 1 (16.7) 1 (33.3) 0 0 3 (33.3) 5 (18.5)
Pyrexia 0 0 1 (16.7) 0 3 (33.3) 4 (14.8)
Arthralgia 1 (16.7) 0 2 (33.3) 0 1 (11.1) 4 (14.8)
Hypotension 1 (16.7) 0 1 (16.7) 2 (66.7) 0 4 (14.8)
Vom iting 2 (33.3) 1 (33.3) 1 (16.7) 0 0 4 (14.8)
Diarrhea 0 0 2 (33.3) 0 2 (22.2) 4 (14.8)
Hypertension 2 (33.3) 0 1 (16.7) 0 0 3 (11.1)
Tachycardia 2 (33.3) 0 1 (16.7) 0 0 3 (11.1)
Constipation 0 1 (33.3) 1 (16.7) 0 1 (11.1) 3 (11.1)
Contusion 1 (16.7) 0 0 0 2 (22.2) 3 (11.1)
CRP Increased 0 0 1 (16.7) 1 (33.3) 1(11.1) 3 (11.1)
Neuropathy 
peripheral0 0 0 0 2 (22.2) 2 (7.4)
Chest discomfort 0 1 (33.3) 1 (16.7) 0 0 2 (7.4)
Chest pain 0 0 2 (33.3) 0 0 2 (7.4)
Oedem a peripheral 0 1 (33.3) 0 0 1 (11.1) 2 (7.4)
Blood urea increased 0 0 1 (16.7) 1 (33.3) 0 2 (7.4)
Neutrophil count 
decreased0 1 (33.3) 0 0 1(11.1) 2 (7.4)
Hyperglycaemia 1 (16.7) 0 0 1 (33.3) 0 2 (7.4)
Hypokalaemia 0 0 1(16.7) 1 (3.3) 0 2 (7.4)
Hypomagnesaemia 0 0 2 (33.3) 0 0 2 (7.4)
Nasopharyngitis 0 0 0 1 (33.3) 1 (11.1) 2 (7.4)
Upper respi[INVESTIGATOR_19629]0 1 (33.3) 0 0 1 (11.1) 2 (7.4)
Urinary tract 
infection0 0 1 (16.7) 0 1 (11.1) 2 (7.4)
Pain in extremity 0 1 (33.3) 0 0 1 (11.1) 2 (7.4)
Cough 0 0 0 1 (33.3) 1 (11.1) 2 (7.4)
Hypoxia 0 0 2 (33.3) 0 0 2 (7.4)
Thrombocytopenia 0 0 0 0 2 (22.2) 2 (7.4)
Data cutoff date: 28 January 2015
Source: CSLCT -AML-11-73 Interim report
The majority  of adverse events were Common Terminology  Criteria for Adverse Events 
(CTCAE )Grade [ADDRESS_199088] from the 0.3 mg/kgcohort was reported with Grade 3 
hypertension. The remaining subjects with drug-related adverse events were from the 1.0 mg/kg
cohort. One subject was reported with Grade [ADDRESS_199089] was reported with Grade 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
47
Status: Approved, Date: [ADDRESS_199090] to change.
Pharmacokinetics and Immunogenicity: Theserum CSL362 concentrat ionsappear to be dose 
proportional for doses ranging from 3 to 9 mg/kg. The terminal half-life determined after the 6th 
dose at 3 mg/kg was 4.7 day s and the accumulation index after every  2 weeks dosing was 1.7 for 
maximum observed concentration (Cmax) and 1.9 for the area under the curve (AUC). Low level 
anti-CSL362 antibody  titers were detected coincident with troug h concentrations of CSL362 in 
6of 18 subjects tested thus far, with no apparent effects on pharmacokinetics or association with 
adverse events. 
Pharmacodynamics and Biomarkers: Indicative of the specific mode -of-action, ADCC ,a 
rapid and complete in vivo depletion of CD123 -expressing basophils and pDCs in the peripheral 
blood wa s observed for up to 15 days at CSL362 doses ≥3mg/kg. Binding of CSL362 to CD123 
on monocy tes demonstrates rapid and sustained saturation over the 14-day inter-dosing interval 
at CSL 362 dose levels ≥3 mg/kg. 
1.2.1. Recommended Phase 2 Dose (RP2D) :
Based on PK, PD, and safet y data generated in the ongoing Phase 1 study , 9 mg/kg of CSL362 
every  14 dayshas been selected as the dose and regimen for Phase 2 based on the following 
considerations:
Adequate PK and consistent saturation of CD123 target receptors on surrogate monocytes, 
and desired concentration of CSL362 at all si tes of action, including bone marrow.
Based on preliminary  data from the Phase 1 study , PK/PD modeling revealed that the 
concentration of 3 µg/mL of serum CSL362 is the upper bound aryof the 90% CI of systemic 
concentration corresponding to at least 90% ta rget engagement on monocy tes.
While CD123 receptor occupancy  on monocy tes provides a convenient measure to monitor and 
characterize the PK/PD relationship in the peripheral compartment, it is important to note that a
keypharmacological target of CSL362 isin theleukemic stem cell niche in the bone marrow. 
Only a fraction of an antibody  dose (approximately  30%) is distributed to the bone marrow,1and
it is anticipated thatthePD effect may bereduced in the bone marrow at doses that completel y 
saturate peripheral targets. In addition, patients with active AML  may  also have higher leukemic 
blasts and higher levels of CD123 targets than the patient population in the Phase [ADDRESS_199091]-AML -11-73. Thus, higher systemic exposure may be required in order to ensure 
sustained target saturation throughout the dosing interval at the site of action.
Taking into consideration the serum CSL362 concentration of 3 µg/mL (which ensures 
peripheral target engagement and the limited biodistribution into the site of action), the desired 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
48
Status: Approved, Date: 31 October 2017   target serum concentration of CSL362 is projected to be 9 µg/ml, approxima tely 3 fold higher to 
ensure adequate and sustained exposure at the site of action. 
Based on simulations from a preliminary  population PK model, 9 mg/kg every  14 days is the 
selected dose/dosing regimen to achieve sustained exposure above 9 µg/mL throughout the 
dosing interval. 
Acceptable safety profile 
No DLT or AEs ≥Grade 3 related to CSL362 occurred in subjects dosed at 9 mg/kg every 
14days. Premedication with hydrocortisone and a prolongation of the infusion time to [ADDRESS_199092] Grade ≥ 3 infusion reactions. Since implementation of the protocol 
amendment to premedicate with hydrocortisone , no subjects treated at the 3 mg/kg or 9 mg/kg 
dose levels experienced a severe (Grade ≥ 3) infusion -related reaction. A cohort testing a higher 
dose of 12 mg/kg every  14 days is currently  open for enrollment in the Phase I trial 
(CSLCT-AML -11-73 ).In summary , 9 mg/kg every  [ADDRESS_199093] dose that provides adequate exposure and sustained target saturation at the site of action 
throughout the entire dosing interval.
1.3. DACOGEN (decitabine)
Decitabine (5 aza-2’-deoxy cytidine) has a unique molecular mode -of-action. As a deox ycytidine 
nucleoside analog decitabine is primarily  an inhibitor of DNA methy ltransferase interfering w ith 
cytosine methy lation in DNA.15At low doses decitabine induces a hypomethy lating effect when 
incorporated into DNA thus, reversing the aberrant epi[INVESTIGATOR_170090]. However, at higher doses decitabine may 
produce direct cy totoxic effects via DNA strand breaks.8These activities of decitabine have been 
shown to correlate with the re-expression of silenced genes,cellular differentiation as well as 
with the inhibition of cell growth and the induction of apoptosis.24
In a randomized Phase 2 study  comparing three dosing regimens, DACOGEN at a dose of 
20mg/m2per day infused IV over one hour on [ADDRESS_199094] clinical efficacy .19With this regimen the 
half-life of decitabine was determined to be approximately  30minutes and systemic
accumulation was not observed. In a randomized Phase 3 study  conducted in patients with newly 
diagnose d AML and poor-or intermediate -risk cytogen etics, DACOGEN given asthe 5-Day 
regimen demonstrated superior clinical efficacy  compared to a treatment choice of supportive 
care or low-dose cytosine arabinos ide.21Decitabine treatment resulted in significantl y improved 
rates of CRand CR without platelet recovery  (CRp) compared with treatment choice.26While 
the primary analysis for OSdemonstrated an advantage favoring decitabine (7.7 months versus
5months), which was however not statistically  significant (p=0.108), anunplanned analysis of 
more mature survival data reached statistica l significance (p=0.037) .26Based on the results of 
this Phase 3 study , DACOGEN was approved in the European Union (EU)and 21 other 
countries (as of November 2014 ) for the treatment of adult patients age ≥ 65 years with newly 
diagnosed de novo or secondary  acute myeloid leukemia (AML), who are not candidates for 
standard induction chemotherap y. In addition, in the [LOCATION_003] decitabine is a recommended 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
49
Status: Approved, Date: 31 October 2017   treatment option for AML  patients 60 years or older who are not candidates for intensive 
chemotherap y according tothe guidelines of the National Comprehensive Cancer Network.28
The adverse event profile of decitabine primarily includes myelosuppression (neutropenia, 
anemia, and thrombocy topenia) and consequences of myelosuppression (infections, fatigue, and 
febrile neutr openia) .Nonhematologic adverse events associated with decitabine include nausea, 
vomiting, diarrhea, stomatitis, and alopecia. Generall y these toxicities can be managed with 
supportive care measures, pharmacologic intervention, and dose adjustments. Speci fic 
information on the safety  of decitabine isoutlined in the prescribing information and can be 
found in the Investigator Brochure.[ADDRESS_199095] population of leukemic stem cells 
(ie,LSCs) residing in the bone marrow that are able to self -renew and to propagate into leukemic 
blasts.37In contrast to the highl y proliferative blast cells, the pool of LSCsis often not affected 
by [CONTACT_170138][INVESTIGATOR_170091] (i) persist in a quiescent G0 cell cycle 
phase and are not actively  dividing (ii) reside inthebone marrow microenvironment that 
provides protection against apoptosis, and (iii) overexpress the multidrug resistance protein that 
enhances drug efflux .[ADDRESS_199096] cells as well as the quiescent and resistant LSC pool in order to achieve higher 
rates of durable CRs and more importantly  longer disease -free- and overall survival (OS) . As an 
antimetabolite and hypomethy lating agent ,decitabine targets proliferating leukemic blast cells 
and is a recognized treatment option for the therapy  of patients with AML who are not eligible 
for intense chemotherap yor HSCT .Among different agents that may  be used to deplete the L SC 
pool and kill leukemia blasts, antibodies that are able to penetrate the bone marrow and are 
capable of eliciting a potent, cytotoxic immune response have the potential to improve clinical 
outcomes.11,29Effective targeting of the LSC pool is dependent on the ability  of the antibody  to 
specificall y ablate leukemic blasts and the population of LSCs without affecting the regeneratio n 
of normal hematop oietic stem cells.
Although the exact phenoty pes of CD34+/CD38 -AML  stem cells remain controversial, the 
constitutive over-express ionofthe CD123 antigen is common.11CD123 over-expression on 
LSCsis conserved on the emerging leukemic blast cells and constitutes a marker of poor clinical 
prognosis because of the association with (i) known adverse immune -phenoty pes such as FLT3 
internal tandem duplication (FLT3 -ITD) , (ii) a lower rate of complete response s following 
conventional chemotherapy  and (iii) shorter disease -free survival and overall survival 
(OS).10,34,36Levels of CD123 in normal hematopoietic stem cells and early hematopoietic 
progenitor cells areconsiderabl y lower than the overexpression found on LSCsand blasts in 
AML .10,17Results from the ongoing Phase [ADDRESS_199097] normal hematopoiesis.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
50
Status: Approved, Date: [ADDRESS_199098] been designed 
to supplement the biophy sical and preclinical toxicol ogy comparability  testing of the anti-CD123 
monoclonal antibody produced in different Chinese hamster ovary  cell lines; CSL362 was 
produced in the CHO -S cell line and used for the Phase 1 study while talacotuzumab was 
produced in GS-CHOK1SV cells and will be used for all subsequent clinical studies .Results 
from preclinical testing are provided in Section 1.1and the talacotuzumab (JNJ-56022473)
Investigator’s B rochure.16
The scientific rationale for theseamless Phase 2/3portion of this study (Part B)is that the
combination of decitabine and talacotuzumab may have a complimentary /synergistic effect on 
the leukemic cells. 
The complimentary  and as such more pronounced therapeutic efficacy of the combination 
regimen is expected to evolve from the different underly ing mechanisms of action and the 
different leukemic cell populations targeted by[CONTACT_170139]. Therap y with decitabine reverses 
the hypermethy lation -induced gene silencing and restores the proliferation control and the 
apoptosis sensitivity  in proliferating leukemic blast cells. Talacotuzumab has the potential to
elicit a direct immunotherapeutic effect against CD123 overexpressing quiescent LSCsand 
leukemic blasts through re-direction of NK-cells and induction of ADCC. These [ADDRESS_199099] non- overlappi[INVESTIGATOR_95607]; decitabine is primarily  myelosuppressive 
while the most frequent toxicity  from administration of talacotuzumab is infusion reactions.
Addit ionally , the administration of the [ADDRESS_199100]. It has been shown that decitabine at continuous, low doses 
improves innate immunity  by [CONTACT_170140], survival, and activity  of NK-cells.23,31In 
an initial series of experiments, decitabine treatment stimulated and augmen ted NK reactivity  
measured by [CONTACT_20129]γ mRNA expression and protein release in response to activating stimuli in 
vitro.31In a follow -up study , it was demonstrated that exposure to decitabine at low doses
(7mg/m2)over 5 days decreased the expression of inhibitory receptors (eg,KIR) and increased 
the expression of activating receptors (eg, NKG2D and NKp44) on activat edNK cells in vitro.23
The authors propose that novel therapeutic strategies involving decitabine should aim at 
combining the “ direct effect of decitabine on malignant cells with its ability  to enhance reactivity  
of NK cells in immunotherapeutic approac hes”.31Thus, decitabine exposure at the approved low 
dose of 20 mg/m2 over the extended treatment period of 5 days may stimulate innate NK 
cell-mediated immunity and thus enhance the ADCC -dependent anti-leukemic activity of
talacotuzumab. 
In the dosing schedule proposed for thecombination regimen, talacotuzumab will be given after
decitabine in order to take advantage of the potential stimulation of the innate immunity . This 
will allow the combination of full therapeutic doses of decitabine (eg, 20mg/m2) and 
talacotuzumab (9 mg/kg, confirmed in Part A). Additionally ,the safet y profiles of theagents
indicate that toxicities are not overlappi[INVESTIGATOR_170092].
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
51
Status: Approved, Date: 31 October 2017   2. OBJECTIVE S, ENDPOINTS, AND HYPOTHESIS
2.1. Objectives and Endpoints
2.1.1. Objectives
Primary Objective s
Part A:to assess the safety  of talacotuzumab monotherap y and confirm the RP2D in subjects
with AML  for whom experimental therap y is appropriate (as assessed by [CONTACT_34427]).
Part B:The primary  objective sof the study  areto assess CR rate and OSin subject s with 
previously  untreated AML who are not eligible for intense induction chemotherap yand who are 
randomly  assigned to receive decitabine plus talacotuzumab at the RP2D or decitabine alone. 
Secondary Objectives (Part B)
The secondary  objectives are: 
To assess EFS ;
To determine the o verall response r ate (ORR) defined as rate of complete response ( CR) and 
complete response with incomplete blood count recovery  (CRi);
To determine the rate of CR plus MRD negative CRi
To assess the relapse -free s urvival (RFS) ;
To assess time to response and duration of response for subjects who achieve CR/CRi;
To assess minimal residual disease (MRD) ; 
To assess the safet y profile of talacotuzumab in combination with decit abine ;
To assess the pharmacokinetics of talacotuzumab and decitabine alone and in combination;
To assess the immunogenicity  talacotuzumab alone (Part A) and in combination with 
decitabine (Part B) ;
To assess patient -reported outcomes (PROs) using the FACT -Leu and E Q-5D- 5L.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
52
Status: Approved, Date: 31 October 2017   Exploratory Objectives
The exploratory  objectives are:
To explore PK/PD relationships of talacotuzumab through analysis of talacotuzumab PK,
biomarkers, PD markers ,and clinical end points ;
To explore biomarkers predictive of clinical response;
To collect medical resource utilization (MRU) data that may be used in future economic 
modeling (the construction and reporting of the economic model will be conducted 
separately  from this study ).
2.1.2. Endpoints
Primary Endpoint (Part A)
Safetyand DLT determination
2 Primary Endpoints (Part B)
CR rate
OS 
Secondary Endpoints (Part B)
EFS, defined as the time from randomization to treatment failure, relapse from CR/CRi, or 
death from any cause, whichever occurs first. Treatment failure is defined as >25% absolute 
increase in the bone marrow blast count from baseline to the present assessment.
ORR rate (CR + CRi) ;
Rate of CR plus MRD negative CRi;
Time to response , defined for subjects who achieved best response of CR or CRi as time 
from randomization to achieving the best response;
Duration of response, defined for subjects who achieved best response of CR or CRi as time 
from achieving CR or CRi to relapse;
Relapse -free survival (RFS) defined for subjects who achieved CR or CRi as the time from 
achieving CR or CRi to disease relapse or death from any cause;
Safety  profile;
Pharmacokinetics; 
Immunogenicit y;
MRD ;
Patient-reported outcomes (PROs) using the FACT -Leu and EQ 5D 5L. 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
53
Status: Approved, Date: 31 October 2017   Exploratory Endpoints (Part B))
Pharmacokinetic/pharmacody namic relationships associated with biomarkers, PD markers 
and clinical end points; 
To explore biomarkers associated with clinical response;
Medical resource utilization .
2.2. Hypothesis
In patients with previously untreated AML who are not eligible for intense induction 
chemotherap yit is hypothesized that treatment with a combination regimen of decitabine and 
talacotuzumab as compared with decitabine alone, will improve CR rate or extend survival or 
both.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a 2-part, open -label, multicenter, seamless Phase 2/3study  conducted in subjects with 
AML who are suitable for experimental therap y (Part A) and in subjects with untreated AML 
who are not eligible for intense induction chemotherap yor hematopo ietic stem cell 
transplantation (HSCT ; hereafter referred to as not el igible for intense chemotherap y)(Part B) .
In Study Part A, the safety , PKand PDprofile , and RP2D of 9 mg/kg talacotuzumab will be 
confirmed .In Part B, subjects will be randomized 1:1 into either Arm 1 (decitabine + 
talacotuzumab ) or Arm 2 (decitabine alone ). Blood and bone marrow sampling for disease 
assessment, PK, PD, and biomarkers will be mandatory  for all subjects in the study .
Part A: Recommended Phase [ADDRESS_199101] similarl y in 
biophy sical, biochemical, and preclinical assessments. See Section 1.1and the talacotuzumab
(JNJ-56022473) Investigator’s Brochure16for information regarding the biophy sical and 
preclinical to xicology  studies .
Sixsubje ctswill be enrolled in PartA and receive 1 dose of talacotuzumab at 9mg/kg on Day 1 
as a 180-minute IV infusion. Dose -limiting toxicities (DLTs) will be assessed during the DLT 
evaluation period (Cycle 1; 14days). All subjects will receive premedication with 
hydrocortisone or equivalent IV steroid to prevent infusion reactions. Refer to the Dosage and 
Administration schedule (Section 6Dosage and Administration) for further detail.
Pharmacokinetic and pharmacod ynamic assessments will be conducted during the 14-day 
talacotuzumab evaluation period (see Time and Events Schedule Table 2A). Upon completion of 
dosing , there will be a review of all available study  data by a Study Evaluation Team (SET) to 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
54
Status: Approved, Date: 31 October 2017   confirm the RP2D of 9 mg/kg talacotuzumab. If no DLTs are observed or are observed in 1 of 
the 6 subjects, the dose of 9 mg/kg talacotuzumab may be established as the RP2D by  [CONTACT_66859]. If 
DLTs are observed in ≥2 of the6 subjects, Part A may continue with additional enrollment of 
3to 6 subjects at a lower dose level of talacotuzumab to be determined b y the SET.
Dose -limiting toxicities (DLT)are adverse events that occur up tothe end of Cycle 1,meet the 
following criteria ,and areconfirmed b y the SET:
CTCAE Grade 4 non hematological toxicities
CTCAE Grade 3 non hematological toxicities that persists for ≥ [ADDRESS_199102] 
supportive care according to institutional standards. 
After the RP2D for talacotuzumab is confirmed, Part B can be initiated .
Subjects in Part A willcontinue on study  (remaining in Part A) and start subsequent cy clesof the 
combined study  therap y with decitabine at the dose of 20 mg/m2IV on Day 1 to Day 5 followed 
by 9 mg /kg (or a lower dose if determined by  [CONTACT_66859]) talacotuzumab on Day  8 and Day  22of a 
28-day cycle. Subjects will continue study  therapy  as outlined in Section 6until treatment failure 
(as defined in Section [IP_ADDRESS] ), relapse from CR/CRi, unacceptable toxicity , or death as described 
in Se ction 10.2.
Part B:
Part B is designed to be a seamless Phase 2/3 study with 2 primary  endpoints ,CR rate and OS. 
Subjects will be randomized in a 1:1 ratio to receive either decitabine + talacotuzumab (Arm 1) 
or decitabine alone (Arm 2). Randomization will be stratified by [CONTACT_170141] (0 -1 versus 2) andtype of AML (de novo versus secondary ). The study  will have [ADDRESS_199103] interim analy sis will occur after approximately  80 subjects (40 subjects per 
arm) have been randomized and followed for at least 4 months. Guided by [CONTACT_170142]+CRi rates and central review of data (see Section 11.2), the study 
will either continue enrollment to the full pre-specified Phase [ADDRESS_199104] been 
randomized by [CONTACT_170143]. No changes in design 
elements are planned based on this interim analy sis.
If the enrollment continues to400 subjects (approximately  200 subjects per arm), the 
pre-specified design elements are :
A second interim analysis occurs after 160 subjects (approx imately 80 subjects per arm) 
have been randomized and followed for at least 4 months; this is the final analysis for CR 
and the first interim analysis for OS. The study  will not be stopped on the basis of the CR 
results ;
A third interim analy sis (ie, the second interim analy sis ofOS) will be conducted when 
[ADDRESS_199105] occurred;
The final analysis of OS will take place when [ADDRESS_199106].
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
55
Status: Approved, Date: [ADDRESS_199107] occurred.
Part A and Part B:Subject participation will include a Screening Phase, a Treatment Phase, 
and a Follow -up Phase. The Screening Pha se will be up to 28 day s prior to start of study  therapy  
in Part A or up to 28 days prior to randomization in Part B. The Treatment Phase begins with
start of study  therap y (Part A)or randomization (Part B)and continues until the 
End-of- Treatment Visit. The Follow -up Phase begins immediately  following the 
End-of- Treatment Visit, and continues until death, loss to follow up, consent withdrawal for 
study  participation, or study  end, whichever occurs first. Subjects will receive study  treatment 
until treatme nt failure , relapse from CR/CRi, or death, unless discontinued early  because of 
unacceptable toxicity , or other reasons specified in Section 10.2. The median time to response in 
a Phase [ADDRESS_199108] evidence of 
treatment failure tocontinue decitabine treatment .Subjects inArm 1may discontinue one of the 
study  agents (decitabine or talacotuzumab ) because of unacceptable toxicity  and continue 
treatment with the other agent until treatment failure, relapse from CR/CRi, or death, unless 
discontinued earl y because of unaccepta ble toxicity .
All study  evaluations will be conducted according to the Time and Events Schedule Table s 1A,
1B,1Cand 1D. Disease evaluations will include clinical presentation, peripheral blood ,and bone 
marrow assessments. Disease status will be evaluated according to the modified “Response 
Criteria in AML ” (Section [IP_ADDRESS] ).9During the Treatment Phase, safety evaluations will include 
adverse event monitoring, vital sign measurements, physical examinations, clinical laboratory  
parameters (hematology and chemistry ), and Eastern Cooperative Oncology  Group (ECOG) 
performance status. Additional blood samples will be drawn for assessment of pharmacokinetic 
and pharmacod ynamics parameters and a pharmacogenomics blood sample will be collected to 
allow for exploratory  biom arker activities. 
Study Evaluation Team (SET) :A SET will monitor preliminary  safety  and study  conduct data 
on an ongoing basis during the study for Part A. The SET will consist of selected investigators, 
sponsor medical monitors, thesponsor’s statistici an, and the sponsor’s clinical pharmacologist, 
or their designees. The scope of this safety  review will be detailed in the SET Charter. Decisions 
regarding DLT determination, dose de-escalation , changes in the timing of pharmacokinetic or 
pharmacod ynamic sampling, exploration of alternative schedule(s), cy cle duration, or other study 
conduct recommendations, will be made by [CONTACT_170144] a SET decision 
document and distributed to investigators. The Institutional Review Board (IRB) will be notif ied 
before implementation of any SET decision, if required. This document will be provided in the 
sponsor’s instruction manual and retained in the study  master file and in the study  center’s files.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
56
Status: Approved, Date: 31 October 2017   During Part A,the SET will review all available data upon completion of the 14-day period 
following talacotuzumab treatment (Cycle 1 )to determine DLTs, and subsequently , will confirm
the RP2D .Additionally , accumulated safet y data will be reviewed forsubjects in Part A who are 
receiving combination therapy  prior to the start of Part B. The following data will be reviewed as 
available: study  compliance (includi ng drug exposure as applicable), adverse event and safety
profile, PK, and PD. The SET recommendations will be documented in a SETrecommendations 
document and distributed to investigators. 
Independent Data Monitoring Committee : An Independent Data Monitoring Committee 
(IDMC) will be established toevaluate safet y and efficacy  data collected during Part B of the 
study .
The IDMC will conduct asafet y review of accumulated data from Part A and Part Bwhen 
approximately  20subjects from Part B(10 subjects from each arm) have been enrolled and 
followed for at least [ADDRESS_199109]. AnIDMC charter
will d escribe the policies and procedures.
Independent Central Review: In addition to evaluations by [CONTACT_431], disease status will be 
reviewed and determined by [CONTACT_170145] a blinded fashion. A charter will 
describe the policies and procedures in detail .
Note : After review of the data from Interim Anal ysis #2, the IDMC informed the Sponsor that 
the futility  criterion for OS was met and that the CR rate did not meet per-protocol defined 
statistical significance. Given the lack of efficacy advantage of talacotuzumab + decitabine 
versus decitabine alone, the incidence of infusion- related reactions, and the complexities with 
premedications for drug administration, the benefit/ risk ratio is not favorable to continue 
treatment with talacotuzumab. The IDMC recommended closure of enrollment to the study  and 
that subjects receiving talacotuzumab + decitabine should discontinue talacotuzumab treatment 
and may continue decitabine alone, according to Principal Investigator [INVESTIGATOR_170093]. All subjects will continue to be followed for survival and subsequent anti-cancer 
therap y. During the treatment phase with decitabine, subjects will be monitored for serious 
adverse events.
The end of study  data collection is defined as when [ADDRESS_199110]. At that time, follow up of subjects will end. 
Subjects who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170146]; during this period, only serious adverse events 
will be monitored and entered into the Company  safety repository  as described under 
Amendment 7.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
57
Status: Approved, Date: 31 October 2017   3.2. Study Design Rationale
Rationale for Single A gent Talacotuzumab Monotherapy in Part A
Studies with CSL362 identified 9 mg/kg as the RP2D. Talacotuzumab is produced in a different 
cell line with a different process compared with thePhase 1study (CSL CT-AML -11-73) 
CSL362drug product . To confirm the safety  andRP2D of talacotuzumab, a safet yrun-in period
of talacotuzumab at 9 mg/kg will be evaluat ed first as monotherap y in Part Aof this study .
Rationale for DACOGEN
Decitabine is an appropriate comparator in this study  as it is approved for the treatment of this 
AML  population in the Europe an Union ( EU)and 21 other countries (as of November 2014 ) and 
is a treatment option recommended in treatment guidelines such asthe National Comprehensive 
Cancer Network.9,28
The proposed schedule of decitabine administered at a dose of 20 mg/m2body  surface area by  [CONTACT_170147] 1 hour repeated daily  for 5 consecutive days (ie, 5 doses per treatment cycle) is
outlined in more detail in the prescribing information. The total daily  dose of decitabine must not 
exceed 20 mg/m2and the total dose per treatment cyclemust not exceed 100 mg/m2. 
Rationale for Dose of T alacotuzumab
Safety : The talacotuzumab dose and schedule for this study  was planned using CSL362 results 
from a Phase 1 study (CSLCT -AML -11-73). CSL362 has been deemed safe and well tolerated as 
no AE≥CTCAE Grade 3 has occurred in 9subjects dosed at 9 mg/kg every  14 days in the 
CSL-sponsored Phase 1 study . Despi[INVESTIGATOR_170094] (CTCAE 
Grade 3) infusion -related reaction at low doses, no subject at the 9 -mg/kg dose level experienced 
a severe infusion related reaction after the institution of mandatory  pre-medication and a 
prolonged infusion time to 3 hours. 
Pharmacokinetics :With CSL362, the 9 mg/kg dose exhibits predictable PKabove the nonlinear 
pharmacokinetic range where higher clearance and shorter half -life was observed at lower doses. 
Additionally , the half -life of 4 to 5 days supports the every  14-day dosing frequency . At 
9mg/kg, the trough concentration of CSL 362 from the majority  of subjects is expected to exceed 
the estimated concentration needed to saturate the CD123 target as measured by [CONTACT_170148] r monocy tes. This dose is selected to ensure sustained target saturation throughout the 
dosing period , particularly  considering that 1 of the therapeutic target sis anticipated to be the 
leukemic stem cell niche in the bone marrow. 
Pharmacod ynamics : For CSL362, t he pharmacody namic pattern and kinetics of biomarkers, 
including basophils, pDC cells, NK cells, monocy tes, etc. are generally  comparable regardless of 
the cy cle number. Aside from CD123 expressing cell t ypes, CSL362 at 9mg/kg does not seem to 
significantl y affect other cells, or only affect transiently  with return to baseline expected within 
3days, as in the case of NK cells. In summary , 9 mg/kg every  2 weeks is a safe dose within the 
linear PKdose range that is expected to provide adequate expo sure and sustained target 
saturation throughout the dosing interval for both peripheral and bone marrow blasts and L SCs. 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
58
Status: Approved, Date: 31 October 2017   Rationale for T alacotuzumab Dose in Combination with DACOGEN
Decitabine has a safety  profile that allows for its use as an outpatient therapy  for elderl y and 
physicall y impaired patients with AML.25Treatment with decitabine is associated with 
myelosuppression and adverse events related to myelosuppression (ie, thrombocy topenia, 
anemia, neutropenia, and febrile neutropenia) which are however common in both treated and 
untreated patients with AML .15Decitabine administered at the recommended dose (20mg/m2) 
and schedule (Day s 1 to 5) currently  is being tested incombination with a variety  of 
experimental compounds.25,26The safet y and PKdata obtained for CSL362 in the ongoing Phase 
[ADDRESS_199111] cells, the addition of 
talacotuzumab may not lead to an aggravation of the myelosuppression or extension of the time 
of hematopoietic recovery  observed in AML  patients receiving decitabine . Lastl y, 
pharmacokinetic drug-drug interaction between decitabine and talacotuzumab is not expected 
given the different absorption, distribution, metabolism, and excretion ( ADME ) properties and 
metabolic pathway s utilized by [CONTACT_170149]. 
Rationale for Randomization
In Part B,subjects will be randomized to receive either decitabine + talacotuzumab (Arm 1)or 
decitabine alone (Arm 2). Randomization will minimize bias in the assignment of subjects to 
treatment groups, to increase the likelihood that known and unknown subject attributes 
(eg,demographic and baseline characteristics) are evenl y balanced across treatment groups, and 
to enhance the validity  of statistical comparisons across treatment groups. Additionally , 
enrollment into the treatment arms is stratified by [CONTACT_170150] G performance status score 
(0-1versus 2)andtype of AML  (de novo versus secondary ),prognostic factors known to affect 
clinical outcomes.9
After Interim Analy sis #2, enrollment to the study  was closed. Subjects receiving talacotuzumab 
+ decitabine (Arm 1) stopped talacotuzumab treatment and were allowed to continue to receive 
decitabine alone, according to Principal Investigator [INVESTIGATOR_170076]. This was 
based on an IDMC review that noted alack of efficacy  advantage of talacotuzumab + decitabine 
versus decitabine alone, the incidence of infusion- related reactions, and the complexities with 
premedications for drug administration that made the benefit/ risk ratio not favorable to continue 
treatment with talacotuzumab. 
Rationale for Primary Endpoints
For this Phase 2/3study , CR rate and OS arechosen as the [ADDRESS_199112] meaningful measure oftreatment 
benefit .32
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
59
Status: Approved, Date: 31 October 2017   Rationale for Biomarker Evaluation
Biomarker samples will be collected to evaluate the mechanism of action ofthe combination of
decitabine +talacotuzumab , to establish the threshold of CD123 expression needed for clinical
response, and to help explain inter-individual variability in clinical outcomes or to identify  
population subgroups that respond differently  to decitabine + talacotuzumab or decitabine alone . 
Rationale for Pharmacodynamic Marker Evaluation
Previous CSL362 pre-clinical and clinical studies in subjects with AML  demonstrated that 
CD123- positive pDC and basophils are reliable cellular pharmacod ynamic markers for CSL362 
activity .3,33These cells were completel y depleted within hours of CSL 362 infusion and depletion 
was sustained for ≥ 15 days at doses ≥ 3.0 mg/kg. Natura l killer cells are critical to the 
mechanism of action of talacotuzumab (CSL 362) and quantification may reveal an association 
with clinical response. Natural killer cell counts are reduced in the first few hours after dosing 
but stabilized at Day 3 and thereafter, indicating that this fluctuation may be caused by [CONTACT_170151].33
Rationale for Assessment of CD123 Expression
CD123 is expressed in AML blasts and LSCs in a large percentage of AML patients 
(75-89%).14,17,27The percentage of CD123+ leukemic blasts at diagnosis has been correlated 
with a poor response to intensive chemotherap y.36In a  study by [CONTACT_170152],1078% of newl y 
diagnosed AML patients had AML  blasts that were positive for CD123 expression. The cutoff 
for positi ve flow measurements in this study  was set to >10, based on the geometric mean 
fluorescence intensities (MFIs) of CD123 in blasts in relation to the MFIs of lymphocy tes 
(considered negative for CD123).10
Rationale for Minimal Residual Disease Assessment
Assessment of minimal residual disease (MRD) is becoming an important evaluation to 
determine the depth of response beyond clinical CR in AML and other hematologic 
malignancies,13and it has been shown that MRD assessment adds prognostic value beyond both 
karyotype and specific gene mutations .2,18
Rationale for Immunophenotypi[INVESTIGATOR_170095] (CD123) and recruit 
effector cells of the immune system for cell killing. Therefore, the ultimate activity  of this agent 
depends not only on expression of the target by [CONTACT_170153], but also on the fitness of 
the host immune system. Therefore, we will determine the state of the host’s immune system. In 
addition, the biomarker plan will attempt to address the effect of decitabine on the host immune 
system, with particular attent ion to NK effector cell number and function.
4. SUBJECT POPULA TION
The screening period for eligible subjects for this study  will be performed within [ADDRESS_199113] dose of stud y therap y(Part A) or within 28 day s before randomization (Part B ).
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
60
Status: Approved, Date: [ADDRESS_199114] satisfy  all of the following criteria to be enrolled in the study .These 
criteria are applicable for both Part A and Part B of the study  unless otherwise noted.
1 Criterion Modified per Amendment 1
1.1
1.2Criterion Modified per Amendment 2
AML  according to WHO 2008 criteria35fulfilling all of the following criteria:
For Part A: 
Patients with AML  (treatment naive or relapsed) for whom experimental therap y is 
appropriate (as assessed by  [CONTACT_97505]); 
For Part B :
≥75 y ears of age or
≥65up to [ADDRESS_199115] one of the following:
oCongestive heart failure or ejection fraction ≤50%
oCreatinine >2 mg/dL, dialy sis or prior renal transplant
oDocumented pulmonary disease with lung diffusing capacit y for carbon 
monoxide (DLCO) ≤65% of expected, or forced expi[INVESTIGATOR_4034] 
1second (FEV1) ≤65% of expected or d yspnea at rest requiring oxy gen
oECOG performance status of 2
oPrior or current malignancy  that does not require concurrent treatment
oUnresolved infection
oComorbidity  that, in the Investigator’s opi[INVESTIGATOR_1649], makes the patient unsuitable 
for intensive chemotherapy  and must be documented and approved by [CONTACT_170154]
De novo or secondary  AML (post myelody splastic syndrome [MDS] or 
myeloproliferative neoplasm [MPN] or after leukemogenic chemotherap y); 
Previously  untreated AML (except: emergency leukopheresis and/or hydrox yurea 
during the screening phase to control hy perleukocy tosis but must be discontinued at 
least one day  prior to start of study  therapy );
Not eligible for an allogeneic hematopoietic stem cell transplantation.
2. ECOG Performance Status score of 0, 1 or 2.
3. Criterion Modified per Amendment 1
3.1
3.2Criterion modified per Amendment 2
Criterion modified per Amendment 3
The following clinical laboratory  values at screening:
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
61
Status: Approved, Date: 31 October 2017   Hematology : 
Platelet count ≥ 10x 109/L(with or without transfusions)
White blood cell count (WBC) ≤ 40x 109/L(Note: leukopheresis or hydroxyurea is 
permitted to decrease WBCcount but must be discontinued 1 day  prior to start of study  
therap y)
Hepatic: 
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.[ADDRESS_199116]; for subjects with leukemic infiltration of the liver, AST and ALT ≤ 5 times UL N 
is permitte d
Total Bilirubin ≤ 1.[ADDRESS_199117] unless bilirubin rise is due to Gilbert’s syndrome or of 
non-hepatic origin
4. A woman must be either:
Not of childbearing potential: postmenopausal (>[ADDRESS_199118] 12 months );
Of childbearing potential and practicing a highly  effective method of birth control 
consistent with local regulations regarding the use of birth control methods for subjects 
participating in clinical studies for at least 3 months: eg, established use of oral,
injected or implanted hormonal methods of contraception; placement of an intrauterine 
device (IUD) or intrauterine system (IUS); barrier methods: condom with spermicidal 
foam/gel/film/cream/suppository  or occlusive cap (diaphragm or cervical/vault caps) 
with spermicidal foam/gel/film/cream/suppository ; male partner sterilization (the 
vasectomized partner should be the sole partner for that subject); true abstinence (when 
this is in line with the preferred and usual lifest yle of the subject)
Note: If the childbearing potential changes after start of the study  (eg, woman who is 
not heterosexually  active becomes active, premenarchal woman experiences menarche) 
a woman must begin a highly effective method of birth control, as described above.
5.A woman of childbearing potential must have a negative serum (-human chorionic 
gonadotropin [ -hCG]) or urine pregnancy test at screening. 
6.A man who is sexually  active with a woman of childbearing potential and has not had a 
vasectom y must agree to use a barrie r method of birth control eg, either condom with 
spermicidal foam/gel/film/cream/suppository  or partner with occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/c ream/suppository  for at least 3months 
after last stud y treatment.
7.Each subject (or their legally  acceptable representative) must sign an informed consent 
form (ICF) indicating that he or she understands the purpose of and procedures required for 
the study  and are willing to participate in the study. 
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study .These criteria are applicable for both Part A and Part B of the study  unless 
otherwise noted. 
1. A cute prom yeloc ytic leukemia with t(1 5;17), or its molecular equivalent (PML -RAR α).
2. For Part B only: Known leukemic involvement or clinical symptoms of leukemic 
involvement of the central nervous s ystem.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
62
Status: Approved, Date: 31 October 2017   3. Criterion Modified per Amendment 1
3.1 Subjects who received prior treatment with a h ypomethy lating agent. 
4. For Part A only: Subjects who did not recover from all clinicall y significant toxicities 
(excluding alopecia and hematologic toxicities) of any previous surgery , radiotherap y, 
targeted therapy , or chemotherapy  to less than or equal to Grade 1;
5. Criterion modified per Amendment 1
5.1
5.2Criterion Modified per Amendment 2
A diagnosis of other malignancy  that requires concurrent treatment.
6
6.1.Criterion Modified per Amendment 2
Any uncontrolled active systemic infection that requires treatment with IV antibiotics 
7. Criterion Modified per Amendment 1
7.1 A history  of human immunodeficiency  virus (HIV) antibody  positive or tests positive for 
HIV if tested at screening 
8.
8.1Criterion Modified per Amendment 2
Active systemic hepatitis infection requiring treatment or other clinically  active liver 
disease
9.
9.1Criterion Modified per Amendment 2
Criterion modified per Amendment 3
Unstable angina 
10.
10.1Criterion Removed per Amendment 2
11.QTcF > [ADDRESS_199119] (eg, compromise the well -being) or physical limitations that 
could prevent, limit, or confound the protocol -specified assessments
15. M ajor surgery , (eg, requiring general anesthesia) within 4weeks before screening, or will 
not have fully recovered from surgery , or has surgery  planned during the time the subject 
is expected to participate in the study
Note: subjects with planned surgical procedures to be conducted under local anesthesia 
may participate. In such cases, the investigator must notify  the sponsor before 
randomization. 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
63
Status: Approved, Date: 31 October 2017   NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's clinical status changes (including any available laboratory  results or receipt of 
additional medical records) after screening but before 1) Cycle 1 Day 1 for Part Aor 2) 
randomization for Part Bsuch that he or shenolonger meets all eligibility  criteri a, then the 
subject should be excluded from participation in the study . Section 17.4, Source Documentation, 
describes the required documentation to support meeting the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
1. Refer to Section 8PRESTUDY AND CONCOMI TANT THERAPY for details 
regarding prohibited and restricted therap y during the study.
2. Agree to follow all requirements that must be met during the study  as noted in the 
Inclusion and Exclusion Criteria (eg, contraceptive requirements).
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation
Procedures for Randomization and Stratification
Central randomization will be implemented in this study for Part B using an interactive web 
response system (IWRS) . Subjects will be stratified by [CONTACT_170155] 
(0-1 versus 2)andtype of AML (de novo versus secondary )and then assigned randoml yto 1 of 
2treatment groups based on a computer -generated randomization schedule prepared before the 
study  by [CONTACT_170156] t he sponsor.
After Interim Analy sis #2, enrollment to the study  was closed and therefore the IWRS was 
closed to randomization of new subjects.
Blinding
As this is an open study , blinding procedures are not applicable.
6. DOSA GE A ND A DMINISTR ATION
6.1. Dosing Schedule
6.1.1. Part A
In Part A of the stud ydosing will occur as per Table 2below .
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
64
Status: Approved, Date: 31 October 2017   Table 2: Dosing Schedule for Part A
Cycle 1
Talacotuzum ab All subsequent cycles 
Study Day 1 2-14 1 2 3 4 5 6-7 8 9-21 22 23-28
Decitabine
(20 m g/m2)X X X X X
Talacotuzum ab
(9 mg/kg)X X X
Cycles may  be delay ed due to recovery  from toxicity  or other causes. 
6.1.2. Part B
In Part B of the study , subjects will receive study  therap y according to the arm to which they are 
assigned .The start of each cy cle is defined as the date of the first dose of decitabine . Cycles may  
be delay ed due to recovery  from toxicity  or other causes. Study  treatment continues until 
treatment failure, relapse from CR/CRi, unacceptable toxicity ,death, or other reasons specified 
in Section 10.2.
In Arm 1, study  therapy  Cycle 1 will start with decitabine at a dose of 20 mg/m2IV administered 
daily  for five consecutive days followed by [CONTACT_170157] (at the RP2D ) on 
Days 8 and 22 (± 24 hours) of a 28 -day cycle. Subsequent cy cles of study  therapy  will follow the 
same dosing schedule as Cy cle 1 as outlined in Table 3.
Table 3: Dosing Schedule for Part B -Arm  1 
All treatm ent cycle s
Study Day 1 2 3 4 5 6-7 8 9-21 22 23-28
Decitabine
(20 m g/m2)X X X X X
Talacotuzum ab
(RP2D mg/k g)X X
Subjects assigned toArm 2 will receive decitabine at a dose of 20 mg/m2IV administered daily 
for five consecutive days. A Cycle of study  therapy  will be repeated every  [ADDRESS_199120] 
dose of decitabine onwards. The dosing schedule for Arm 2 is outlined in Table 4 .
Table 4: Dosing Schedule for Part B -Arm  2 
All treatm ent cycles
Study Day 1 2 3 4 5 6-28
Decitabine
(20 m g/m2)X X X X X
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
65
Status: Approved, Date: 31 October 2017   Investigators should be aware that for treatment with decitabine as monotherap y or in 
combination, it is recommended that subjects be treated for a minimum of 4 cycles; however, a 
complete or partial response may  take longer than 4 cy cles.
Study  treatment is to continue until treatment failure, relapse from CR/CRi, ordeath, unless 
discontinued early  because of unacceptable toxicity . Subjects in Arm 1 may discontinue 1 of the 
study  treatments (decitabine or talacotuzumab ) because of unacceptable toxicity  and continue 
treatment the other agent until treatment failure, relapse from CR/CRi, or death, unless 
discontinued earl y because of unacceptable toxicity .
Following Amendment 6, enrollment to the study was closed and subjects receiving 
talacotuzumab + decitabine should discontinue talacotuzumab treatment and may continu eto 
receive decitabine alone, according to Principal Investigator [INVESTIGATOR_170076].
Following Amendment [ADDRESS_199121] is 
enrolled (whichever occurs first), follow up of subjects and data collection will end. Subjects 
who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170158]; during this period, only serious adverse events will be 
monitored and entered into the Company  safet y repository .
6.2. Decitabine
6.2.1. Preparation and A dministration of Decitabine
Decitabine will be supplied as a lyophilized powder in a single -dose vial of 50 mg per vial. 
Decitabine powder should be reconstituted as outlined in the prescribing information. D ecitabine
will be administered at a dose of 20 mg/m2 by [CONTACT_22694] 1 hour repeated daily 
for 5 daysat the start of each cycle. The 5-Day decitabine treatment will be repeated every
28days. 
6.2.2. Decitabine : Premedication
As outlined in the prescribing information, subjects receiving decitabine may be premedicated 
with anti-emetic therapi[INVESTIGATOR_170096]. 
6.2.3. Decitabine Dose Modifications
Treatment with decitabine may be delayed for up to 28days at the discretion of the investigator, 
if the subject experiences disease related complications such as myelosuppression- associated 
complications (such as: febrile neutropenia [ temperature ≥38.5°C and absolu te neutrophil count 
<1000/µL ], active viral, bacterial or fungal infection [ie, requiring intravenous anti-infectives or 
extensive supportive care ],hemorrhage [gastrointestinal, genito -urinary , pulmonary  with 
platelets <[ZIP_CODE]/µL  or any central nervous system hemorrhage ]). The treatment with decitabine
may be resumed once these conditions have improved or have been stabilized with adequate 
treatment (anti-infective therap y, transfusions, or growth factors). If there is more than a 28-day 
dose delay , the subject may  be permitted to continue treatment if the investigator believes it is in 
the best interest of the subject. Dose reduction is not recommended.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
66
Status: Approved, Date: [ADDRESS_199122] containing 100mg of active 
pharmaceutical ingredient (50mg/mL after reconstitution with 2.0 mL sterile water for 
injection). 
The talacotuzumab dose administered will be dependent upon the subject’s weight at the Day [ADDRESS_199123]’s 
weight changes by >10%. Talacotuzumab will be administered as a [ADDRESS_199124] be readily available (eg, epi[INVESTIGATOR_238], corticosteroids, 
intravenous antihistamines, bronchodilators, oxygen). Attention to staffing should be considered 
when multiple subjects will be dosed at th e same time.
The rate of the talacotuzumab infusion is as follows:
First Four Cycle s:Initiate the IVinfusion at a rate of 10 mL/hr. In the absence ofanyinfusion-
related reaction during the first 30 minute s, increase theinfusion rate to 20 mL /hr for 30 minutes, 
if no infusion reaction is observed during this 30 minute period, increase the infusion rate to 
40mL/hr for the next 30 minutes. If no infusion reaction is observed during this 30 minute 
period, increase the infusion rate to 60 ml/hr for the remai nder of the infusion. The infusion rate 
should not exceed 60 mL/hrat any time.Subjects should be monitored for infusion reactions for 
one hour after completion of the talacotuzumab infusion.
Subsequent Cycles (after the first 4cycles) :If no infusion reaction is observed inthefirst 
4cycles, initiate the IVinfusion at a rate of 40 mL/hrfor 30 minutes and if no infusion- related 
reactions are observed during this period increase the infusion rate by 40 mL/hr every 
30minutes. The infusion rate should not exceed 150mL/hrat any time.Subjects should be 
monitored for infusion reactions f or 1 hour after completion of the talacotuzumab infusion.
If an infusion-related reaction is observed during the administration of talacotuzumab, then 
follow the procedures described in Section 6.3.4 .
6.3.2. Talacotuzumab : Premedication 
All subjects receiving talacotuzumab in the current study  must receive premedication during the 
first 4cycles, as outlined in Table 5.If no infusion -related reactions ,independent ofseverity ,are 
seen for [ADDRESS_199125] 4cycles of talacotuzumab treatment , then 
premedication may be modified per investigator discretion after discussion with the Sponsor for
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
67
Status: Approved, Date: 31 October 2017   Cycle 5 and subsequent talacotuzumab treatments. In the event an infusion -related reaction 
(independent of severit y) occurs in subsequent talacotuzumab treatments, premedication needs to 
be reintroduced. If a subject has a medical condition or clinical need that precludes complete 
administration of premedications at any time, notification to and discussion with the Sponsor’s 
study  physician is required. 
Table 5: Prem edication for Subjects Receiving Talacotuzum ab
Part A and
Part B –Arm  1Infusion -related 
ReactionMandatory Prem edication2
Cycle 1 -Cycle 4 Dexamethasone 8 mg P O (or equivalent) twice per day approx. 2 days 
prior to infusion and approx. 3 h rs prior to infusion 
Methylprednisolone (100mg IV)1
approx. 1- 2 hrs prior to infusion
Acetaminophen (paracetamol) 650 –1000 mg IV or PO approx.1 hr 
prior to infusion
Antihistamine s:diphenhydramine 25 –50mg IV or PO3and c imetidine 
300 mg PO (or equivalent4) approx. 1 hr prior to infusion
Leukotriene inhibitor (montelukast 10 mg PO, or equivalent), approx.
1-2 hrs prior to infusion 
Cycle 5 +
Subsequent cyclesIf Prior Event: Dexamethasone 8 mg PO (or equivalent) twice per day approx. 2 days 
prior to infusion and approx. 3 h rs prior to infusion 
Methylprednisolone (100mg IV)1
approx. 1- 2 hrs prior to infusion
Acetaminophen (paracetamol) 650 –1000 mg IV or PO approx.1 hr
prior to infusion
Antihistamines: diph enhydramine 25 –50mg IV or PO3and c imetidine 
300 mg PO (or equivalent4) approx. 1 hr prior to infusion
Leukotriene inhibitor (montelukast 10 mg PO, or equivalent), approx.
1-2 hrs prior to infusion 
No Prior Event
for 2 
consecutive 
cycles :Prem edication may be modified per investigator discretion and after 
discussion with the Sponsor
1If methylprednisolone is not available at the institution, consult with Sponsor regarding corticosteroid selection. 
Dose and frequency may be increased at th e discretion of the investigator.
2Additional doses of steroids prior to treatment with talacotuzumab may be given at the discretion of the 
investigator. 
3Or similar sedating antihistamine per institutional standards; avoid the use of promethazine .
4 For example: famotidine 20 mg (PO or IV), r anitidine 150 mg PO or 50 mg IV, ornizatidine (150 mg PO) 
6.3.3. Talacotuzumab Dosing Modification s
Refer to Section 6.3.4 for details on management of infusion -related reactions. 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
68
Status: Approved, Date: 31 October 2017   In Part B of the study ,dose reduction of talacotuzumab is not permitted and dose delay  is the 
primary  method for managing talacotuzumab -related toxicities. 
A dose delay  should occur if any of the following criteria is meteven if the event in the opi[INVESTIGATOR_170097] :
Febrile neutropenia;
Grade 3 or higher hemorrhagic event
Toxicity  that in the opi[INVESTIGATOR_871], requires delay .
If the dose of talacotuzumab is delay ed by [CONTACT_726] [ADDRESS_199126] discontinues talacotuzumab because of unacceptable toxicity , they should 
continue treatme nt with decitabine alone.
If a dose delay  occurs, then pharmacokinetic and biomarker assessments should be performed on 
the actual administration day  of talacotuzumab , not on the original scheduled administration day .
Dose reduction in Part A:Stepwise dose reductions described in the table below are permitted 
if requested and approved by [CONTACT_170159]-hematologic Grade ≥ 3 AE or Grade 4 hematologic toxicity  lasting more than 14 days and 
not responsive to t reatment and/or supportive care. 
Talacotuzumab dosing
0 9 mg/kg
-1 6 mg/kg
-2 3 mg/kg
6.3.4. Management of Potential Hy persensitivity / Infusion -related Reactions
Subjects who experience treatment emergent adverse events during the IV infusion of 
talacotuzumab must be treated according to the investigator’s judgment and best clinical 
practice. The following guidelines may  apply :
Subjects should be treated with acetaminophen, H1-antihistamine, or corticosteroids.
Intravenous saline may be indicated. For bronchospasm, urticaria, or dyspnea, subjects may
require H1-antihistamines, oxygen, corticosteroids, or bronchodilators. For hypotension,
subjects may  require vasopressors.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
69
Status: Approved, Date: 31 October 2017   In the event of a life-threatening infusion-related reaction (which may include pulmonary  or
cardiac events), or anaphy lactic reaction, talacotuzumab should be discontinued and no
additional talacotuzumab should be administ ered to the subject.
[IP_ADDRESS]. Guidelines for the Interruption of T alacotuzumab Infusion due to 
Infusion -related Reacti on
Infusion -Related Events of Grade [ADDRESS_199127]’s condition is stable, the infusion may be restarted at the 
investigator’s discretion. Upon restart, the infusion rate should be half of that used before the 
interruption. Subsequently , the infusion rate may be increased at the investigator’s discretion but 
should not exceed 60 mL/hr for Cy cles 1 to 4 and 150 mL /hr for subsequent cy clesat an y time .
If the subject experiences a Grade [ADDRESS_199128] be observed carefull y until resolution of the TEAE or until the intensity  of the 
event decreases to Grade 1or baseline , at which point the infusion may be restarted at the 
investigator’s discretion. Upon restart, the infusion rate should be half of that used before the 
interruption. Subsequently , the infusion rate may be increased at the investigator’s discretion but
should not exceed 60 mL/hr for Cycles 1 to 4 and150 mL /hrfor subsequent cycles at any time.
If the intensity  of the TEAE returns to Grade 3 after restart of the infusion, then the procedure 
described in this section may  be repeated at the investigator’s discretion. 
For infusion-related TEAEs that are Grade 4, the infusion should be stopped and treatment with
talacotuzuma b will be discontinued for that subject.
7. TREA TMENT COMPLIA NCE
Decitabine and talacotuzumab will be administered as IV infusions by [CONTACT_170160] .Additional details are provided in 
the S ite Investigational Product Procedures Manual.
Following Amendment [ADDRESS_199129] is 
enrolled (whichever occurs first), the eCRFs will be closed.
8. PRESTUDY AND CONCOMI TANT THERAPY
Prestudy  therapi[INVESTIGATOR_43710]28 days before the first dose of study  drug (Part A)or 
28days before randomization (Part B)must be recorded at screening. Prior systemic therapi[INVESTIGATOR_170098]. 
Concomitant therapi[INVESTIGATOR_170099] 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
70
Status: Approved, Date: [ADDRESS_199130] be notified in advance (or as soon as possible thereafter) of any instances in which 
prohibited therapi[INVESTIGATOR_23730].
Following Amendment [ADDRESS_199131] is 
enrolled (whichever occurs first) , follow up of subjects and data collection will end. Subjects 
who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170158]; during this period, only serious adverse events will be 
monitored and entered into the Company  safet y repository.
8.1. Permitted Medications and Supportive Therapi[INVESTIGATOR_170100], as clinicall y 
indicated. All supportive therapi[INVESTIGATOR_014], other than anticancer treatment needed for the management 
of subjects enrolled in this study , are encouraged .
The following medications and supportive therapi[INVESTIGATOR_170101] g the study :
Short -term (<3 days) treatment with low doses of systemic corticosteroids when medicall y 
necessary  for the control of acute s ymptoms or for premedication of talacotuzumab ;
Prophy lactic antibacterial, antifungal, or antiviral agents need to be used per institutional 
guidelines ;
Growth factors are strongl y recommended to be used for the treatment of febrile neutropenia 
(temperature ≥ 38.5°C and absolute neutrophil count < 1,000/µL ) or an active bacterial or 
fungal infection (ie, requiring intrave nous anti-infectives or extensive supportive care) in 
neutropenic subjects. Growth factors need to also be used to prevent treatment delay  due to 
neutropenia.
Red blood cell and platelet transfusions per institutional guidelines .
8.2. Prohibited Therapi[INVESTIGATOR_170102] :
Concurrent systemic corticosteroids except for short -term treatment and mandatory 
premedication ;
Plasmapheresis, cytoreduction by [CONTACT_170161] .Of 
note: treatment with hydroxy urea and plasmapheresis hasto be discontinued prior to start of 
study  therapy ; 
Any investigational agent; and
Any live attenuated vaccination.
8.3. Subsequent A ntineoplastic Therapi[INVESTIGATOR_170103] , for reasons other than treatment failure
(defined in Section [IP_ADDRESS] )or relapse from CR/CRi , is strongly  discouraged until treatment 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
71
Status: Approved, Date: 31 October 2017   failure or relapse is established. After treatment failure or relapse is established, subsequent 
therap y is permitted at the investigator’s discretion. Subsequent therapy  (including start date, end 
date, and best response) should be documented in the appropriate section of the eCRF.
9. STUDY EVA LUATIONS
Following Amendment 6, which incorporated the IDMC’s recommendations to close enrollment 
to the study  and discontinue talacotuzumab treatment for subjects receiving talacotuzumab + 
decitabine and offer to continue decitabine alone, all subjects will continue to be followed for 
survival and subsequent anti-cancer therapy . During the treatment phase with decitabine, 
subjects will be monitored for serious adverse events.
Following Amendment [ADDRESS_199132] is 
enrolled (whichever occurs first) , follow up of subjects and data collection will end. Subjects 
who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170158]; during this period, only serious adverse events will be 
monitored and entered into the Company  safet y repository.
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule s:Table s 1A, 1B,1C,1D,2A, and 2Bsummarize the frequency  
and timing of efficacy, pharmacokinetic, immunogenicit y, pharmacody namic, biomarker, 
pharmacogenomic, patient- repor ted outcomes, and safet y measurements applicable to this study .
Every  effort should be made to keep subjects on the study  schedule as planned from Study 
Day 1. At each visit, study  assessments should be completed before study  drug administration. 
All PRO assessments should be conducted/completed before any tests, procedures, or other 
consultations to prevent influencing subject perceptions but prior to and on the day of the actual 
study  drug administration.
Post-baseline disease evaluations may be conducte d 7days from the scheduled visit date, if 
necessary . At the following visit, the subject should return to the original planned schedule. 
Additional serum or urine pregnancy  tests may be performed, as determined necessary  by [CONTACT_41011], to establish the absence of pregnancy  at any time 
during the subject's participation in the study .
Medical resource utilization data will be collected. Refer to Section 9.8for details.
Assuming a study  duration of [ADDRESS_199133] 
will be approximately 336 mLsfor subjec ts participating in Part A, 541 mLsfor subjects 
participating in Part B Arm 1 (decitabine + talacotuzumab) and 387 mLs for subjects 
participating in Part B Arm 2 ( decitabine only). Repeat or unscheduled samples may  be taken for 
safet y reasons or for technical issues with the samples.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
72
Status: Approved, Date: 31 October 2017   9.1.2. Screening Phase
The signed informed consent form (ICF)must be obtained before any study -specific procedures 
are performed. The Screening Phase begins when the first screening assessment is conducted 
(that was not performed as part of the subject’s standard of care). During the Screening Phase, 
eligibility  criteria will be reviewed and a complete clinical evaluation will be performed as 
specified in Time and Events Schedule Table s 1Aand 1B. Screening procedures will be 
performed within 28days before first dose (Part A)or within 28 days before randomization 
(Part B). 
9.1.3. Open -Label Treatment Phase
Details of the procedures performed during the Treatment Phase are outlined in the Time and 
Events Schedule Table s 1A,1B, and 1C. For Part A,treatment will start onDay 1with an IV 
infusion of talacotuzumab and proceed as described inSection 6.1. Subjects will continue on 
study  and receive open label talacotuzumab in combination with decitabine in Part A until 
treatment failure, relapse from CR/CRi, unacceptable toxicity , death or ot her reasons specified in 
Section 10.2.
ForPart B ,treatment with study  drug should start within 3 day safter randomization and continue
until treatment failure ,relapse from CR/CRi, unacceptable toxicity , death , or other reasons 
specified in Section 10.2. 
All subjects in Part A and Part Bwill be closely  monitored for adverse events, laboratory  
abnormalities, and disease status. Clinical evaluations and laboratory  studies may be repeated 
more frequently , if clinically  indicated. If treatment failure or relapse from CR/CRi occurs, then 
the subject will compl ete the End-of- Treatment Visit and enter the Follow -up Phase. Subjects 
randomized into the decitabine + talacotuzumab arm can discontinue 1 drug (decitabine or 
talacotuzumab ); while continuing treatment with the other drug .
End ofTreatment
All subjects should have an End -of-Treatment Visit, u nless a subject withdraws consent for study  
participation or is lost to follow up. The End- of-Treatment Visit is to occur within 30 days
(+/- 7days)after the last dose of study  drug. Every  effort should be made to conduct the 
End-of-Treatment Visit before the subject starts subsequent treatment. 
9.1.4. Follow -up Phase
The Follow -up Phase will begin once a subject has completed the End-of-Treatment Visit . 
Subjects who discontinue before treatment failure or relapse from CR/CRi must continue to have 
disease evaluations according to the Time and Events Schedule Table s 1A,1B, and 1C.Subjects 
with unresolved drug-related adverse events of Grade 3 or higher as well as ongoing drug-related
serious adverse events (SAEs )will be followed until event resolution. After treatment failure or 
relapse is documented, only subsequent anticancer therapy ,concomitant therapy to treat a 
continuing drug-related adverse events (AE)≥ Grade 3 or serious adverse event (SAE ), survival 
status, and other malignancies will continue to be collected .If thisinformation is obtained via 
telephone contact, then written documentation of the communicat ion must be available for 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
73
Status: Approved, Date: [ADDRESS_199134]. At that time, follow up of subjects will end. 
Subjects who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170146]; during this period, only serious adverse events 
will be monitored and entered into the Company  safety repository  asdescribed under 
Amendment 7.
9.1.5. Disease Evaluation and Clinical Cutoff
Disease evaluations will be performed for each subject per the Time and Events Schedule Table s
1Aand 1Buntil treatment failure , relapse from CR/CRi, or until the study  has reached the 
clinical cutoff for OS or EFS, whichever occurs first.If the study continues enrollment to 
400subjects then theclinical cut-off for the final analy sis of OS is when [ADDRESS_199135] occurred. Enrollment was terminated after Interim 
Analy sis #[ADDRESS_199136] status. Bone marrow biopsy  material is not 
required, unl ess an aspi[INVESTIGATOR_170104] (dry  tap).
[IP_ADDRESS]. Disease Status 
Subjects will be assessed for d isease status according to the “Response Criteria in AML”9with a 
modification by [CONTACT_170162] (Table 6). The modification is necessary 
because the original criteria were intended for evaluation of standard induction therap y with 
3days of an anthracy cline and 7 day s of cy tarabine (3+7) or therapi[INVESTIGATOR_170105] y.
If treatment failure is suspected due to clinical indications or increased peripheral blast counts,
then a bone marrow sample must be obtained to confirm treatment failure as defined below. In 
the case of overt leukostasis, uncontrollable coagulopathy , or new extramedullary  leukemia 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
74
Status: Approved, Date: [ADDRESS_199137].
For this study ,treatment failure is defined as>25% absolute increase in the bone marrow blast 
count from baseline to the present assessment (eg, from 20% to 46%) on bone marrow aspi[INVESTIGATOR_337] 
(or biopsy  in case of dry  tap).
Stable disease is defined as response that does not qualify  for a complete or partial response and 
does not meet t he criteria for treatment failure.
The sponsor must be notified before subjects discontinue study  treatment. Before subjects 
discontinue the Treatment Phase due to treatment failure or relapse from CR/CRi, sites will 
document treatment failure or relapse as soon as possible and within 48 hours. The primary 
reason for discontinuation of study  treatment is to be recorded in the eCRF . For all subjects, the 
Sponsor should be informed as soon as treatment failure or relapse from CR/CRi is confirmed.
Discontinuation criteria for all subjects must be reviewed and confirmed by [CONTACT_170163].
Based on investigator’s disease assessments across all cycles of treatment, overall best response 
during the entire study  will be derived by [CONTACT_1034]. For an overall best response of stable 
disease, disease stabilization must have lasted for at least 8 weeks.
Table 6: Response Assessments
Category Definition
Com plete re sponse (CR)1Bone marrow  blasts <5%; absence ofblasts with Auer rods; absence of 
extramedullary disease; absolute neutrophil count >1.0 × 109/L (1000/μL); 
platelet count >100 × 109/L (100 000/μL); independence of red cell transfusions 
CR with incomplete recovery 
(CRi)2All CR criteria except for residual neutropenia (<1.0 × 109/L [1000/μL]) or 
thrombocytopenia (<100 × 109/L [100 000/μL]) 
Morphologic leukemia -free 
state3Bone marrow  blasts <5%; absence of blasts with Auer rods; absence of 
extramedullary disease; no hematologic recovery required 
Partial response (PR) Relevant in the setting of Phase 1 and 2 clinical trials only; all hematologic 
criteria of CR; decrease of bone marrow  blast percentage to 5% to 25%; and 
decrease of pretreatment bone marrow  blast percentage by [CONTACT_2669] 50% 
Cytogen etic CR (CRc)4Reversion to a normal karyotype at the time of morphologic CR (or CRi) in cases 
with an abnormal karyotype at the time of diagnosis; based on the evaluation of 
20 metaphase cells from bone marrow  
Molecular CR (CRm)5No standard definition; depends on molecular target
Relapse6Bone marrow blasts ≥5%; or reappearance of blasts in the blood; or developm ent 
of extramedullary disease 
Treatment failure7>25% absolute increase in the bone marrow  blast count from baseline to the 
present assessment (eg, from 20% to 46%) on bone m arrow aspi[INVESTIGATOR_337] (or biopsy in 
case of dry tap)
Stable disease8Doesnot qualify for a complete or partial response and has no evidence of
treatment failure.
Source: Dohner 20109with modification by [CONTACT_170164] b y Cheson 1990 .5
1All criteria need to be fulfilled; marrow  evaluation should be based on a count of 200 nucleated cells in an 
aspi[INVESTIGATOR_337] w ith spi[INVESTIGATOR_170106]; if ambiguous, consider repeat exam after 5 to 7 days; flow cytometric evaluation may help 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
75
Status: Approved, Date: 31 October 2017   to distinguish between persistent leukemia and regenerating normal marrow ; a marrow  biopsy should be 
performed in cases of dry tap, or if no spi[INVESTIGATOR_170107]; no minimum duration of r esponse required.
2The criterion of CRi is of value in protocols using intensified induction or double induction strategies, in which 
hematologic recovery is not awaited, but intensive therapy will be continued. In such protocols, CR may even 
not be achie ved in the cycle of the entire treatment plan. In these instances, the overall response rate should 
include CR and CRi patients. Some patients may not achieve complete hematologic recovery upon longer 
observation times.
3This category may be useful in the clinical development of novel agents within phase 1 clinical trials, in which a 
transient morphologic leukemia -free state may be achieved at the time of early response assessment.
4Four studies showed that failure to convert to a normal karyotype at the time of CR predicts inferior outcome.
5As an example, in core binding factor (CBF )AML low -level PCR -positivity can be detected in patients even in 
long-term response. Norm alizing to [ADDRESS_199138] percentages (5 -10%), a repeat marrow should be performed to confirm relapse. 
Appearance of new dysplastic changes should be closely monitored for emergin g relapse. In a patient who has 
been recently treated, dysplasia or a transient increase in blasts may reflect a chemotherapy effect and recovery 
of hematopoiesis. Cytogenetics should be tested to distinguish true relaps e from therapy -related MDS/AML.
7, 8Modified by [CONTACT_170165].
9.3. Pharmacokinetics and Immunogenicity
9.3.1. Evaluations
For all subjects participating in the study , pharmacokinetic samples to determine plasma
concentrations of decitabine and serum concentrations of talacotuzumab will be obtained 
according to the Time and Events Schedule Table s 2A and 2B. 
Venous blood samples (approximate 7.5mL per sample) will be collected to determine serum 
concentration of talacotuzumab and the serum will be divided into 4aliquots of approximate 
equal volume (1 aliquot for pharmacokinetic analy sis, 1aliquot for antibodies to talacotuzumab
analysis [whe n appropriate], and 2 aliquots asbackup). If needed, samples collected for 
determining serum concentrations of talacotuzumab in this study  may be used for determining 
immunogenicit y, further characterization of immunogenicit y, such as the ability  of anti-drug 
antibodies to neutralize the effect of talacotuzumab, address questions about drug characteristics 
that may arise at a later time point , or evaluation of safet y or efficacy aspects that address 
concerns arising during or after the study  period . Venous blood samples (approximate 0.5mL 
per sample) will be collected to determine plasma concentration of decitabine. Genetic analyses 
will not be performed on these samples, and subject confidentiality  will be maintained. 
The exact dates and times of blood sampling must be recorded. Refer to the Laboratory  Manual 
for sample collection , handling, and shippi[INVESTIGATOR_29356]. Collected samples must be stored 
under the specified and controlled conditions for thetemperatures indicated in the Laboratory  
Manual.
9.3.2. Analytical Procedures
Serum samples will be analy zed to determine concentrations of talacotuzumab andgeneration of 
antibodies to talacotuzumab (immunogenicity ) using validated immunoassay  methods by [CONTACT_170166]’s bioanaly tical facility as indicated by [CONTACT_170167] 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
76
Status: Approved, Date: 31 October 2017   Schedule Table s 2A and 2B. If need ed,interim analy ses of the serum talacotuzumab
concentrations from Part A may be conducted . All bioanal ytical results from the interim analy sis 
will be considered final and these samples will not be re -assay ed at the end of the study .
Plasma samples will be analyzed to determine the concentration of decitabine using a validated 
LC/MS/MS method b y or under the supervision of the sponsor’s bioanaly tical facilit y. The 
complete bioanal ytical report, describing the assay methodologies and results, will be included as 
an appendix to the pharmacokinetic report which is contained within the integrated st udy report.
9.3.3. Pharmacokinetic Parameters
Plasma concentrations of decitabine and serum concentrations of talacotuzumab will be 
measured and resulting concentration over time data will be summarized by [CONTACT_3148]. 
Population PK models will be explored and developed if data are sufficient from this study . If 
sufficient data are available, the pharmacokinetic parameters such as the ones listed below for 
talacotuzumab may be calculated.
AUCt 1-t2 Area under the concentration -time curve between time t1
and t 2
CL total sy stemic clearance of drug after IV administration
Cmax maximum observed concentration
Cmin minimum observed concentration
V volume of distribution
Pharmacokinetic samples to determine the plasma concentration of decitabine and the serum 
concent ration of talacotuzumab will be obtained from all applicable subjects in the study as 
described in Time and Events Tables 2A and 2B.
9.3.4. Immunogenicity  Assessments
For all subjects in Part A and those randomized to receive decitabine + talacotuzumab in PartB, 
venous blood samples will be drawn to assess the generation of antibodies to talacotuzumab
(immunogenicit y),as specified in the Time and Events Schedule Table s 2A and 2B. 
Additionally , blood samples to assess immunogenicity  should be collected at the final visit for 
subjects who discontinue treatment or withdrawn from the study . Subjects who discontinue 
treatment in Part B will also be asked to return for an immunogenicit y evaluation during the 
Follow -up Phase. 
All samples collected for immunogenicit y analy sis will be evaluated for talacotuzumab serum 
concentration to ensure appropriate interpretation of immunogenicit y data. At each time point, 
immunogenicit y and serum talacotuzumab concentration analy ses will be performed on aliquots 
from the same blood draw and no additional sampling is required. Procedures for sample 
collection, preparation, identification, storage, and shipment will be provided in the Laboratory 
Manual or equivalent document. 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
77
Status: Approved, Date: 31 October 2017   Serum samples will be screened for antibodies binding to talacotuzumab and serum titer will also 
be determined from confirmed positive samples using validated assay  methods by [CONTACT_117185]. Other immunogenicity  analyses (eg, assessment of neutralizing 
capabilities) may  be performed to further characterize the immune responses that are generated. 
Any time an infusion-related reaction is observed or reported during the study , a blood sample 
should be drawn for determination of antibodies to talacotuzumab. T alacotuzumab serum 
concentration will also be determined from the same infusion- related reaction sample for the 
purpose of interpreting immunogenicit y data. These samples will be stored and evaluated if 
deemed necessary . If the infusion-related reaction results in treatment discontinuation, then 
subjects should undergo all scheduled safet y and efficacy  evaluations. Samples collected for the 
analysis of talacotuzumab immunogenicity /serum concentration may additionally  be used to 
evaluate safet y or efficacy  aspects that address concerns arising during or after the study  period 
or for the evaluation of relevant biomarkers b y the sponsor or sponsor’s designee. 
9.4. Pharmacokinetic/Pharmacod ynamic Evaluations
If sufficient data are available, pharmacokinetic/pharmacod ynamic modeling may be performed, 
including exploring the relationship between serum concentrations of talacotuzumab and 
biomarkers , PD markers, or endpoints of clinical efficacy . If these analyses are performed, the 
details and results will be presented in a separate report.
9.5. Biomarkers
Biomarker anal yses are dependent upon the availability  of appropriate biomarker assay s and may 
be deferred or not performed if, during or at the end of the study , it becomes clear that the 
analysis will have no scientific value, or if there are not enough samples or not enough 
responders to allow for adequate biomarker evaluation. In the event the study  is terminated early 
or shows poor clinical efficacy , completion of biomarker assessments is based on justification 
and intended utility  of the data. Samples for biomarker evaluations will be collected as specified 
in the Time and Events Schedule Table s 2A and 2B.
9.5.1. Assessment of Pharmacody namic Markers (Part A  and Part B)
Changes in cell numbers of cellular biomarkers (basophils, pDC s,monocytes, NK cells and 
eosinophils) as well asCD123 expression and receptor occupancy will be measured by [CONTACT_170168] . 
9.5.2. Assessment of CD123 Expression (Part B)
CD123 expression and density willbe determined in AML  blasts and LSCs in bone marrow and 
blood by [CONTACT_170169] a central laboratory and may be compared with other methods such 
as reverse transcriptase – quantitative polymerase chain reaction (RT- qPCR) ,CD123 expression 
may be followed when bone marrow aspi[INVESTIGATOR_170108]/CRi ,and at End-Of-
Treatment to evaluate changes in CD123 expression in the myeloid blast and LSCpopulation 
with talacotuzumab treatment (Time and Events Schedule Table 1B and 1C).
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
78
Status: Approved, Date: 31 October 2017   9.5.3. Minimal Res idual Disease A ssessment (Part B)
Minimal residual disease assessments will be performed on bone marrow aspi[INVESTIGATOR_170109] 1B. The objective is to compare MRD in subjects from both arms who achieve a 
CR or CRi response. Minimal residual disease negativity  is defined as less than [ADDRESS_199139] or 
leukemic stem cell in 10,000 leukocy tes (MRD level <104).Flow cytometry  will be utilized as 
the primary  method of MRD analysis, and when available, may be compared toother molecular 
approaches such as PCR or next- generation sequencing (NGS) of specific genomic 
abnormalities.
9.5.4. Immunophenotypi[INVESTIGATOR_007] (Part B)
Bone marrow aspi[INVESTIGATOR_4026] (as available per Time and Events Schedule Table 1B)or whole blood 
may be utilized for immunophenoty pi[INVESTIGATOR_007] (performed by [CONTACT_170170] /CyTOF) which includes analyses of NK cells, T cells, and B cells as well as other 
potential immune cell subpopulations. The main mechanism of action of talacotuzumab is 
ADCC through NK cell activation; therefore, NK cell counts and activation will be assessed by 
[CONTACT_4133] (Time and Events Schedules Tables 1B, 2A,and 2B). Patients receiving 
decitabine will be analy zed pre -and post -decitabine treatment for NK cell number and activity  in 
an attempt to address the effect of decitabine on NK cell function (Time and Events Schedules 
Tables 2Aand 2B). Subjects in PartA will only be assessed for NK cell activit y and cell 
numbers by [CONTACT_4133]  (Time and Events Schedule Table 2A).To investigate whether an 
immune fitness signature [CONTACT_170201], 
whole blood samples may also be subject edto RNA profiling (RNA -seq, gene expression 
profiling), or methy lation assessment to evaluate novel technologies for immune profiling in 
bone marrow and whole blood, and to compare these methodologies to standard flow cytometry
or Cy TOF . These assessments will be evaluated for association with clinical outcome. 
9.5.5. Cytokine A nalysis
Samples (blood) for cytokine analysis will be collected as described in the Time and Events 
Schedule 2B.
Infusion -related reactions occur with the administration of talacotuzumab. Cy tokine analy sis will 
be performed to determine the association of cytokines with infusion-related reactions and to 
help gain an understanding of the mechanism of these reactions .
9.6. Pharmacogenomic (DNA and RNA ) Evaluations (Part B)
DNA or RNA samples will be used for research related to talacotuzumab (CSL 362) and/or 
decitabine or AML. They  may also be used to develop tests/assays related to talacotuzumab 
(CSL 362) and/or decitabine and AML. Pharmacogenomic research may  consist of the analy sis of 
one or more candidate genes or of the analysis of genetic markers throughout the genome in 
relation to talacotuzumab or AML clinical endpoints. 
More specificall y, myeloid specific genomic profiling may be done employ ing a panel of genes 
with known myeloid mutations such as NPM1, FLT3 -ITDD, DNMT3a, TET2, IDH1/2 that will 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
79
Status: Approved, Date: 31 October 2017   be sequenced and analy zed in correlation to prognosis and response to talacotu zumab or 
decitabine treatment. Additional analy ses may be conducted if it is hypothesized that this may 
help resolve issues with the clinical data.
Gene expression and DNA methy lation analyses may be analyzed on bone marrow aspi[INVESTIGATOR_170110]/or peripheral blood samples at baseline and post decitabine exposure if deemed necessary  to 
evaluate the decitabine effect in combination with talacotuzumab . Single nucleotide 
polymorphism (SNPs) associated with ADCC or NK-cell activity  may be evaluated if warranted 
based on additional clinical data.
9.7. Patient -reported Outcomes
9.7.1. FACT-Leu
The FACT -Leu, a self-administered PRO measure, will be used in this study . It will enable the 
evaluation of asubject’s perceptions of health- related quality  of life. 
The FACT -Leu is a 44-item, self-reported leukemia -specific measure that is used to 
quantitatively  assess an individual’s perception of how the disease affects their day -to-day life. It 
includes 5 subscales, ie, physical well- being, social/family  well-being, emotional well-being, 
functional well-being, and leukemia -specific concerns. All FACT -Leu subscale and aggregated 
scores showed high internal consistency  and high test-retested reliability .4A sample of the 
FACT -Leu containing representative questions is provided in Attachment 1.
9.7.2. EQ-5D-5L
The EQ-5D- 5L is a generic measure of health status. For purposes of this study , the EQ-5D- 5L 
will be used to generate utility  scores for use in cost effectiv e analyses. The EQ-5D- 5L is a 
5item questionnaire that assesses 5 domains including mobility , self-care, usual activities, 
pain/discomfort and anxiety /depression plus a visual analog scale rating “health today ” with 
anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state) .7,22
The scores for the 5 separate questions are categorical and cannot be analyzed as cardinal 
numbers. However, the scores for the 5 dimensions are used to compute a single utility  score 
ranging from zero (0.0) to 1 (1.0) representing the general health status of the individual. A 
sample of the EQ -5D-5L that contains representative questions is provided in Attachment 2.
9.8. Medical Resource Utilization 
Medical resource utilization data, associated with medical encounters, will be collected in the 
CRF by [CONTACT_70449] -site personnel for all subjects throughout the study . 
Protocol -mandated procedures, tests, and encounters are excluded. The data collected may be 
used to conduct exploratory  economic anal yses and will include:
Duration of hospi[INVESTIGATOR_059] (total days length of stay, including duration by [CONTACT_54006]; 
eg,intensive care unit)
Outpatient medical encounters and treatments (including physician or emergency  room 
visits, selected tests and procedures, and medications)
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
80
Status: Approved, Date: [ADDRESS_199140] be recorded on the Adverse 
Event section of the eCRF .Any clinicall y significant abnormalities persisting at the end of the 
study /early  withdrawal will be followed by [CONTACT_43727] a clinically  
stable endpoint is reached. The study  will include the following evaluations of safety  and 
tolerability  according to the time points provided in the Time and Events Schedule Table s 1A ,
1B, 1C, and 1D :
Adverse Events
Adverse events will be reported by [CONTACT_423] (or, when appropriate, by a caregiver, surrogate, 
or the subject's legally acceptable representative) from the time a signed and dated informed 
consent form is obtained. Adverse events will be reported until [ADDRESS_199141] is 
enrolled (whichever occurs first) , follow up of subjects and data collection will end. Subjects 
who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170158]; during this period, only serious adverse events will be 
monitored and entered into the Company  safet y repository.
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology will be collected as specified in the Time 
and Events Schedule Tables 1Aand 1Band 1C. Additional clinical laboratory  tests may be 
performed as indicated by  [CONTACT_170171]. Hematology  and serum chemistry  laboratory  evaluations may be 
repeated as clinicall y indicated. The investigator must review the labora tory results ,document 
this review, and record any clinical ly relevant changes occurring during the study  in the adverse 
event section of the eCRF . The laboratory  reports must be filed with the source documents.
Screening laboratory  results must be available to the investigator for evaluation before the first 
dose of study  drug on Day  1 of C ycle 1.
The following tests will be performed b y the local laboratory :
Hematology  Panel
-hemoglobin
-absolute white blood cell (WBC) count
-platelet count
-absolute monocy tecount
-absolute basophil count
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
81
Status: Approved, Date: [ADDRESS_199142] count
Coagulation: 
-activated partial thromboplastin time (aPTT)
-International normalized ratio (INR) or prothrombin time (PT)
Serum Chemistry  Panel
-sodium -aspartate aminotransferase (AST)
-potassium -alanine aminotransferase (ALT)
-magnesium -alkaline phosphatase
-creatinine -calcium
-total bilirubin -blood urea nitrogen (BUN)
-phosphate -uric acid
Serum -hCG or urine pregnancy  testing for women of childbearing potential only
(screening onl y)or if clinically  indicated or required by  [CONTACT_427].
Electrocardiogram (ECG)
Electrocardiogram will be performed forall subjects during screening as indicated in the Time 
and Events Tables 1Aand 1B. Abnormalities noted at screening should be included in the 
medical history . During the collection of ECGs, subjects should be in a quiet setting without 
distractions (eg, television, cell phones). Subjects should rest in a supi[INVESTIGATOR_21683] 
5minutes before ECG collection and should refrain from talking or moving arms or legs. If 
blood sampling or vital sign measurement is scheduled for the same time point as ECG 
recording, then the proce dures should be performed in the following order: ECG(s), vital signs, 
blood draw. 
In Part A, QTcF will be assessed at the time of screening and in the Open -Label Treatment Phase 
if clinicall y required. If QTcF is >470 milliseconds , refer to the Time and Events Schedule 
Tables 1A ,1B, and 1C for additional assessment procedures. 
In Part B, ECG monitoring for subjects in Arm 1 will occur during screening and on C ycle 1 Day 
8 and Day  22 after the talacotuzumab IV infusion, then every  2 cy cles thereafter on Day 22 after 
the talacotuzumab IV infusion and at EOT. For subjects in Arm 2, ECG monitoring will occur 
during screening and on Cycle 1 Day 5 after the decitabine IV infusion and then every  2 cycles 
thereafter on Day  5 after the decitabine IV infusion and at EOT .
Multi Gated Acquisition (MUGA) Scan / Echocardiography
Baseline left ventricular ejection fraction (LVEF) measured by (MUGA or echocardiogram) 
must be assessed and be within institutional limits for subjects to be eligible for this study  and 
may be repeated throughout the study  when clinically  indicated and at EOT . When the exam is 
repeated, the same measurement modality  should be used.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
82
Status: Approved, Date: [ADDRESS_199143] in a quiet setting without distractions (eg, television, cell phones).
Physical Examination
A full physical examination will be performed at screening. Subsequently , a directed physical 
examination (including all organ sy stems that were previously  abnor mal or involved with disease 
and documentation of any  clinically  relevant abnormalities in any  organ) will be performed at the 
timepoints specified in the Time and Events Schedule Table s 1A ,1B, and 1C. Any changes that 
are clinically  significant will be recorded on the AE page . Height will be measured at Screening 
only; weight will be measured prior to the start of each cy cleand at the EOT.
ECOG Performance Status
The ECOG Performance Status scale will be used to grade changes in the subject’s daily  living 
activities. The ECOG Performance Status scale is provided in Attachment 3.The frequency  of 
ECOG Perfo rmance Status assessment is provided in the Time and Events Schedule Table s 1A
and 1B.
9.10. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. When applicable, blood samples should be collected from the arm contralateral 
to the drug infusion arm. If blood samples are collected via an indwelling cannula, an appropriate 
amount (1 mL) of serosanguineous fluid slightly  greater than the dead space volume of the lock 
will be removed from the cannula and discarded before each blood sample is taken. Refer to the 
Time and Events Schedule Tables 2Aand 2Bfor the timing and frequency  of all sample 
collections.
For samples collected forthe central laboratory , sample dates and times must be recorded on the 
laboratory  requisition form. Further instructions for the collection, handling, storage, and 
shipment of samples are found in the laboratory  manual that will be provided. Collection, 
handling, storage, and shipment of samples must be under the specified, and where applicable, 
controlled temperature conditions as indicated in the laboratory  manual .
10. DISCONTINUA TION OF STUDY TR EATMENT/ WITHDRA WALFROM STUDY
10.1. Completion
A subject will be considered to have completed the study  if he or she has finished all 
protocol -specified procedures, has not been lost to follow up, andhas not withdrawn consent for 
study  participation before the end of study data collection .In addition, subjects who die prior to 
the end of study data collection will be considered to have completed. Subjects in the Follow -up 
Phase will be considered to have completed the study  when the end of study data collectio nhas 
been reached ([ADDRESS_199144]; see Section 9.1.4 ).Following Amendment 7, follow up of subjects and data 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
83
Status: Approved, Date: 31 October 2017   collection will end. Subjects who are continuing to derive benefit from decitabine treatment as 
assessed by  [CONTACT_170172]; during this period, only  serious 
adverse events will be monitored and entered into the Company  safet y repository .
10.2. Discontinuation of the Treatment Phase
If a subject's study  treatment must be discontinued before the end of the treatment regimen, then
this will not result in automatic withdrawal of the subject from the study . A subject’s 
participation in the T reatment Phase will be discontinued ifany of the following occur :
The subject experiences treatment failure (defined in Section [IP_ADDRESS] ) or relapse from 
CR/CRi;
The subject experiences unacceptable toxicity (In Arm 1, subjects may discontinue 1 drug 
while continuing treatment with the other drug );
The subject experiences a severe infusion reaction with cardiovascular collapse;
The subject initiates treatment with a prohibited medication;
The investigator or sponsor believes (eg, that for safet y or tolerability  reasons such as an 
adverse event) it is in the best interest of the subject to discontinue treatment ;
The subject becomes pregnant; or
The subject (or the subject’s legall y acceptable representative) withdraws consent for 
administration of study  treatment . 
Before subjects discontinue the Treatment Phase due to treatment failure or relapse from 
CR/CRi , sites will document treatment failure or relapse as soon as possible and within 48 hours. 
The primary  reason for discontinuation of study  treatment is to be recorded in the eCRF. For all 
subjects, the Sponsor should be informed as soon as treatment failure or relapse from CR/CRi is 
confirmed and all treatment discontinuations will be reviewed for approval by [CONTACT_1034] .
After discontinuation from the Treatment Phase, all subjects in both treatment groups should 
have an End-of- Treatment Visit and enter the Follow -up Phase. Follow -up assessments should 
continue as specified in the Time and Events Schedule s (Table s 1A,1B, 1C, and 1D). 
10.3. Withdrawal From the Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent
The study  investigator or Sponsor, for any reason, stops the study  or stops the subject’s 
participation in the study
If a subject is lost to follow -up, every reasonable effort must be made by  [CONTACT_170173]/withdrawal. The measures 
taken to follow up must be documented.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
84
Status: Approved, Date: [ADDRESS_199145] may withdraw consent for use of sample sfor research (refer toSectio n 16.2.5 , 
Long -Term Retention of Samples for Additional Future Research). In such a case, samples will 
be destro yed after they are no longer needed for the clinical study . Details of the sample 
retent ionfor research are presented in the main ICF.
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
11.1. Subject Information
The primary  analysis population will be the all-randomized population, which will include all 
subjects in Part B. Safety  will be evaluated for all subjects who have received at least [ADDRESS_199146] deviation, and range. Categorical variables will be 
summarized using frequency  tables.
11.2. Interim and Final A nalyses
Safety  reviews will be performed in Part A and Part B. The safety  assessments by [CONTACT_170174] (SET)in Part A will occur prior to the initiation of Part B. This will include 
available PK and PD data from both single agent talacotuzumab and the combination of 
decitabine + talacotuzumab . In addition, a safet y review by [CONTACT_170175]  20 subjects (10subjects from each arm) have been 
enrolled in Part B and followed for at least 1 month to assess the safet y and tolerability  of the 
combination treatment. This review will also include all safet y, PK, and PD data available from 
Part A.
Part B of the study  includes an interim analy sis based on response rates of CR and CR+CRi that 
will occur after approximately  80 subjects (40 subjects per arm) have been randomized and 
followed for at least 4 months. The results of this interim analysis will be used to guide if the 
study  continues enrollment to the pre -specified 400 subjects or stops enrollment. Enrollment will 
continue during the interim analy sis;it is estimated that approximately  [ADDRESS_199147] interim analy sis are available. 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
85
Status: Approved, Date: 31 October 2017   The statistical criteria to guide the decision making will be based on the difference (Δ) in 
response rate between the 2 treatment arms (decitabine + talacotuzumab minus decitabine alone) 
as the following:
If ΔCR ≥15% or Δ(CR+CRi) ≥25%, then the study  may continue enrollment to 
400 subjects; 
If ΔCR <15% and Δ(CR+CRi) <25%, then the study  may stop enrollment at 
approximately  120 subjects. 
The IDMC will use the above response rate criteria as well as the totality  of the data to guide the 
recommendation regarding enrollment continuation to 400 subjects or stop pi[INVESTIGATOR_170111]. The final decision will be made by [CONTACT_170176] , totality of the data, and other development considerations.
If the study  continues enrollment to 400 subjects, then the overall Type 1 error of 0.05 (2-sided) 
will be allocated between the primary  endpoints of CR rate and OS using a gate -keepi[INVESTIGATOR_170112]:
There will be a formal statistical testing for superiority  for CR at the interim analy sis of 
80subjects with 2-sided α=0.001. The final analy sis of CR(in terms of formal statistical 
hypothesis testing ) will ta ke place after [ADDRESS_199148] been randomized and followed for 
4 months (to occur at the same time as the 1stinterim analysis of OS) with 2-sided α=0.0 09. 
The study  and collection of response data continue after the final CR analysis regardless of 
the outcome of the anal ysis.
Overall 2-sided α=0.04 for OS; and if the final analysis of CR achieves statistical 
significance, then α=0.009 allocated to this CRanaly siscan be reclaimed by  [CONTACT_170177], ie, 
OS can be tested at the overall level of 0.0 49.
The 2interim analyses and final analysis for OS will utilize the O’Brien -Fleming 
α-spending procedure.
If the study  stops enrollment after the first interim analy sis, then the clinical cut-off will be when 
[ADDRESS_199149].
The overall statistical inference of the stud y can be summarized as in Table 7.
Table 7: Overall Statistical Inference
Enrollment, 
No. of 
SubjectsAnalysis Clinical Cutoff 2-Sided α
40 subjects 
per armInterim analysis of CR 
and CR+CRi to 
determine enrollment 
continuation4 months after 40 subjects per arm
are randomized0.001
Continue to 
approx. 400CR final analysis 4 months after 160 subjects are 
randomized0.009
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
86
Status: Approved, Date: 31 October 2017   OS interim analysis No.1 At the time of final CR analysis 0.0002
OS interim analysis No.2 180 deaths 0.0088/0. 0116a
OS final analysis 270 deaths 0.0372/0. 0454a
Stop with 
approx. 120 EFS final analysisb90 EFS events NA
a If CR final analysis reaches statistical significance
b Exploratory without formal statistical hypothesis testing
11.3. Sample Size Determination
Part A:
Approximately  6subjects will be enrolled in Part A of the study  in order to confirm the RP2D of 
talacotuzumab for Part B .
Part B:
The first interim analysis to guide the decision forstudy  continuation will occur after 
approximately  80 subjects (40 subjects per arm) have been randomized and followed for at least 
4 months; the operating characteristics of the criteria are shown in Table 8.
Table 8: Study Continuation Decision Rule, Operating Characteristics 
Sample size 40/arm
Enrollment may continue to approximately 400 subjects CR ≥15% or(CR+CRi) ≥25%
Enrollment may stop with approximately 120 subjects CR < 15% and(CR+CRi) <25 %
False positive error ratea0.[ADDRESS_199150] of decitabine alone and decitabine +
talacotuzumab are the same : CR=15%, CR+CRi=25%
b Decision for stoppi[INVESTIGATOR_170113] [ADDRESS_199151] of decitabine alone: 
CR=15%, CR+CRi=25% , and trueeffect of decitabine +talacotuzumab : CR=40%, CR+CRi=55%
=difference in response rate, decitabine +talacotuzumab minus decitabine alone
If the study  continues enrollment to 400 subjects, both primary  endpoints (CR rate and OS)will 
be powered for 80% with overall α allocation of 0.01 and 0.04, respectivel y (Table 9 ).
If the study  stops enrollment after the first interim analy sis,it is expected that approximately 
120subjects would have been randomized to the study . In thiscase, the primary  focus will be 
exploratory  to assess if there is a clinically  relevant improvement in EFS for decitabine + 
talacotuzumab- treated subjects compared with subjects treated with decitabine alone. Assuming 
median EFS of 4months for the decitabine alone arm, an improvement of 2.8 months in the 
talacotuzumab + decitabine arm (or hazard ratio HR=0.59) is considered clinically  meaningful. 
For this purpose, 90 EFS events will provide 80% power to rule out a HR=1.0 (no differenc e in 
EFS between the 2 treatment arms) using a 90% confidence interval. If [ADDRESS_199152] is 
randomized.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
87
Status: Approved, Date: 31 October 2017   Overall power and sample size determinations ar e summarized in Table 9 .
Table 9: Sample Size Determination
Endpoint (s)Effect Size ,
Decitabine +Talacotuzumab
vs. D ecitabine alone PowerOverall
2-side αTotal No. 
of EventsTotal 
Sample 
Size
Primary: CR Rate 40% vs. 15% 80% 0.01 160
Primary: OS Median 11.[ADDRESS_199153] ratio=0.7080% 0.04 270 400
Secondary: EFS Median 6.[ADDRESS_199154] ratio=0.5980% 90% CIa90 [ADDRESS_199155] ratio estimate and 
corresponding 90% confidence interval (CI).
11.4. Efficacy  Analyses
Kaplan -Meier estimates oftime to events, including OS andEFS will be prese nted, along with a 
stratified (by [CONTACT_170178] ) log-rank test comparing the 
2treatment arms. Median OSalong with corresponding 95% confidence intervals (CIs) will be 
obtained from the Kaplan -Meier estimates. Cox’s regression (stratified by [CONTACT_170179] )will be applied to obtain the hazard ratio estimate 
and the corresponding 95% CI. Additional Cox’s regression may be performed to include 
appropriate baseline prognostic variables.
Number and percent of subjects who have CR ,CR+ CRi, and CR plus MRD negative CRi will be 
calculated and compared between the 2 treatment arms using Fisher’s exact test. Time to 
response and duration of response will also be summarized for subjects who have CR, CR+CRi , 
and CR plus MRD negative CRi.
Descriptive anal ysis will be performe d for RFS.
Statistical analy ses will be performed for all randomized subjects, as well as for subgroups 
defined by [CONTACT_170180], including CD123 status. A dditional 
efficacy  anal yses may be performed to include appropriate d ata from Part A .
11.5. Pharmacokinetic A nalyses
Pharmacokinetic analyses will be performed on the pharmacokinetic- evaluable population, 
defined as subjects who have received at least [ADDRESS_199156] -infusion sample available . 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
88
Status: Approved, Date: 31 October 2017   Data will be listed for all subjects with available talacotuzumab or decitabine concentrations. 
Subjects will be excluded from the PK analy sis if their data do not allow for accurate assessment 
of the PK (eg, incomplete administration of the study agent). All analyteconcentrations below 
the lowest quantifiable concentration and any missing data will be labeled as such in the 
concentration data presentation. Concentrations below the lowest quantifiable concentration will 
be treated as zero in the summary  statistics. All subjects and samples excluded from the analysis 
will be clearl y documented in the study report. 
Descriptive statistics, including mean, standard deviation, coefficient of variation (%CV), 
median, minimum, and maximum, will be used to summarize decitabine plasma concentrations 
and talacotuzumab serum concentrations at each sampling time point . If appropriate, 
pharmacokinetic parameters of talacotuzumab such as Cmin, C max, AUCt 1-t2, CL,and Vmay be 
calculated. Graphical exploratio n of data may  be performed if deemed useful.
Population PK analy sis of decitabine and talacotuzumab will be explored. If sufficient data are 
available, then population pharmacokinetic analy sis of plasma concentration x time data of 
decitabine or serum conc entration xtime data of talacotuzumab will be performed using 
nonlinear mixed -effects modeling. Data may be combined with those of other studies to suppor t 
a relevant structural model. In addition, available subject characteristics (eg, demographics, 
laboratory  data, etc.) may be tested as potential influential covariates affecting PK parameters. If 
the population pharmacokinetic analysis is conducted, then details will be given in a population 
pharmacokinetic analysis plan and the results of the analysis will be presented in a separate 
report.
11.6. Immunogenicity  Analyses
The incidence of antibodies to talacotuzumab (immunogenicit y) will be summarized for all 
subjects who receive at least [ADDRESS_199157] appropriate samples for detection 
of antibodies to talacotuzumab.
A listing of subjects who are positive for antibodies to talacotuzumab will be provided. The 
maximum titers of antibodies to talacotuzumab will be summarized for subjects who are po sitive 
for antibodies to talacotuzumab .
Other immunogenicit y analy ses may be performed to further characterize the immune responses 
that are generated.
11.7. Pharmacokinetic/Pharmacody namic A nalyses
If sufficient data are available, then the relationship between serum concentrations of 
talacotuzumab or plasma concentrations of decitabine , and PD markers, biomarkers or endpoints 
of clinical efficacy could be explored using population approaches (eg, non-linear mixed effects 
approaches) . Details and results of such analy sis willbe presented in a separate report . 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
89
Status: Approved, Date: 31 October 2017   11.8. Biomarker A nalyses
Biomarker studies are designed to identify  markers predictive of response (or resistance) to 
talacotuzumab. Anal yses will be stratified by [CONTACT_170181] (eg, parametric or non-parametric, univariate or multivariate, 
analysis of variance [ANOVA], or survival analysis, depending on the endpoint). Correlation of 
baseline expression levels or changes in expression levels with clinical parameters will identify  
responsive (or resistant) subgroups in addition to immune cells, genes and pathway s attenuated 
following treatment with talacotuzumab. 
Basophils and pDC s, as potential pharmacodynamic measures, will be listed, tabulated, and 
where appropriate, plotted. Subjects may be grouped by [CONTACT_9084], dose, or clinical response. Data 
from CD123 expression will be used as prognostic factors for clinical outcomes to explor e if 
potential thresholds can be established for future subject selection. Results of biomarker and 
pharmacod ynamic analyses may be presented in a separate report. Planned analyses are based on 
the availability  of clinically  valid assay s and may be deferre d if emerging study  data show no 
likelihood of providing useful scientific information.
11.9. Pharmacogenomic A nalyses
All pharmacogenomic measures will be listed, tabulated, and where appropriate, plotted. 
Correlation of response and pharmacogenomics measures will be explored. Results may be 
presented in a separate report. Planned analyses are based on the availability  of clinically  valid 
assay s and may be deferred if emerging study  data show no likelihood of providing useful 
scientific information.
11.10. Patient -repo rted Outcomes and M edical Resource Utilization
FACT -Leu and EQ-5D- 5L scores will be summarized at each time point. Medical resource 
utilization will be descriptively  summarized by [CONTACT_1570]. Duration of hospi[INVESTIGATOR_059] 
(total days length of stay, including duration by [CONTACT_54006]; eg, intensive care unit), frequencies of 
outpatient medical encounters and treatments will be calculated and tabulated.
11.11. Safety  Analyses
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_23820] (MedDRA). Toxicities will be graded for 
severit y according to NCI-CTCAE, version 4.03. All reported adverse events with onset during 
the treatment phase (ie, treatment -emergent adverse events, and adverse events that have 
worsened since baseline) will be included in the analy sis. For each adverse event, the percentage 
of subjects who experience at least 1occurrence of the given event will be summarized by 
[CONTACT_1570].
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
90
Status: Approved, Date: 31 October 2017   Specificall y, the following will be summarized:
All adverse events;
Grade 3 or higher adverse events;
Serious adverse events;
Adverse events leading to discontinuation of treatment;
Adverse events leading to death; and
Adverse events of special interest. 
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, who discontinue treatment due to an adverse event, or who experience a severe 
or a serious adverse event.
Clinical Laboratory Tests
Laboratory  data will be summarized by [CONTACT_23821]. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data. Descriptive statistics will be calculated for each laboratory  analyte at baseline. 
Parameters with predefined National Cancer Institute Common Terminology  Criteria for 
Adverse Events (NCI -CTCAE) toxicity  grades will be summarized. Change from baseline to the 
worst adverse event grade experienced by [CONTACT_170182].
Electrocardiogram (ECG)
Electrocardiogram data will be presented b y descriptive anal ysis only .
Vital Signs
Descriptive statistics of heart rateand supi[INVESTIGATOR_9204] (systolic and diastolic) values and 
changes from baseline will be summarized. The percentage of subjects with clinically  important 
changes from baseline will be summarized.
11.12. Independent Data Monitoring Committee 
An IDMC, consisting of at least 2 clinicians and 1 statistician who are independent experts 
otherwise not participating in the study , will be established to review efficacy  and safet y results 
at the planned interim analyses. After the interim review, they will make recommendations 
regarding the continuation or stoppi[INVESTIGATOR_68660] . Study  investigators and the sponsor’s study 
team will not have access to the blinded data provided to the IDMC.
In addition, the IDMC will review safet y data after the first [ADDRESS_199158] 1 month in Part B. The details will be provided in a separate IDMC charter.
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
91
Status: Approved, Date: [ADDRESS_199159] Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_43765].
Method of Detecting Adverse Events and Serious Adverse Events
Care will be taken not to introduce bias when detecting adverse events or serious adverse events. 
Open -ended and nonleading verbal questioning of the subject is the preferred method to inquire 
about adverse event occurrence. For some studies, subjects are not always able to provide valid 
verbal responses to open ended questions. In these circumstances, caregivers or guardians would
provide information regarding adverse event occurrence. 
Solicited Adverse Events
Solicited adverse events are predefined local and systemic events for which the subject is 
specificall y questioned.
Unsolicited Adverse Events
Unsolicited adverse events are all adverse events for which the subject is specifically  not 
questioned.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinica l study  subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or disease temporally  associated 
with the use of a medicinal (investigational or non-investigational) product, whether or not 
related to that medicinal (investigational or non-investigational) product (Definition per 
International Conference on Harmonisation [ICH]) . This includes any occurrence that is new in 
onset or aggravated in severity  or frequency  from the baseline condition, or abnormal results of 
diagnostic procedures, including laboratory  test abnormalities. Note: The sponsor collects 
adverse events starting with the signing of the ICF (refer to Section 12.3.[ADDRESS_199160] adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
92
Status: Approved, Date: 31 October 2017   Is life -threatening
(The subjec t was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or sign ificant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited report ing is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospi[INVESTIGATOR_23738]. 
These should usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study  endpoint (eg, all -cause mort ality).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity  is not consistent with the 
applicable product reference safet y information. For talacotuzumab and decitabine , the 
expectedness of an adverse event will be determined by [CONTACT_170183]'s Brochur e.
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel yby [CONTACT_23826] 12.1.2 .
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
93
Status: Approved, Date: 31 October 2017   Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by [CONTACT_170184]). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by [CONTACT_4867], eg,concomitant drug(s), concomitant disease(s). The relationship 
in time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
The severity  assessment for an adverse event or serious adverse event should be completed using 
the NCI CTCAE Version 4.03. Any adverse event or serious adverse event not listed in the NCI 
CTCAE Version 4.03will be graded according to investigator clinical judgment by [CONTACT_170185]:
Grade 1(Mild) : Awareness of symptoms that are easily tolerated, causing minimal discomfort 
and not interfering with every day activities.
Grade 2 (Moderate) : Sufficient discomfort is present to cause interference with normal activity .
Grade 3(Severe) : Extreme distress, causing significant impairment of functi oning or 
incapacitation. Prevents normal every day activities.
Grade 4: Life -threatening of disabling adverse event
Grade 5: Death related to the adverse event
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study drug
Suspected abuse/misuse of a sponsor study  drug
Inadvertent or accidental exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name [CONTACT_2976])
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
94
Status: Approved, Date: 31 October 2017   Speci al reporting situations should be recorded in the eCRF . Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF .
12.3. Procedures
Following Amendment 6, which incorporated the IDMC’s recommendations to close enrollment 
to the study  and discontinue talacotuzumab treatment for subjects receiving talacotuzumab + 
decitabine and offer to continue decitabine alone, all subjects will contin ue to be followed for 
survival and subsequent anti-cancer therapy . During the treatment phase with decitabine, 
subjects will be monitored for serious adverse events.
Following Amendment [ADDRESS_199161] is 
enrolled (whichever occurs first) , follow up of subjects and data collection will end. Subjects 
who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170158]; during this period, only serious adverse events will be 
monitored and entered into the Company  safet y repository.
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICFis obta ined until [ADDRESS_199162] be reported using the Serious Adverse Event Form. The 
sponsor will evaluate any safety information that is spontaneously  reported by [CONTACT_170186]. Anticipated events will be recorded and reported 
as described in Attachment 4.
Treatment failure or relapse from CR/CRi should not be recorded as an adverse event or serious 
adverse event term; instead, signs and symptoms resulting from disease relapse/lack of efficacy 
will be reported if they fulfill the serious adverse event definition (refer to Section 12.1.1
Adverse Event Definitions and Classifications). Death should not be recorded as an adverse 
event or serious adverse event, but as the outcome of an adverse event. The adverse event that 
resulted in the death should be reported as a serious adverse event. All events that meet the 
definition of a serious adverse event will be reporte d as serious adverse events, regardless of 
whether they  are protocol -specific assessments.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
95
Status: Approved, Date: [ADDRESS_199163] be recorded using medical terminology  in the source document and the eCRF . Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739]"). Investigators must record in the eCRF their opi[INVESTIGATOR_23740] . All measures required for adverse event 
management must be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]R s).For 
anticipated events reported as individual serious adverse events the sponsor will make a 
determination of relatedness in addition to and independent of the investigator’s assessment. The 
sponsor will periodicall y evaluate the accumulating data and, when there is sufficient evidence 
and the sponsor has determined there is a reasonable possibility  that the drug caused a serious 
anticipated event, they  will submit a safety  report in narrative format to the investigators (and the 
head of the investigational institute where required).
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_199164] telephone number (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All serious adverse events occurring during thestudymust be reported to the appropriate sponsor 
contact [CONTACT_170187] -site personnel within 24hours of their knowledge of the event.
Information regarding serious adverse events will be transmitted to the sponsor using the Serious 
Adverse Event Form, which must be completed and signed by a physician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a serious 
adverse event should be made b y facsimile (fax) .
All serious adverse events that have not resolved by [CONTACT_2054] , or that have not 
resolved upon discontinuation of the subject's participation in the study , must be followed until 
any of the following occurs:
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
96
Status: Approved, Date: 31 October 2017   The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstrati on 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) 
that occurs during the cycleof a subject's participation in a study  must be reported as a serious 
adverse event , except hospi[INVESTIGATOR_23741]:
Hospi[INVESTIGATOR_23742] (eg, social reasons 
such as pending placement in long-term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospi[INVESTIGATOR_23743], and where 
the underl ying condition for which the hospi[INVESTIGATOR_23744] ,will 
not be considered serious adverse events. Any  adverse event that results in a prolongation of 
the originall y planned hospi[INVESTIGATOR_23745] a new serious adverse event.
Treatment failure or relapse from CR/CRi should not be recorded as an adverse event or serious 
adverse event term; instead, signs and symptoms of clinical sequelae resulting from treatment 
failure or relapse will be reported if they fulfill the serious adverse event definition (refer to
Section 12.1.1 , Adverse Event Definitions and Classifications).
12.3.3. Pregnancy
All initial reports of pregnancy  must be reported to the sponsor by [CONTACT_1758] -sitepersonnel
within 24 hours of their knowledge of the event using the appropriate pregnancy  notification 
form. Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, and ectopic pregnancy ) are considered serious adverse events and must be reported 
using the Serious Adverse Event Form. Any subject who becomes pregnant during the study  
must be promptly  withdrawn from the study  anddiscontinue further study treatment. Follow -up 
information regarding the outcome of the pregnancy  and any postnatal sequelae in the infant will 
be required.
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study  will be reported as noted above .
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding thestudy  are listed on the Contact [CONTACT_23832](s), which will be provided as a separate document.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
97
Status: Approved, Date: [ADDRESS_199165] qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a produ ct, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investiga tors, 
and the sponsor , and are mandated by [CONTACT_23824]. The sponsor has 
established procedures in conformity  with regulatory requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_111168].
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_199166] report the PQC to the sponsor according to the serious adverse event 
reporting timelines (refer to Secti on12.3.2 , Serious Adverse Events). A  sample of the suspected 
product should be maintained for further investigation if requested b y the sponsor .
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of theindividuals who should be contact[CONTACT_41035](s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of S tudy Drug(s)
Talacotuzumab will be supplied as a lyophilized product containing 100mg of active 
pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection ). 
It will be manufactured and provided under the responsibilit y of the sponsor . Decitabine will be 
supplied as a lyophilized powder in a single -dose vial of 50 mg per vial and provided by [CONTACT_103]. D ecitabine powder should be reconstituted as outlined in the prescribing information.
14.2. Packaging
The investigational supplies will be uniquel y packaged to assure that they are appropriatel y 
managed throughout the supply  chain process.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
98
Status: Approved, Date: [ADDRESS_199167] be stored at 
controlled temperatures ranging from 36°F to 46°F (2°C to 8°C) and protected from exposure to 
light. Decitabine is supplied as a lyophilized preparation. Each 20 mL vial containing 50 mg 
decitabine should be stored at or below 25 °C.
Refer to the Site Investigational Product Manual for additional guidance on study  drug preparation ,
handling , and storage .
14.5. Drug Accountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study .The study  drug administered to the subject must be 
documented on the drug accountability  form. All study drug will be stored and disposed of 
according to the sponsor's instructions. Study-site personnel must not combine contents of the 
study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug must be available for verification by [CONTACT_456]'s 
study  site monitor during on-site monitoring visits. The return to the sponsor of unused study 
drug will be documented on the drug return form. When the study  site is an authorized 
destruction unit and study  drug supplies are destroy ed on-site, this must also be documented on 
the drug return form.
Potentially  hazardou s materials such as used ampules, needles, syringes ,and vials containing 
hazardous liquids should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes. The immediate destruction of these drug supplies 
should be documented in the drug accountability  records on site. 
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel, or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study .Study  drug may not be relabeled or reassigned for use by 
[CONTACT_23837]. The investigator agrees neither to dispense the study  drug from, nor store it at, 
any site other than the study  sites agreed upon with the sponsor.
Following Amendment [ADDRESS_199168] is 
enrolled (whichever occurs first) , follow up of subjects and data collection will end. Subjects 
who are continuing to derive benefit from decit abine treatment as assessed by [CONTACT_170158]; during this period, only serious adverse events will be 
monitored and entered into the Company  safet y repository.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provid ed with the following supplies:
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
99
Status: Approved, Date: 31 October 2017   Investigator Brochure s
Pharmacy  manual/ study  site investigational product manual
Laboratory  manual
Patient- reported outcomes ( PRO )questionnaires and user manuals
Interactive web response sy stem ( IWRS )Manual
Electronic data capture ( eDC)Manual
Sample I CF
NCI CTCAE version 4.[ADDRESS_199169] study  of the combination of decitabine + talacotuzumab. These [ADDRESS_199170] non-overlappi[INVESTIGATOR_95607]; decitabine is primarily  myelosuppressive 
while the most frequently  reported toxicity  from administration of talacotuzumab is infusion 
reactions. Additionall y, the administration of the [ADDRESS_199171] interactions of the combination. 
Pharmacokinetic drug interactions are not anticipated because ADME properties of a nucleoside 
analog (decitabine) are different from those of a monoclonal antibody  (talacotuzumab ). The 
sponsor will evaluate the available safety  of the combination of talacotuzumab and decitabine 
tested during Part A before proceeding to Part B. 
Part B, the randomized portion of this study , will start after the RP2D for talacotuzumab is 
confirmed in Part A. Part B will use talacotuzumab at the RP2D + decitabine prior to the 
complete evaluation of safet y for talacotuzumab + decitabine in Part A. The rationale for starting 
Part B is that randomization will provide a more informative safet y analysis of the combination 
than that of the single -arm design of Part A. Furthermore, an IDMC will be formed to monitor 
safet y and anal yze efficacy . Acomprehensive safety  review of all available data from Part A and 
Part B will be conducted by [CONTACT_170188]  [ADDRESS_199172] subjects from being exposed to an ineffective treatment.
After review of the data from Interim Anal ysis #2, the IDMC informed the Sponsor that the 
futility  criterion for OS was met and tha t the CR rate did not meet per -protocol defined statistical 
significance. Given the lack of efficacy  advantage of talacotuzumab + decitabine versus 
decitabine alone, the incidence of infusion -related reactions, and the complexities with 
premedications for drug administration, the benefit/ risk ratio is not favorable to continue 
treatment with talacotuzumab. The IDMC recommended closure of enrollment to the study  and 
that subjects receiving talacotuzumab + decitabine should discontinue talacotuzumab treatment 
and may continue decitabine alone, according to Principal Investigator [INVESTIGATOR_170093]. All subjects will continue to be followed for survival and subsequent anti-cancer 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
100
Status: Approved, Date: [ADDRESS_199173] is 
enrolled (whichever occurs first) , follow up of subjec ts and data collection will end. Subjects 
who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170158]; during this period, only serious adverse events will be 
monitored and entered int o the Company  safet y repository.
Infusion -related reactions have been reported with CSL362 in a Phase [ADDRESS_199174] their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential adverse events of the study , and provide their consent voluntaril y will be enrolled.
The volume of blood to be drawn is considered to be acceptable for subjects participating in a 
cancer clinical stud y and reasonable over the time frame of the study.29
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements. Good Clinical Practice is an international ethica l and scientific 
quality  standard for designing, conducting, recording, and reporting studies that involve the 
participation of human subjects. Compliance with this standard provides public assurance that 
the rights, safety , and well- being of study  subject s are protected, consistent with the principles 
that originated in the Declaration of Helsinki, and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the
Independent Ethics Committee/ Institutional Review Board (IEC/IRB )with current and complete 
copi[INVESTIGATOR_23747] (as required b y local regulations) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
101
Status: Approved, Date: 31 October 2017   Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name [CONTACT_8152], institutional affiliations, other po tential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, exclu ding the ones that are purel y administrative, with no 
consequences for subjects, data or study  condu ct, unless required locall y),the ICF, applicable 
recruiting materials, and subject compensation programs, and the sponsor has received a copy  of 
this appro val. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved by  [CONTACT_456]
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study  drug
New information that may adversel y affect the safety of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
102
Status: Approved, Date: 31 October 2017   For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study where 
requir ed. 
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion (if applicable, the notification will be submitted through the head of 
investigational institution) .
16.2.3. Informed Consent
Each subjec t (or a legally acceptable representative) must give written consent according to local 
requirements after the nature of the study  has been fully  explained. The ICF(s) must be signed 
before performance of any study-related activity . The ICF(s) that is/areused must be approved 
by [CONTACT_117199]/IRB and be in a language that the subject can read 
and understand. The informed consent should be in accordance with principles that originated in 
the Declaration of Helsinki, current ICH and GCP guidelines, applicable regulatory  
requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects or their legall y acceptable representatives the aims, 
methods, reasonabl y anticipated benefits, and potential hazards of the study ,and any discomfort 
participation in the study  may entail. Subjects will be informed that their participation is 
voluntary  and that they may withdraw consent to participa te at any time. They  will be informed 
that choosing not to participate will not affect the care the subject will receive for the treatment 
of his or her disease. Subjects will be told that alternative treatments are available if they refuse 
to take part and that such refusal will not prejudice future treatment. Finally , they will be told 
that the investigator will maintain a subject identification register for the purposes of long-term 
follow up if needed and that their records may be accessed by [CONTACT_170189], to the extent permitted by 
[CONTACT_6983](s) or regulations. By [CONTACT_117200] y acceptable 
representative is authorizing such access ,including permission to obtain information about his or 
her survival status, and agrees to allow his or her study  physician to recontact [CONTACT_41039] y evaluations, if needed ,and subsequent 
disease -related treatments, or to obtain information about his or her survival status.
The subject or legally  acceptable representative will be given sufficient time to read the ICF and 
the opportunity  to ask questions. After this explanation and before entry  into the study , consent 
should be appropriatel y recorded by [CONTACT_41040]'s or his or her legall y acceptable 
representative's personally  dated signature. After having obtained the consent, a copy of the ICF
must be given to the subject.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
103
Status: Approved, Date: [ADDRESS_199175] or legally  acceptable representative is unable to read or write , an impartial witness 
should be present for the entire informed consent process (which includes reading and explaining 
all written information) and should personally  date and sign the ICFafter the oral consent of the 
subject or legall y acceptable represe ntative is obtained.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study. These data must be 
collected and processed with adequate precautions to ensure confidentiality  and compliance with 
applicable data privacy protection laws and regulations. Appropriate technical and organizational 
measures to protect the personal data against unauthorized disclosures or access , accidental or 
unlawful destruction, or accidental loss or alteration must be put in place. Sponsor personnel 
whose responsibilities require access to personal data agree to keep the identity  of subjects 
confidential.
The informed consent obtained from the subject (or his or her legall y acceptable representative) 
includes explicit consent for the processing of personal data and for the investigator /institution to 
allow direct access to his or her original medical records (source data/documents) for study -
related monitoring, audit, IEC/IRB review, and regulatory  inspection. This consent also 
addresses the transfer of the data to other entities and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  DNA, pharmacod ynamics, biomarker ,pharmacokinetics, and immunogenicit y 
research is not conducted under standards appropriate for the return of data to subjects. In 
addition, the sponsor cannot make decisions as to the signific ance of any findings resulting from 
exploratory  research. Therefore, exploratory  research data will not be returned to subjects or 
investigators, unless required by [CONTACT_23844] . Privacy  and confidentiality  of data 
generated in the future on stored samples will be protected by [CONTACT_23845].
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand the function of
talacotuzumab and decitabine ,to understand the biology  ofAML , to understand differential drug 
responders, and to develop tests/assays related to talacotuzumab and decitabine .The research 
may begin at any  time during the study  or the post -study  storage period. 
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
104
Status: Approved, Date: 31 October 2017   Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research ( refer to Section 10.4, Withdrawal From the Study  (Withdrawal From the Use 
of Samples in Future Research) .
16.2.6. Country Selec tion
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product if the need for the product persists , unless explicitly  
addressed as a specific ethical consideration in Sectio n16,Study -Specific Design 
Considerations.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by [CONTACT_456]. All protocol amendments must be issued by  [CONTACT_456], and signed and dated by 
[CONTACT_093]. Protocol amendments must not be implemented witho ut prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IRB (and IEC where required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_43779] (see Contact [CONTACT_23774](s) provide d separatel y). Except in emergency 
situations, this contact [CONTACT_41042]. In 
all cases, contact [CONTACT_43780]. The data recorded in the eCRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notificat ion
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
105
Status: Approved, Date: [ADDRESS_199176] be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458]
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) by [CONTACT_23851].
Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748] .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 157 2), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial a greement
Any other documentation required by  [CONTACT_43782]:
Completed investigator financial disclosure forms from all subinvestigators
Documentation of sub investigator qualifications (eg, curriculum vitae)
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
106
Status: Approved, Date: [ADDRESS_199177] be available for the 
following: subject identification, eligibility , and study  identification; study  discussion and date of 
signed informed consent; dates of visits; results of safet y and efficacy  parameters as required by 
[CONTACT_760]; record of all adverse events and follow -up of adverse events; concomitant 
medication; drug receipt/dispensing/return records; study  drugadministration information ; and 
date of study  completion and reason for early discontinuation of study  drug or withdrawal from 
the study , if applicable. In addition, the author of an entry  in the source documents should be 
identifiable.
Specific details required as source data for the studyand source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring 
guidelines (or other equivalent document).
Subject -and investigator -completed scales and assessments designated by [CONTACT_456] (eg, PRO 
assessments ) will be recorded and will be considered source data.
The minimum source documentation requirements for Section 4.1,Inclusion Criteria and 
Section 4.2,Exclusion Criteria that specify  a  n eed for documented medica l history  are as 
follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_170190] (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
107
Status: Approved, Date: [ADDRESS_199178] to document medical care (eg, electronic source documents) as well as 
the clinical study -specific data fields as determined by [CONTACT_760]. This data is electronicall y 
extracted for use by [CONTACT_456]. If the electronic source system is utilized, references made to 
the CRF in the protocol include the electronic source system but information collected through 
the electronic source system may not be limited to that found in the CRF. Data in this system 
may be considered source documentation.
17.5. Case Report Form Co mpletion
Case report forms are prepared and provided by [CONTACT_66888]. 
All CRF entries, corrections, and alterations must be made by [CONTACT_170191] -site personnel. The investigator must verify  that all data entries in the CRF are accurate 
and correct.
The study  data will be transcribed by [CONTACT_3449]-sitepersonnel from the source documents onto an 
electronic CRF , if applicable. Study -specific data will be transmitted in a secure manner to the 
sponsor .
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksheets will become part of the subject's source documentation. Data must be entered 
into CRFs in English. The CRF must be completed as soon as possible after a subject visit, and 
the forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, pain scale information or other questionnaires) will be 
completed by [CONTACT_23856].
If necessary , queries will be generated in the eDC tool. If corrections to a CRF are needed after 
the initial entry  into the CRF, this can be done in either of the following way s:
• Investigator and study -site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]).
• Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_23858] -site personnel.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
108
Status: Approved, Date: 31 October 2017   17.6. Data Quality  Assuran ce/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , periodic monitoring visits by [CONTACT_456]. Written 
instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonne l before 
the start of the study .The sponsor will review eCRF for accuracy  and completeness during 
on-site monitoring visits and after transmission to the sponsor; any  discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study database 
they will be verified for accuracy  and consistency  with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF s 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical devel opment of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_43785]. It is the responsibility  of the sponsor to inform the 
investigator/instit ution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
109
Status: Approved, Date: [ADDRESS_199179]-initiation visit will be made as soon as possible after enrollment has begun. At these visits, 
the monitor will compare the data entered into the eCRF s with thesource docum ents (eg, 
hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records). The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
eCRF are known to the sponsor and study -site personnel and are accessible for verification by 
[CONTACT_43786] -site contact. If electronic records are maintained at the study site, the method 
of verification must be discussed with the study -sitepersonnel . 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the eCRF are consistent with the original source data. Findings 
from this review of eCRF and source documents will be discussed with the study -site personnel. 
The sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study to provide feedback on the study conduct.
17.9. Study Completion/Termination
17.9.1. Study Compl etion / End of Study
The end of study  data collection is defined as when [ADDRESS_199180]. At that time, follow up of subjec ts will end. 
Subjects who are continuing to derive benefit from decitabine treatment as assessed by [CONTACT_170146]; during this period, only serious adverse events 
will be monitored and entered into the Company  safetyrepository  as described under 
Amendment 7.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and suf ficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of astudy site by [CONTACT_11004]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
110
Status: Approved, Date: 31 October 2017   Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspec tion. Subject privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and 
available for consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_170192]. 
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding talacotuzumab and decitabi ne
or the sponsor's operations (eg,patent application, formulas, manufacturing processes, basic 
scientific data, prior clinical data, formulation information) supplied by [CONTACT_170193], and any data, includin g pharmacogenomic or 
exploratory  biomarker research data, generated as a result of this study , areconsidered 
confidential and remain the sole property  of the sponsor. The investigator agrees to maintain this 
information in confidence and use this information only to accomplish this study , and will not 
use it for other purposes without the sponsor's pr ior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_170194] , and thus 
may be disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by [CONTACT_170195] .Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator . Results of pharmacogenomics or 
exploratory biomarker analy ses performed after the Clinical Study  Report has been issued will 
be reported in a separate report and will not require a revision of the Clinical Study  Report. 
Study  subject identifiers will not be used in publication o f results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by [CONTACT_40999]) shall be 
the propert y of the sponsor as author and owner of cop yright in such work.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
111
Status: Approved, Date: [ADDRESS_199181] the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy  of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_170196], the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulator y compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. Formulticenter study  designs and substudy  approaches, secondary results generall y 
should not be published before the primary  endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study by [CONTACT_41055], within 12 months of the availability  of the final data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study  publication. 
Authorshi p of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant
contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
112
Status: Approved, Date: 31 October 2017   REFERENCES
1. Badger C, Davis J, et al. Biodistribution and Dosimetry following Infusion of Antibodies Labeled with Large 
Amounts of 13II1.Cancer Research 1991; 51, 5921 -5928.
2. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to 
postconsolidation minimal residual disease assessment by [CONTACT_170197]. B lood 2010;116:2295 -2303.
3. Busfield SJ, Biondo M, Wong M, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti -
CD123 mAb engineered for optimal ADCC. Leukemia. 2014;1 -9. 
4. Cella D, Jensen S, Webster K, et al. Measuring health -related q uality of life in leukemia: the functional 
assessment of cancer therapy –leukemia (FACT -Leu) questionnaire. Value in Health. 2012;15:1051 –1058.
5. Cheson BD, Cassileth PA, Head DR et al, Report of the National Cancer Institute -sponsored w orkshop on 
definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813 -819.
6. DACO -016 Clinical Study Report. Randomized Phase 3 trial of decitabine versus patient’s choice w ith 
physician’s advice of either supportive care or low -dose cytarabine for t he treatment of older patients with 
newly diagnosed acute myeloid leukemia. 4 April 2011.
7. De Charro F, Rabin R. EQ -5D-5L from the EuroQol group: an update. QOL Newsletter, 2000 ;25:6 -7.
8. D’Incalci M, Covey JM, Zaharko DS, Kohn KW. DNA Alkali- labile Sites In duced by  [CONTACT_170198] 5 -Aza-
2'-deoxycytidine into DNA of Mouse Leukemia L1210 Cells. Cancer Res 1985;45:3197 -3202.
9. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: 
recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 
2010;115:453 -474. 
10. Ehninger A, Kramer M, Rollig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 
in acute myeloid leukemia. Blood Cancer J. 2014;4:e218. 
11. Guzman ML, Allan JN. Concise Review: Leukemia stem cells in personalized medicine. Stem Cells. 
2014;32:844 -851. 
12. Hercus TR, Dhagat U, Kan WLT, et al. Signalling by [CONTACT_941] c family of cytokines. Cytokine & Growth Factor 
Rev. 2013;24:189 -201. 
13. Hourigan CS, Karp JE. Minim al residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol 2013;
doi:10.1038/nrclinonc.2013.100 . 
14. Hwang K, Park C -J, Jang S, et al. Flow  cytom etric quantification and immunophenotypi[INVESTIGATOR_170114] 201 2;91:1541 -1546.
15. Investigator’s Brochure: JNJ-30979754 DACOGEN (decitabine for Injection) March 2015.
16. Investigator’s Brochure: JNJ-56022473(CSL362) April 2015.
17. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin -3 receptor alpha chain is a unique marker for 
human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777 -1784.
18. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease 
in patients with core binding factor acute myeloid leukemia. Blood 2013; doi:10.1182/blood -2012 -10-462879 .
19. Kantarjian H, Oki Y, Garcia -Manero G, et al. Results of a randomized study of 3 schedules of low -dose 
decitabine in higher -risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 
2007;109:52 -57.
20. Kantarjian H, Ravandi F, O’Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 
years or older) w ith acute myeloid leukemia. Blood 2010;116:4422 -4429.
21. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, Randomized, Open -Label, Phase III Trial of 
Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low -Dose Cytarabine 
for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 
2012;30:2670 -2677.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
113
Status: Approved, Date: 31 October 2017   22. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a [LOCATION_008] 
national questionnaire survey. BMJ 1998;316:[ADDRESS_199182] on natural killer cell viability, phenotype, 
and function under p roliferative conditions. Molecu lar Immunology 2013;54:296 -301.
24. Kuykendall JR. 5 -azacytidine and decitabine monotherapi[INVESTIGATOR_170115] . Ann Pharmacother 
2005;39:1700 -1709.
25. Malik P, Cashen AF . Decitabine in th e treatment of acute myeloid leukemia in elderly patients. Cancer 
management and Research 2014;6:53 -61.
26. Montalban -Bravo G, Garcia- Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia 
2014;1 -10, doi:10.1038/leu.2014.244 .
27. Munoz L, Nom dedeu JF, Lopez O, et al. Interleukin -3 receptor a chain (CD123) is w idely expressed in 
hematologic malignancies. Haematologica 2001;86:1261 -1269.
28. National Comprehensive Cancer Netw ork (NCCN) Guidelines Acute Myeloid Leukemia version 1.2015.
29. POLICY: Guidelines for Limits of Blood Drawn for Research Purposes in the Clinical Center at 
https://irb.research.chop.edu/sites/default/files/documents/g_nih_blooddraws.pdf . accessed 08 June 2016
30. Qiu S, Jia Y, Xing H, et al. N-cadherin and Tie2 positive C D34+CD38 -CD123+ leukemic stem cell 
populations can develop acute myeloid leukemia more effectively in NOD/SCID mice. Leukemia Res. 
2014;38:[ADDRESS_199183] stimulation. Int J Cancer 2011;128:2911 -2922.
32. Smith BD, Karp JE. What Are the Endpoints of Therapy for Acute Leukemias? Old Definitions and New  
Challenges. Clin Lymphoma Myeloma. 2009; 9(Suppl 3): S296 –S301 .
33. Smith BD, Roboz GJ, Walter RB, et al. Abstract [ADDRESS_199184] -in Man, Phase 1 Study of CSL362 (Anti -IL3Rα / 
Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High 
Risk for Early Relapse. Am erican Society for Hematology meeting 2014.
34. Testa U, Riccioni R, Militi S, et al. Elevated expression of IL -3Rα in acute myelogenous leukemia is 
associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980 -
2988.
35. Vardiman JW, Thiele J, Arber DA, et al . The 2008 revision of the World Health Organization (WHO) 
classification of myeloid neoplasms and acute leukemia: rationale and important changes . Blood. 
2009;114:937 -951.
36. Vergez F, Green AS, Tamburini J, et al. High levels of CD34 +CD38low/-CD123+ blasts are predictive of an 
adverse outcome in acute myeloid leukemia: a GOELAMS study. Haematologica. 2011;96:1792 -1798. 
37. Wang JCY, Dick JE. Cancer stem cells: lessons from leukemia. Trends in Cell Biology. 2005;15:494 -501.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
114
Status: Approved, Date: 31 October 2017   Attachment 1: Sample F ACT-Leu (Version 4)
Below is a list of statements that other people with your illness have said are important. Please 
circle or mark one number per line to indicate your response as it applies to the past 
7days .
PHYSICAL WELL -BEING Not at 
allA little 
bitSome -
whatQuite
a bitVery 
much
GP
1I have a lack of energy ................................ ................................ [ADDRESS_199185] pain ................................ ................................ 0 1 2 3 4
GP
5I am bothered b y side effects of treatment ................................ 0 1 2 3 4
GP
6I feel ill ................................ ................................ 0 1 2 3 4
GP
7I am forced to spend time in bed ................................ 0 1 2 3 4
SOCIAL/FAMILY WELL -BEING Not at 
allA little 
bitSome -
whatQuite
a bitVery 
much
GS
1I feel close to my  friends ................................ ................................ 0 1 2 3 4
GS
2I get emotional support from my  famil y................................ 0 1 2 3 4
GS
3I get support from m y friends ................................ 0 1 2 3 4
GS
4My family  has accepted my  illness ................................ 0 1 2 3 4
GS
5I am satisfied with family  communication 
about my  illness ................................ ................................ 0 1 2 3 4
GS
6I feel close to my  partner (or the person who 
is my  main support) ................................ ................................ 0 1 2 3 4
Q1 Regardless of your current level of sexual 
activity, please answer the following question. If 
you prefer not to answer it, please mark this box    
and go to the next section.
GS
7I am satisfied with my  sex life ................................ 0 1 2 3 4
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
115
Status: Approved, Date: [ADDRESS_199186] my  illness ............................ 0 1 2 3 4
GE
4 I feel nervous ................................ ................................ .................0 1 2 3 4
GE
5 I worry  about dy ing................................ ................................ 0 1 2 3 4
GE
6 I worry  that m y condition will get worse ................................ 0 1 2 3 4
FUNCTIONAL WELL -BEING Not 
at 
allA little 
bitSome
-whatQuite
a bitVery 
muc
h
GF1I am able to work (include work at home) ................................ 0 1 2 3 4
GF2My work (include work at home) is fulfilling ............................... [ADDRESS_199187] accepted m y illness ................................ .............................0 1 2 3 4
GF5I am sleepi[INVESTIGATOR_102641] ................................ ................................ 0 1 2 3 4
GF6I am enjo ying the things I usually  do for fun ................................ 0 1 2 3 4
GF7I am content with the quality  of my  life right 
now................................ ................................ ................................0 1 2 3 4
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
116
Status: Approved, Date: [ADDRESS_199188] 
7 days.
ADDITIONAL CONCERNS Not at 
allA little 
bitSome -
whatQuite
a bitVery 
much
BRM3I am bothered b y fevers (epi[INVESTIGATOR_170116]) ................................ ................................ [ADDRESS_199189] night sweats ................................ ................................ 0 1 2 3 4
LEU1I am bothered b y lumps or swelling in 
certain parts of m y bod y (e.g., neck, 
armpi[INVESTIGATOR_10022], or groin) ................................ ................................[ADDRESS_199190] emotional ups and downs ................................ 0 1 2 3 4
LEU7I feel isolated from others because of m y 
illness or treatment ................................ ................................ 0 1 2 3 4
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
117
Status: Approved, Date: 31 October 2017   Attachment 2: Sample EQ -5D-5L
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
118
Status: Approved, Date: 31 October 2017   
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
119
Status: Approved, Date: 31 October 2017   
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
120
Status: Approved, Date: 31 October 2017   Attachment 3: ECOG Performance Status Score
ECOG PERFORMANCE STATUS*
Grade ECOG
0 Fully  active, able to carry  on all pre -disease performance without restriction
1 Restricted in phy sically  strenuous activity  but ambulatory  and able to carry  out work of 
a light or sedentary  nature, e.g., light house work, office work
2 Ambulatory  and capable of all selfcare but unable to carry  out an y work activities. Up 
and about more than 50% of waking hours
3 Capable of onl y limited selfcare , confined to bed or chair more than 50% of waking 
hours
4 Completely  disabled. Cannot carry  on any  selfcare. Totally  confined to bed or chair
5 Dead
* As published in Am. J. Clin. Oncol.:
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity 
And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649 -655, 1982.
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
121
Status: Approved, Date: 31 October 2017   Attachment 4:Anticipated Events
Anticipated Event
An anticipated event is an adverse event (serious or non-serious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen.
For the purposes of this study the following events will be considered anticipated events:
Disease Based:
 Thrombocytopenia
 Anemia
 Febrile neutropenia
 Leukopenia
 Pneumonia
 Sepsis
 Urinary tract infection
 Broncopneumonias
 Bacteremia
 Pyrexia
 Asthenia
 Fatigue
 Dyspnea
 Cardia dysrhythmias (i.e., atrial fibrillation)
Population Based:
 Congestive heart failure
Report ing of Anticipated Events
All adverse events will be recorded in the CRF regardless of whether considered to be anticipated events 
and will be reported to the sponsor as described in Section 12.3.1 , All Adverse Events. Any anticipated 
event that meets serious adverse event criteria will be reported to the sponsor as described in 
Section 12.3.2 , Serious Adverse Events. These anticipated events are exempt from expedited reporting as 
individual single cases to Health Authorities. However if based on an aggregate review, it is determined 
that an ant icipated event is possibly related to study drug, the sponsor will report these events in an 
expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-specified 
anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
Talacotuzumab (JNJ -56022473)
Clinical Protocol 56022473AML2002 Amendment 7
122
Status: Approved, Date: 31 October 2017   INVESTIGA TOR AGREEME NT
[STUDY_ID_REMOVED]